Ohio State Navbar

Directory

John Byrd, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-8330

Email: byrd.96@osu.edu

 

Current OSU Appointments

Professor, Hematology

Professor, Pharm CBO/Coll

Physician, FGP-Hematology

 

Academic Advising

2010 - present Kami Maddocks Ohio State University College of Medicine. Graduated 2011. HSP90 as a Target in CLL
 

Certifications

1993 - present Medical License: Commonwealth of Virginia
1994 - present Diplomat: American Board of Internal Medicine
1997 - present Diplomat: American Board of Medical Oncology
2001 - present Medical License: State Medical Board of Ohio
2007 - present Diplomat: American Board of Hematology
 

Chapters in Books

Byrd JC. "Therapy of Chronic Lymphocytic Leukemia: It is time to move onto the next important question." In ASCO Educational Book Spring. 167-177. n/a: ASCO, January 1999.

Stock W, Byrd JC, Frankel SR, Bloomfield CD. "Adult Acute Lymphoblastic Leukemia." In Clinical Oncology. 2nd ed. 2451-2489. New York, NY, US|USA: Churchill Livingstone, January 2000.

Frankel SR, Stock W, Byrd JC, Bloomfield CD. "Acute Lymphoblastic Leukemia." In Cancer Treatment. Fifth ed. Edited by Haskell CM. 1438-1474. Philadelphia, PA, US|USA: W. B. Saunders Company, January 2000.

Weitzler M, Byrd JC, Bloomfield CD. "Acute and Myeloid Leukemias." In Harrisons Principals of Internal Medicine. 15th ed. 449-456. n/a, DE|DEU: Springer-Verlag, January 2001.

Byrd JC, Grever MR. "Finding new therapies for patients with CLL." In Chronic Lymphocytic Leukemias. 2nd ed. 417-434. n/a: n/a, January 2001.

Byrd JC, Lucas M, Cheson B, Flinn IW. "Monoclonal antibody therapies for patients with chronic lymphocytes leukemia." In Chronic Lymphocytic Leukemias. 2nd ed. 91-112. n/a: n/a, January 2001.

Lin TS, Lucas M, Byrd JC. "Monoclonal Antibodies for patients with chronic lymphocytic leukemia." In Chronic Lymphcotic Leukemia. -. n/a: Informa Healthcare, January 2002.

Byrd JC, Farag S, Lucas M, Lin T. "New Therapies for CLL." In Hematology (Am Soc Hematol Educ Program). 193-213. n/a: n/a, January 2002.

Wetzler M, Byrd JC, Bloomfield CD. "Acute and chronic myeloid leukemia." In Harrison's Principles of Internal Medicine. Edited by Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. -. n/a: McGraw-Hill Publishing, January 2003.

Byrd JC, Farag S, Lucas M. Lin T. "Old and New Therapies for CLL." In ASCO Education Book. Spring ed. -. n/a: n/a, January 2003.

Bloomfield CD, Archer KJ, Mrózek K, Byrd JC, Whitman SP, Dodge RK, Carroll AJ, Larson RA, Caligiuri MA. "Cytogenetics for treatment stratification in de novo adult acute myeloid leukemia." In Acute Leukemias IX-Basic Research, Experimental Approaches and Novel Therapies. 366-376. Berlin-Heidelberg, DE|DEU: Springer-Verlag, January 2003.

Lin TA, Byrd JC. "Chronic Lymphocytic Leukemia and Related Chronic Leukemias." In Adv Pharmacol 51. 127-167. n/a: n/a, January 2004.

Lin TA, Awan F, Byrd JC. "Chronic Lymphocytic Leukemia." In Hoffman’s Hematology. 5th ed. -. n/a: n/a, January 2009.

Lin TS, Lucas M, Byrd JC. "Monoclonal Antibodies for patients with chronic lymphocytic leukemia." In Chronic Lymphocytic Leukemia. -. n/a: n/a, January 2009.

Marcucci G, Wezler M, Byrd JC, Mrozek K, Bloomfield CD. "Leukemias." In Medical Oncology. Edited by Franco Cavallie, Stan B. Kaye, Heine H. Hansen, James O. Armitage, martine Piccart. -. New York: Informa Healthcare; 4 edition (August 27, 2009), January 2009.

Byrd JC, Rai KR. "Chemotherapy and immunotherapy in chronic lymphocytic leukemia and hairy cell leukemia." In The Chemotherapy Source Book. 3rd ed. -. n/a: n/a, January 2009.

 

Degrees

1987 B.A., Hendrix College

1991 M.D., University Of Arkansas

 

Editorial Activities

present New England Journal of Medicine
present Journal of Clinical Oncology
present Clinical Infectious Diseases
present Clinical Cancer Research
present Cancer Cell
present Cancer
present Bone Marrow Transplant
present Blood
present Annals of Hematology
present American Journal of Hematology
present Leukemia
present Cancer Treatment Review
present Cancer Research
present Annals of Oncology
present Leukocyte Biology
present Leukemia Research
present Journal of the National Cancer Institute
present Nature Medicine
present Proceedings of the National Academy of Science
1998 - present Oncology Reports
1998 - present Seminars of Oncology: Chronic Lymphocytic Leukemia
1999 - present Oncology Index and Review
2000 - present Issue of Seminars of Oncology: Novel Therapies in Hematologic Malignancies
2000 - present Seminars in Oncology
2001 - present Frontiers in Hematology Oncology
2002 - present Leukemia Research
2002 - present Clinical Advances in Hematology & Oncology
2003 - present Leukemia
2003 - present Issue of Seminars of Oncology: Monoclonal Antibody Therapy for Hematologic Malignancies
2004 - present Blood
2004 - present Journal of Clinical Oncology
2005 - present Issue of Seminars of Oncology: CLL
2006 - present American Journal of Hematology
2006 - present British Journal of Cancer
2008 - present The Hematologist
2008 - present MAbs
2008 - 2010 The Hematologist
 

Honors

1983 - 1987 Recipient, Dorothy Snyder Scholarship.
1985 Member. Pi Mu Epsilon.
1989 - 1991 Barton Scholar.
1990 AOA. Alpha Omega Alpha Society.
1991 Recipient, Senior Buchanan Key.
1993 Army Achievement Medal. US Army.
1994 General Erskine Award. Outstanding WRAMC resident.
1994 Senior Resident of the Year. Internal Medicine.
1994 Army Commendation Medal. US Army.
1996 American Society of Hematology Travel Award.
1996 AACR Research Course Scholarship.
1997 Fellow of the Year. Internal Medicine.
1997 Kimmel Scholar.
1998 Army Meritous Service Medal. US Army.
2000 Army Meritous Service Medal with Bronze Clover. US Army.
2001 Army Meritous Service Medal with Silver Clover. US Army.
2001 William Crosby Superiority in Research Award.
2005 Elected Member. American Society for Clinical Investigation.
2005 America's Best Doctors.
2006 Stohlman Scholar Award. The Leukemia & Lymphoma Society.
2007 America's Best Doctors. U.S. News & World Report.
2007 The Don V. Unverferth Award.
2007 AAAS Fellow.
2008 Distinguished Scholar Award.
2009 NCI, CTEP Michaele C. Christian Oncology Development Lectureship and Award.
2009 Elected Member, Henry Kunkel Society.
2010 Richard L. Schilsky CALGB Achievement Award. CALGB.
2012 Best Doctors in America. Castle Connolly Medical Ltd..
 

Journal Articles

Wiesen AR, Hospenthal DR, Byrd JC, Glass KL, Howard RS, Diehl LF. "Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding." Ann Intern Med. Vol. 121, no. 4. (January 1994.): 278-280.

Byrd JC, Weiss RB. "Recurrent granulocytic sarcoma. An Unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translation and blast expression of the neural cell adhesion molecule 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule." Cancer. Vol. 8, no. 73. (January 1994.): 2107-2112.

Hospenthal DR, Hicks CB, Green DL, Wiesen AR, Byrd JC, Isenbarger DW, Salzberg DJ. "Trends in the incidence and diversity of fungi recovered from urine." Mycopathologia. Vol. 132, no. 1. (January 1995.): 15-19.

Hospenthal DR, Byrd JC, Weiss RB. "Successful treatment of invasive aspergillosis complicating prolonged treatment-related neutropenia in acute myelogenous leukemia with amphotericin B lipid complex." Med Pediatr Oncol. Vol. 25, no. 2. (January 1995.): 119-122.

Byrd JC, Hertler AA, Weiss RB, Freiman J, Kweder SL, Diehl LF. "Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia." Ann Oncol. Vol. 6, no. 3. (January 1995.): 300-301.

Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. "Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role of Pneumocytis carinii pneumonia prophylaxis." Am J Hematol. Vol. 49, no. 2. (January 1995.): 135-142.

Byrd JC, Edenfield WJ, Shields DJ, Dawson NA. "Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review." J Clin Oncol. Vol. 13, no. 7. (January 1995.): 1800-1816.

Alkins SA, Byrd JC, Morgan SM, Ward FT, Weiss RB. "Anaphylactoid reactions to methotrexate." Cancer. Vol. 77, no. 10. (January 1996.): 2213-2216.

Byrd JC, Edenfield WJ, Dow NS, Aylesworth C, Dawson N. "Extramedullary myeloid tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia." Leuk Lymphoma. Vol. 21, no. 1-2. (January 1996.): 153-159.

Avery RA, Harris JE, Davis CJ Jr, Borgaonkar DS, Byrd JC, Weiss RB. "Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor." Cancer. Vol. 78, no. 1. (January 1996.): 128-132.

McBride CE, Yavorski RT, Moses FM, Robson ME, Solimando DA Jr, Byrd JC. "Acute pancreatitis associated with continuous infusion cytarabine therapy: a case report." Cancer. Vol. 77, no. 12. (January 1996.): 2588-2591.

Kester KE, Byrd JC, Rearden TP, Zacher LL, Cragun WH, Hargis JB. "Granulomatous Pneumocystis carinii pneumonia in patients with low-grade lymphoid malignancies: a diagnostic dilemma." Clin Infect Dis. Vol. 22, no. 6. (January 1996.): 1111-1112.

Gooby Toedt DM, Byrd JC, Omori D. "Coxsackievirus-associated pancreatitis mimicking metastatic carcinoma." South Med J. Vol. 89, no. 4. (January 1996.): 441-443.

Byrd JC, Dow NS, Gaertner E, Hargis JB, Raber TR, Burrell L, Weiss RB. "Leukemic thyroiditis as the initial relapsing sign in a patient with acute lymphocytic leukemia and blast expression of the neural cell adhesion molecule." Am J Hematol. Vol. 55, no. 4. (January 1997.): 212-215.

Shields DJ, Byrd JC, Abbondanzo SL, Lichy JH, Diehl LF, Aguilera NI. "Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment." Mod Pathol. Vol. 10, no. 11. (January 1997.): 1151-1159.

Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD. "Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22)." Blood. Vol. 90, no. 4. (January 1997.): 1643-1648.

Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, Trikha ES, Carroll AJ, Tantravahi R, Qumsiyeh M, Patil SR, Moore JO, Schiffer CA, Bloomfield CD. "Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461." J Clin Oncol. Vol. 15, no. 2. (January 1997.): 466-475.

Vick DJ, Byrd JC, Beal CL, Chaffin DJ. "Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma." Vox Sang. Vol. 74, no. 2. (January 1998.): 122-126.

Bloomfield, Clara D.; Lawrence, David; Byrd JC; Carroll, Andrew; Pettenati, Mark J.; Tantravahi, Ramana; Patil, Shivanand R.; Davey, Frederick R.; Berg, Deborah T.; Schiffer, Charles A.; Arthur, Diane C.; Mayer, Robert J.. "Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype." Cancer Research. Vol. 58, no. 18. (January 1998.): 4173-4179.

Byrd JC, Flinn IW, Grever MR. "Introduction: Chronic Lymphocytic Leukemia." Seminars in Oncology. Vol. 25, (January 1998.): 4-5.

Wiesen AR, Byrd JC, Hospenthal DR, Howard RS, Shorr AR, Glass KL, Diehl LF. "Transient abnormalities in serum bilirubin and lactate dehydrogenase levels following red blood cell transfusions in adults." Am J Med. Vol. 104, no. 2. (January 1998.): 144-147.

Weiss, Raymond B.; Freiman, Joel; Kweder, Sandra L.; Diehl, Louis F.; Byrd JC. "Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia." Journal of Clinical Oncology. Vol. 16, no. 5. (January 1998.): 1885-1889.

Houde L, Sehn L, Weiss RB, Antin J, Byrd JC. "Pancreatitis During the Treatment of Acute Myeloid Leukemia: Cytarabine Related." Annals of Oncology. Vol. 10, (January 1998.): 1373-1376.

Wortmann, Glenn W.; Aronson, Naomi E.; Byrd JC; Grever, Michael R.; Oster, Charles N.. "Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis." Clinical Infectious Diseases. Vol. 27, no. 3. (January 1998.): 509-512.

Byrd JC; Shinn, Charlotte; Waselenko, Jamie K.; Fuchs, Ephraim J.; Lehman, Teresa A.; Nguyen, Phuong L.; Flinn, Ian W.; Diehl, Louis F.; Sausville, Edward; Grever, Michael R.. "Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53." Blood. Vol. 92, no. 10. (January 1998.): 3804-3816.

Byrd JC; Rai, Kanti R.; Sausville, Edward A.; Grever, Michael R.. "Old and new therapies in chronic lymphocytic leukemia: Now is the time for a reassessment of therapeutic goals." Seminars in Oncology. Vol. 25, no. 1. (January 1998.): 65-74.

Byrd JC, Weiss RB. "In Response to: Hemolytic Anemia and Fludarabine Treatment." Journal of Clinical Oncology. Vol. 16, (January 1998.): 3209-3210.

Byrd JC, Lawrence D, Arthur DC, Pettanti MJ, Tantravahi H, Quimsiyeh M, Stamberg J, Davey F, Schiffer CA, Bloomfield CD. "Patients with Isolated Trisomy 8 in Acute Myeloid Leukemia are Not Cured with Cytarabine Based Chemotherapy: Results from CALGB 8461." Clinical Cancer Research. Vol. 4, (January 1998.): 1235-1241.

Pearson, Michael D.; Shinn, Charlotte; Grever, Michael R.; Flinn, Ian W.; Byrd JC. "Rituximab induces in vitro apoptosis in human chronic lymphocytic leukemia cells (cll) independent of complement mediated lysis but requires Fcgamma receptor ligation." Blood. Vol. 94, no. 10 SUPPL. 1 PART 2. (January 1999.): 313b-.

Murphy, Timothy J.; Ling, Geoffrey; Flynn, Ian W.; Lucas, Margaret S.; Park, Kathy; Goodrich, A.; Grever, Michael R.; Byrd JC. "Infusion-related events following rituximab therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll): Association with inflammatory cytokines." Blood. Vol. 94, no. 10 SUPPL. 1 PART 1. (January 1999.): 312a-.

Murray, Clinton K.; Estey, Elihu; Paietta, Elisabeth; Howard, Robin S.; Edenfield, William J.; Pierce, Sherry; Mann, Karen P.; Bolan, Charles; Byrd JC. "Cd56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?." Journal of Clinical Oncology. Vol. 17, no. 1. (January 1999.): 293-297.

Byrd JC; Dodge, Richard K.; Carroll, Andrew; Baer, Maria R.; Edwards, Colin; Stamberg, Judith; Qumsiyeh, Mazin; Moore, Joseph O.; Mayer, Robert J.; Davey, Frederick; Schiffer, Charles A.; Bloomfield, Clara D.. "Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered." Journal of Clinical Oncology. Vol. 17, no. 12. (January 1999.): 3767-3775.

Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, Grillo-Lopez AJ. "Rituximab Therapy in Walderstrom’s Macroglobulinimia: Preliminary Evidence of Clinical Activity." Annals of Oncology. Vol. 10, (January 1999.): 1525-1527.

Willis, Carl; Byrd JC; Shinn, Charlotte; Flinn, Ian W.; Grever, Michael R.. "Ucn-01 chemosensitizes human B-chronic lymphocytic leukemia (b-cll) cells to the effects of fludarabine." Blood. Vol. 94, no. 10 SUPPL. 1 PART 1. (January 1999.): 127a-.

Waselenko, Jamie K.; Flynn, Joseph M.; Byrd JC. "Stem-cell transplantation in chronic lymphocytic leukemia: The time for designing randomized studies has arrived." Seminars in Oncology. Vol. 26, no. 1. (January 1999.): 48-61.

Byrd JC; Willis, Carl R.; Waselenko, Jamie K.; Park, Kathy; Goodrich, Amy; Morrison, Candice; Lucas, Margaret S.; Shinn, Charlotte; Diehl, Louis F.; Grever, Michael R.; Flinn, Ian W.. "Theophylline, pentostatin, and chlorambucil; a dose escalation study to modulate intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders." Blood. Vol. 94, no. 10 SUPPL. 1 PART 2. (January 1999.): 308b-.

Byrd JC; Shinn, Charlotte; Ravi, Rajani; Willis, Carl R.; Waselenko, Jamie K.; Flinn, Ian W.; Dawson, Nancy A.; Grever, Michael R.. "Depsipeptide (fr901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells." Blood. Vol. 94, no. 4. (January 1999.): 1401-1408.

Byrd JC; Shinn, Charlotte A.; Pearson, Michael D.; Flinn, Ian W.; Link, Brian K.; Wang, Hong; Weiner, George; Grever, Michael R.. "Hu1d10 induces apoptosis in vitro in human chronic lymphocytic leukemia cells (cll) independent of compliment mediated lysis but requires Fcgamma receptor ligation." Blood. Vol. 94, no. 10 SUPPL. 1 PART 1. (January 1999.): 314a-.

Byrd JC; Shinn, Charlotte A.; Jansure, Jenny; Hydom, Chris; Pearson, Michael D.; Flinn, Ian W.; Grever, Michael R.. "Campath-1h induces apoptosis in human chronic lymphocytic leukemia cells (cll) in vitro independent of complement mediated lysis or Fcgamma receptor ligation." Blood. Vol. 94, no. 10 SUPPL. 1 PART 1. (January 1999.): 126a-.

Byrd JC; Grever, Michael R.; Davis, Brad; Lucas, Margaret S.; Park, Kathy; Goodrich, Amy; Morrison, Candice; Murphy, Timothy; Kunkel, Lori; Grillo-Lopez, Antonio; Waselenko, Jamie K.; Flinn, Ian W.. "Phase I/ii study of thrice weekly rituximab in chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll): A feasible and active regimen." Blood. Vol. 94, no. 10 SUPPL. 1 PART 1. (January 1999.): 704a-705a.

Byrd JC; Waselenko, Jamie K.; Maneatis, Thomas J.; Murphy, Timothy; Ward, Frank T.; Monahan, Brian P.; Sipe, Melissa A.; Donegan, Sarah; White, Christine A.. "Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance." Journal of Clinical Oncology. Vol. 17, no. 3. (January 1999.): 791-795.

Byrd JC; McGrail, Lisa H.; Hospenthal, Duane R.; Howard, Robin S.; Dow, Nancy A.; Diehl, Louis F.. "Herpes virus infections occur frequently following treatment with fludarabine: Results of a prospective natural history study." British Journal of Haematology. Vol. 105, no. 2. (January 1999.): 445-447.

Daniels, Jasmine T.; Davis, Brad J.; Houde-McGrail, Lisa; Byrd JC. "Clonal selection of Cd56+ t(8;21) Aml blasts: Further suggestion of the adverse clinical significance of this biological marker?." British Journal of Haematology. Vol. 107, no. 2. (January 1999.): 381-383.

Perkins, Jeremy G.; Flynn, Joseph M.; Byrd JC. "Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma (cll/sll): Implications for clinical trials in this patient population." Blood. Vol. 94, no. 10 SUPPL. 1 PART 1. (January 1999.): 540a-.

Flynn, Joseph M.; Howard, Robin S.; Byrd JC. "Second malignancies in B-cell chronic lymphocytic leukemia (cll): Association with Cll but no additional impact with fludarabine or alkylator treatment." Blood. Vol. 94, no. 10 SUPPL. 1 PART 2. (January 1999.): 298b-.

Flynn, Joseph M.; Byrd JC. "Campath-1h monoclonal antibody therapy." Current Opinion in Oncology. Vol. 12, no. 6. (January 2000.): 574-581.

Flinn, Ian W.; Byrd JC; Morrison, Candis; Jamison, Janet; Diehl, Louis F.; Murphy, Timothy; Piantadosi, Steve; Seifter, Eric; Ambinder, Richard F.; Vogelsang, Georgia; Grever, Michael R.. "Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies." Blood. Vol. 96, no. 1. (January 2000.): 71-75.

Byrd JC; Waselenko, Jamie K.; Keating, Michael; Rai, Kanti; Grever, Michael R.. "Novel therapies for chronic lymphocytic leukemia in the 21st century." Seminars in Oncology. Vol. 27, no. 5. (January 2000.): 587-597.

Byrd JC; Grever, Michael R.; Waselenko, Jamie K.; Willis, Carl R.; Park, Kathy; Goodrich, Amy; Lucas, Margaret A.; Shinn, Charlotte; Flinn, Ian W.. "Theophylline, pentostatin (nipent), and chlorambucil: A dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders." Seminars in Oncology. Vol. 27, no. 2 Suppl. 5. (January 2000.): 37-40.

Byrd JC; Grever MR; Waselenko JK; Willis CR; Park K; Goodrich A; Lucas MA; Shinn C; Flinn IW. "Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.." Seminars in oncology. Vol. 27, no. 2 Suppl 5. (January 2000.): -.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger D, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Boststein D, Brown PO, Staudt LM. "Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling." Nature. Vol. 403, (January 2000.): 503-511.

Waselenko, Jamie K.; Grever, Michael R.; Beer, Mario; Lucas, Margaret A.; Byrd JC. "Pentostatin (nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia." Seminars in Oncology. Vol. 27, no. 2 Suppl. 5. (January 2000.): 44-51.

Waselenko, J, K; Grever, M, R; Beer, M; Lucas, M, A; Byrd JC. "Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.." Seminars in oncology. Vol. 27, no. 2 Suppl 5. (January 2000.): -.

Widhopf, George F.; Marathe, Chaitra M.; Rassenti, Laura Z.; Byrd JC; Flinn, Ian W.; Gribben, John G.; Kipps, Thomas J.. "Lack of correlation between immunoglobulin somatic mutation and expression of Cd38 in chronic lymphocytic leukemia." Blood. Vol. 96, no. 11 Part 1. (January 2000.): 367a-.

Patel, S, R; Wiese, W; Patel, S, C; Ohl, C; Byrd JC; Estrada, C A. "Systematic review of diagnostic tests for vaginal trichomoniasis.." Infectious diseases in obstetrics and gynecology. Vol. 8, no. 5-6. (January 2000.): -.

Goodwin, Thomas E.; Boylan, Carole J.; Current, William L.; Byrd JC; Edwards, Clint B.; Fuller, Danny A.; Green, Jennifer L.; Larocca, Christine D.; Raney, Kevin D.; Ross, Ashley S.; Tucker, W. Andrew. "Enhanced Pneumocystis carinii activity of new primaquine analogues." Bioorganic and Medicinal Chemistry Letters. Vol. 10, no. 19. (January 2000.): 2205-2208.

Murphy, Timothy J.; Shinn, Charlotte; Grever, Michael R.; Byrd JC. "Depsipeptide induces histone acetylation and promotes apoptosis in human acute myelogenous leukemia cells with the t(8;21)(q22;q22) translocation." Blood. Vol. 96, no. 11 Part 2. (January 2000.): 214b-.

Byrd JC; Rai KR. "What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?." Seminars in oncology. Vol. 27, no. 4. (January 2000.): -.

Byrd JC, Bannerji R, Perkins J. "New Treatment Approaches for Chronic Lymphocytic Leukemia." Oncology Review. (January 2000.): -.

Ales, Noel C.; Helman, Donald L.; Shorr, Andrew F.; Byrd JC. "Fludarabine associated pulmonary toxicity in chronic lymphoproliferative disorders: A case series." Blood. Vol. 96, no. 11 Part 1. (January 2000.): 756a-757a.

Waselenko, Jamie K.; Burrows, Ann; Lucas, Margaret; Ekstrand, John R.; Myhand, Rick; Lee, Nicole; Edenfield, William J.; Byrd JC. "Low dose recombinent interleukin 2 (ril-2) following high-dose chemotherapy (hdc) and autologous peripheral blood stem cell transplantation (pbsct) in patients with chronic lymphocytic leukemia (cll), mantle cell (mcl), and follicular lymphoma." Blood. Vol. 96, no. 11 Part 2. (January 2000.): 350b-.

Waselenko JK, Grever MR, Beer M, Byrd JC. "A Phase II Study of Chlorambucil and Pentostatin in B-cell Chronic Lymphocytic Leukemia." Seminars in Oncology. Vol. 27, (January 2000.): 44-51.

Flinn, Ian W.; Goodman, Steve; Post, Linda; Jamison, Janet; Miller, Carole B.; Gore, Steve; Diehl, Louis; Willis, Carl; Ambinder, Richard F.; Byrd JC. "Liposomal daunorubicin with cyclophosphamide, vincristine, and prednisone (cop-x) in advanced non-hodgkin's lymphoma." Cancer Investigation. Vol. 18, no. SUPPL. 1. (January 2000.): 15-16.

Venook AP, Egorin MJ, Rosner GI, Hollis D, Mani S, Hawkins M, Byrd JC, Hohl R, Budman D, Meropol NJ, Ratain MJ. "Phase I and Pharmacokinetic Trial of Gemcitabine in Patients with Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565." Journal of Clinical Oncology. Vol. 18, (January 2000.): 2780-2787.

Bannerji, Rajat; Byrd JC. "Update on the biology of chronic lymphocytic leukemia." Current Opinion in Oncology. Vol. 12, no. 1. (January 2000.): 22-29.

Porcu, Pierluigi; Farag, Sherif; Marcucci, Guido; Avalos, Belinda; Rhoades, Chris; Fisher, Beth; Byrd JC; Grever, Michael R.; Caligiuri, Michael A.. "Phase I trial of interleukin-2 (il-2) and rituximab in patients (pts) with relapsed or refractory B-cell lymphomas (r/r-bcl)." Blood. Vol. 98, no. 11 Part 2. (January 2001.): 245b-.

Byrd JC; Shinn, C; Willis, C, R; Flinn, I, W; Lehman, T; Sausville, E; Lucas, D; Grever, M R. "UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.." Experimental hematology. Vol. 29, no. 6. (January 2001.): -.

Byrd JC; Murphy, Timothy; Howard, Robin S.; Lucas, Margaret S.; Goodrich, Amy; Park, Kathy; Pearson, Michael; Waselenko, Jamie K.; Ling, Geoffrey; Grever, Michael R.; Grillo-Lopez, Antonio J.; Rosenberg, Jay; Kunkel, Lori; Flinn, Ian W.. "Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity." Journal of Clinical Oncology. Vol. 19, no. 8. (January 2001.): 2153-2164.

Byrd JC; Grever, Michael R.; Flinn, Ian W.; Waselenko, Jamie K.. "Combination therapy for lymphoproliferative diseases." Official Gazette of the United States Patent and Trademark Office Patents. Vol. 1252, no. 2. (January 2001.): -.

Waselenko, J, K; Shinn, C, A; Willis, C, R; Flinn, I, W; Grever, M, R; Byrd JC. "Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells.." Leukemia & lymphoma. Vol. 42, no. 5. (January 2001.): -.

Marcucci, Guido; Byrd JC; Cataland, Spero R.; Fisher, Diane B.; Lucas, David; Chan, Kenneth K.; Klisovic, Marko; Young, Donn C.; Didier, Lisa A.; Balcerzak, Stanley P.; Frankel, Stanley R.; Kraut, Eric H.; Bloomfield, Clara D.; Grever, Michael R.; Caligiuri, Michael A.. "Clinical and biological activity of Genasensetm (g3139, Genta, Inc.) (gs), a bcl-2 antisense, in refractory (ref) or relapsed (rel) acute leukemia (al): A phase I study." Blood. Vol. 98, no. 11 Part 2. (January 2001.): 216b-.

Maghraby, Eman A.; Murphy, Thimoty; Parthun, Mark R.; Klisovic, Marko; Sklenar, Amy; Archer, Kellie J.; Whitman, Susan; Grever, Michael R.; Caligiuri, Michael A.; Byrd JC; Marcucci, Guido. "Depsipeptide (fr901228) induces lysine-specific histone acetylation, differentiation and apoptosis in acute myeloid leukemia cells and demonstrates synergy with decitabine." Blood. Vol. 98, no. 11 Part 1. (January 2001.): 103a-104a.

Lucas, David M.; Baird, Maureen E.; Neuberg, Donna S.; Tallman, Martin S.; Flinn, Ian W.; Byrd JC; Grever, Michael R.. "Importance of culture conditions for in vitro chemosensitivity assessment in Chronic Lymphocytic Leukemia cells: Preliminary results from laboratory studies, Eastern Cooperative Oncology Group Study 2997." Blood. Vol. 98, no. 11 Part 2. (January 2001.): 284b-.

Bannerji, Rajat; Kitada, Shinichi; Flinn, Ian W.; Pearson, Michael; Lucas, David; Grever, Michael R.; Reed, John C.; Byrd JC. "Campath-1h antibody induces transmembrane signaling in vitro and in vivo in patients with chronic lymphocytic leukemia (cll) and promotes tumor clearance in part through caspase mediated apoptosis." Blood. Vol. 98, no. 11 Part 1. (January 2001.): 808a-.

Baird, Maureen E.; Lucas, David M.; Mone, Andrew P.; Waymer, Sharon; Warrell, Raymond P.; Byrd JC; Grever, Michael R.. "G3139 promotes release of Il-8 by chronic lymphocytic leukemia cells cultured in vitro: Potential implications for therapeutic use." Blood. Vol. 98, no. 11 Part 2. (January 2001.): 281b-.

Aron, Jennifer L.; Murphy, Timothy; Parthun, Mark R.; Bannerji, Rajat; Kanakry, Chris; Lucas, David; Flinn, Ian W.; Marcucci, Guido; Grever, Michael R.; Byrd JC. "The histone deacetylase inhibitor depsipeptide (fr901228) induces apoptosis via activation of the caspase 8 pathway concurrent with lysine specific acetylation in chronic lymphocytic leukemia cells." Blood. Vol. 98, no. 11 Part 1. (January 2001.): 807a-808a.

Drabick, Joseph J.; Davis, Brad J.; Byrd JC. "Concurrent pernicious anemia and myelodysplastic syndrome." Annals of Hematology. Vol. 80, no. 4. (January 2001.): 243-245.

Treon, Steven P.; Agus, David B.; Link, Brian; Rodrigues, Gilberto; Molina, Arturo; Lacy, Martha Q.; Fisher, David C.; Emmanouilides, Christos; Richards, Arthur I.; Clark, Bruce; Lucas, Marjorie S.; Schlossman, Robert; Schenkein, David; Lin, Boris; Kimby, Eva; Anderson, K. C.; Byrd JC. "Cd20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia." Journal of Immunotherapy. Vol. 24, no. 3. (January 2001.): 272-279.

Byrd JC; Shinn, Charlotte; Willis, Carl R.; Flinn, Ian W.; Lehman, Theresa; Sausville, Edward; Lucas, David; Grever, Michael R.. "Ucn-01 induces cytotoxicity toward human Cll cells through a p53-independent mechanism." Experimental Hematology (Charlottesville). Vol. 29, no. 6. (January 2001.): 703-708.

Byrd JC; Peterson, Bercedis; Piro, Lawrence; Saven, Alan; Vardiman, James W.; Larson, Richard A.; Schiffer, Charles A.. "Cladribine has clinical activity in patients with fludarabine refractory chronic lymphocytic leukemia who lack pre-treatment cytopenias: Results from Calgb study 9211." Blood. Vol. 98, no. 11 Part 1. (January 2001.): 634a-.

Byrd JC; Peterson, Bercedis L.; Park, Kathy; Morrison, Vicky L.; Vardiman, James W.; Jacobson, Robert; Rai, Kanti; Larson, Richard A.. "Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (cll) patients: Results from Calgb 9712." Blood. Vol. 98, no. 11 Part 1. (January 2001.): 772a-.

Byrd JC; Mrozek, Krzysztof; Dodge, Richard; Carroll, Andrew J.; Edwards, Colin; Pettenati, Mark J.; Patil, Shivanand R.; Larson, Richard A.; Bloomfield, Clara D.. "Pre-treatment cytogenetics predict initial induction success and overall survival in adult patients with de novo acute myeloid leukemia: Results from Calgb 8461." Blood. Vol. 98, no. 11 Part 1. (January 2001.): 457a-.

Byrd JC, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD. "Recent Gentic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B.: Acute Leukemias VIII Prognostic Factors and Treatment Stragegies." Springer-Verlag. (January 2001.): 449-456.

Ales, Noel; Flynn, Joseph; Byrd JC. "Novel presentation of acute myelogenous leukemia as symptomatic galactorrhea." Annals of Internal Medicine. Vol. 135, no. 4. (January 2001.): 303-304.

Ales, N; Flynn, J; Byrd JC. "Novel presentation of acute myelogenous leukemia as symptomatic galactorrhea.." Annals of internal medicine. Vol. 135, no. 4. (January 2001.): -.

Waselenko, Jamie K.; Grever, Michael R.; Shinn, Charlotte A.; Flinn, Ian W.; Byrd JC. "Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia." Leukemia Research. Vol. 25, no. 6. (January 2001.): 435-440.

Lucas, Margaret S.; Flinn, Ian W.; Goodrich, Amy L.; Murphy, Timothy; Park, Kathy; Grever, Michael R.; Lehman, Theresa; Byrd JC. "Tnf-alpha and Tnf-beta promoter polymorphisms may relate to response to rituximab therapy." Blood. Vol. 98, no. 11 Part 1. (January 2001.): 634a-.

Link, Brian K.; Wang, Hong; Byrd JC; Leonard, John P.; Davis, Thomas A.; Flinn, Ian; Hall, William C.; Turner, John F.; Bowles, Julie; Shannon, Mary; Levitt, Daniel; Weiner, George J.. "Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-hla-dr monoclonal antibody Remitogentm (hu1d10)." Blood. Vol. 98, no. 11 Part 2. (January 2001.): 244b-.

Link, Brian K.; Kahl, Brad; Czuczman, Myron; Powell, Bayard L.; Bartlett, Nancy; Leonard, John P.; Ansell, Stephan; Porcu, Perliuigi; Byrd JC; Lazarus, Hillard M.; Flinn, Ian; Jones, Gary J.; Levitt, Dan; Hall, William C.; Weiner, George J.. "A phase Ii study of Remitogentm (hu1d10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/malt B-cell lymphoma." Blood. Vol. 98, no. 11 Part 1. (January 2001.): 606a-.

Bloomfield CD, Farag SS, Mrozek K, Byrd JC, Dodge RK, Archer KJ, Whitman S, Larson RA, Carrol RJ, Caligiuri MA. "Cytogenetics for Treatment Stratification in Adult Acute Myeloid Leukemia (AML)." Annals of Hematology. (January 2001.): -.

Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards A, Clark B, Lucas MS, Schlossman R, Anderson KC, Byrd JC. "Serotherapy of Walderstrom’s macroglobulinemia." Journal of Immunotherapy. Vol. 24, (January 2001.): 272-279.

Rosenwald, Andreas; Alizadeh, Ash A.; Widhopf, George; Simon, Richard; Davis, R. Eric; Yu, Xin; Yang, Liming; Pickeral, Oxana K.; Rassenti, Laura Z.; Powell, John; Botstein, David; Byrd JC; Grever, Michael R.; Cheson, Bruce D.; Chiorazzi, Nicholas; Wilson, Wyndham H.; Kipps, Thomas J.; Brown, Patrick O.; Staudt, Louis M.. "Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia." Journal of Experimental Medicine. Vol. 194, no. 11. (January 2001.): 1639-1647.

Cataland, Spero R.; Lucas, Margaret; Byrd JC. "Antibody therapy of acute and chronic leukemias." Current Pharmaceutical Biotechnology. Vol. 2, no. 4. (January 2001.): 357-367.

Sooraj, Lakshmi Narayan; Marcucci, Guido; Byrd JC; Bruner, Rebecca J.; Fischer, Beth; Hatton, Patty; Grever, Michael R.; Binkley, Philip F.. "Cardiovascular Response to Depsipeptide: Absence of Cardiotoxicity in Human Recipients.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 4421-.

Lin, Thomas S.; Flinn, Ian W.; Lucas, Margaret S.; Sickler, Jennifer; Moran, Mollie E.; Porcu, Pierluigi; Lucas, David M.; Grever, Michael R.; Byrd JC. "Filgrastim and Alemtuzumab (campath-1h) for Refractory Chronic Lymphocytic Leukemia: High Frequency of Cytomegalovirus Disease and Delayed Neutropenia.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 3168-.

Lin, Thomas S.; Elder, Patrick J.; Penza, Sam L.; Avalos, Belinda R.; Farag, Sherif S.; Molina, Arthur; Mrozek, Ewa; Belt, Patti S.; Porcu, Pierluigi; Marcucci, Guido; Byrd JC; Copelan, Edward A.. "Autologous Stem Cell Transplants Result in Better 5-year Overall, but Not Progression-free, Survival Than Allogeneic Transplants in Patients with Indolent Non-hodgkin's Lymphoma.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 2536-.

Perkins, Jeremy G.; Flynn, Joseph M.; Howard, Robin S.; Byrd JC. "Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: Implications for clinical trials in this patient population." Cancer. Vol. 94, no. 7. (January 2002.): 2033-2039.

Mone, Andrew P.; Lucas, David; Aron, Jennifer; Cheney, Carolyn; Johnson, Amy; Bains, Suneet K.; Tso, J. Y.; Weiner, George; Green, Jennifer; Grever, Michael; Byrd JC. "Hu1d10 Induces Parallel Death and Survival Signals in Chronic Lymphocytic Leukemia (cll) Cells: Justification for Combination Studies of Hu1d10 with Pi3 Kinase Inhibitors.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 1496-.

Marcucci, Guido; Stock, Wendy; Klisovic, Marko I.; Guimond, Martin; Sher, Dorie A.; Moran, Mollie; Zwiebel, James A.; Cataland, Spero R.; Kefauver, Cheryl; Chan, Kenneth K.; Frankel, Stanley R.; Grever, Michael R.; Byrd JC. "In Vivo Activity of Genasensetm (g3139) (gs), a Bcl-2 Antisense Oligonucleotide in Previously Untreated Patients (pts) >60 Years with Acute Myeloid Leukemia (aml): Initial Report of a Phase I Study in Combination with Daunorubicin and." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 1307-.

Marcucci, Guido; Bruner, Rebecca J.; Binkley, Philip F.; Xiao, Jim; Chan, Kenneth K.; Parthun, Mark; Davis, Melanie; Fischer, Beth; Shank, Roshini; Moran, Mollie; Byrd JC; Grever, Michael. "Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (fr901228) in Acute Myeloid Leukemia (aml).." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 317-.

Lucas, David M.; Parthun, Mark R.; Mojica, Ronald D.; Mone, Andrew P.; Byrd JC; Grever, Michael R.. "Ms-275 reduces viability and induces changes in histone acetylation in cells from patients with B-cell chronic lymphocytic leukemia (b-cll)." Proceedings of the American Association for Cancer Research Annual Meeting. Vol. 43, (January 2002.): 69-.

Lucas, David M.; Davis, Melanie; Parthun, Mark R.; Mojica, Ron C.; Mone, Andrew P.; Zwiesler, Julie; Byrd JC; Grever, Michael R.. "Ms-275 Promotes Apoptosis in Cells from Patients with B-cell Chronic Lymphocytic Leukemia (b-cll) Concurrent with Inhibition of Histone Deactylase.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 1500-.

Lucas, David M.; Baird, Maureen E.; Byrd JC; Tschumper, Renee C.; Jelinek, Diane F.; Kitada, Shinichi; Reed, John C.; Rosenwald, Andreas; Staudt, Louis M.; Neuberg, Donna S.; Tallman, Martin S.; Flinn, Ian W.; Grever, Michael R.. "Zap70 and Caspase-3 Protein Expression Independently Associate with Immunoglobulin Vh Gene Mutational Status in Patients with B-cell Chronic Lymphocytic Leukemia (b-cll).." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 1478-.

Lin, Thomas S.; Stock, Wendy; Lucas, Margaret S.; Porcu, Pierluigi; Abhyankar, Vivek V.; Jefferson, Sara K.; Briggs, Bruce; Wang, Hong; Cheney, Carolyn; Flinn, Ian W.; Grever, Michael R.; Dalton, James T.; Byrd JC. "A Phase I Dose Escalation Study of Apolizumab (hu1d10) Using a Stepped Up Dosing Schedule in Patients with Chronic Lymphocytic Leukemia (cll) and Acute Lymphocytic Leukemia (all).." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 3167-.

Lin, Thomas S.; Molina, Arthur; Penza, Sam L.; Farag, Sherif S.; Avalos, Belinda R.; Grever, Michael R.; Copelan, Edward A.; Byrd JC. "Diffuse Alveolar Hemorrhage in Patients Undergoing Non-myeloablative Allogeneic Stem Cell Transplantation after Prior Autologous / Syngeneic Transplantation.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 5300-.

Drabick, J, J; Davis, B, J; Lichy, J, H; Flynn, J; Byrd JC. "Human herpesvirus 8 genome is not found in whole bone marrow core biopsy specimens of patients with plasma cell dyscrasias.." Annals of hematology. Vol. 81, no. 6. (January 2002.): -.

Kay, Neil, E; Hamblin, Terry, J; Jelinek, Diane, F; Dewald, Gordon, W; Byrd JC; Farag, Sherif; Lucas, Margaret; Lin, Thomas. "Chronic lymphocytic leukemia.." Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. (January 2002.): 193-213.

Byrd JC; Kitada, Shinichi; Flinn, Ian, W; Aron, Jennifer, L; Pearson, Michael; Lucas, David; Reed, John C. "The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.." Blood. Vol. 99, no. 3. (January 2002.): 1038-43.

Bruner, Rebecca J.; Marcucci, Guido; Binkley, Philip; Xiao, Jim; Chan, Kenneth; Parthun, Mark; Davis, Melanie; Fischer, Beth; Shank, Roshini; Moran, Mollie; Grever, Michael; Byrd JC. "Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (fr901228) in Fludarabine Refractory Chronic Lymphocytic Leukemia.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 1492-.

Keating, Michael, J; Flinn, Ian; Jain, Vinay; Binet, Jacques-Louis; Hillmen, Peter; Byrd JC; Albitar, Maher; Brettman, Lee; Santabarbara, Pedro; Wacker, Bret; Rai, Kanti R. "Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.." Blood. Vol. 99, no. 10. (January 2002.): 3554-61.

Helman, Donald L Jr; Byrd JC; Ales, Noel, C; Shorr, Andrew F. "Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.." Chest. Vol. 122, no. 3. (January 2002.): 785-90.

Heinrich, Michael C.; Druker, Brian J.; Curtin, Peter T.; Paquette, Ronald; Sawyers, Charles L.; De Angelo, Daniel J.; Gilliland, Gary D.; Stone, Richard M.; Caliguiri, Michael A.; Byrd JC; Heaney, Mark L.; Nimer, Stephen D.; Romanko, Kevin P.; Lambing, Joe L.; Lokker, Nathalie A.; Giese, Neill A.; Gretler, Daniel D.. "A "first in Man" Study of the Safety and Pk/pd of an Oral Flt3 Inhibitor (mln518) in Patients with Aml or High Risk Myelodysplasia.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 1305-.

Daniels, Jasmine T.; Perkins, Jeremy G.; Byrd JC. "Rituximab Is Effective for Patients with Splenic Lymphoma with Villous Lymphocytes.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 4793-.

Smith, Lisa L.; Heerema, Nyla; Hackbarth, Marcy L.; Flinn, Ian W.; Young, Donn; Proffitt, John H.; Byrd JC. "Interphase Cytogenetics Are Predictive of Chronic Lymphocytic Leukemia (cll) Response to Thrice Weekly Rituximab Therapy.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 2147-.

Reed, John, C; Kitada, Shinichi; Kim, Youngsoo; Byrd JC. "Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers.." Seminars in oncology. Vol. 29, no. 1 Suppl 2. (January 2002.): 10-24.

Kitada, Shinichi; Young, Donn; Pearson, Michael; Flinn, Ian W.; Shinn, Charlotte A.; Reed, John C.; Byrd JC. "Mcl-1/bax Ratio Is a Predictor for Outcome of Rituximab Therapy in Patients with Cll.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 1466-.

Byrd JC; Mrozek, Krzysztof; Dodge, Richard K.; Carroll, Andrew J.; Edwards, Colin G.; Arthur, Diane C.; Pettenati, Mark J.; Patil, Shivanand R.; Rao, Kathleen W.; Watson, Michael S.; Koduru, Prasad R. K.; Moore, Joseph O.; Stone, Richard M.; Mayer, Robert J.; Feldman, Eric J.; Davey, Frederick R.; Schiffer, Charles A.; Larson, Richard A.; Bloomfield, Clara D.. "Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (calgb 8461).." Blood. Vol. 100, no. 13. (January 2002.): 4325-4336.

Byrd JC. "Clonal lymphocytosis of uncertain significance (CLUS): What clues will CLUS yield?." Blood. Vol. 100, (January 2002.): 227-.

Byrd JC. "BAFF and related proteins: a new therapeutic target for B-cell malignancies." Blood. Vol. 100, (January 2002.): 227-.

Raval, Aparna; Rush, Laura J.; Funchain, Pauline; Flak, Erin; Davis, Melanie; Johnson, Amy J.; Byrd JC; Plass, Christoph. "Aberrant Dna Methylation in Chronic Lymphocytic Leukemia: A Role in Pathogenesis?." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 1469-.

Rai, Kanti R.; Byrd JC; Peterson, Bercedis L.; Larson, Richard A.. "A Phase Ii Trial of Fludarabine Followed by Alemtuzumab (campath-1h) in Previously Untreated Chronic Lymphocytic Leukemia (cll) Patients with Active Disease: Cancer and Leukemia Group B (calgb) Study 19901.." Blood. Vol. 100, no. 11. (January 2002.): Abstract No. 772-.

Marcucci, Guido; Dai, Guowei; Klisovic, Marko I.; Shen, Tiasheng; Liu, Shujun; Sher, Dorie A.; Lucas, David; Whitman, Susan P.; Vukosavljevic, Tamara; Zwiebel, James A.; Frankel, Stanley R.; Grever, Michael R.; Stock, Wendy; Chan, Kenneth K.; Byrd JC. "Pharmacologic and biologic assessment of Genasensetm (gns, oblimersen sodium), a pro-apoptotic to Bcl-2 oligonucleotide, in combination with daunorubicin and cytarabine: A phase I study in previously untreated elderly acute myeloid leukemia (aml).." Blood. Vol. 102, no. 11. (January 2003.): 874a-.

Marcucci, Guido; Byrd JC; Dai, Guowei; Klisovic, Marko, I; Kourlas, Peter, J; Young, Donn, C; Cataland, Spero, R; Fisher, Diane, B; Lucas, David; Chan, Kenneth, K; Porcu, Pierluigi; Lin, Zhong-Pin; Farag, Sherif, F; Frankel, Stanley, R; Zwiebel, James, A; Kraut, Eric, H; Balcerzak, Stanley, P; Bloomfield, Clara, D; Grever, Michael, R; Caligiuri, Michael A. "Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.." Blood. Vol. 101, no. 2. (January 2003.): 425-32.

Marcucci, Guido; Byrd JC; Dai, Guowei; Klisovic, Marko I.; Kourlas, Peter J.; Young, Donn C.; Cataland, Spero R.; Fisher, Diane B.; Lucas, David; Chan, Kenneth K.; Porcu, Pierluigi; Lin, Zhong-Pin; Farag, Sherif F.; Frankel, Stanley R.; Zwiebel, James A.; Kraut, Eric H.; Balcerzak, Stanley P.; Bloomfield, Clara D.; Grever, Michael R.; Caligiuri, Michael A.. "Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.." Blood. Vol. 101, no. 2. (January 2003.): 425-432.

Lucas, David M.; Zhang, Liwen; Freitas, Michael A.; Wickham, Joseph; Parthun, Mark R.; Davis, Melanie E.; Marcucci, Guido; Byrd JC; Grever, Michael R.. "Ms-275 mediated apoptosis and generation of reactive oxygen species are caspase dependent in B-cell chronic lymphocytic leukemia (cll).." Blood. Vol. 102, no. 11. (January 2003.): 431a-.

Klisovic, M, I; Maghraby, E, A; Parthun, M, R; Guimond, M; Sklenar, A, R; Whitman, S, P; Chan, K, K; Murphy, T; Anon, J; Archer, K, J; Rush, L, J; Plass, C; Grever, M, R; Byrd JC; Marcucci, G. "Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. Vol. 17, no. 2. (January 2003.): -.

Byrd JC; Smith, Lisa; Hackbarth, Marcy, L; Flinn, Ian, W; Young, Donn; Proffitt, John, H; Heerema, Nyla A. "Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.." Cancer research. Vol. 63, no. 1. (January 2003.): 36-8.

Byrd JC; Smith, Lisa; Hackbarth, Marcy L.; Flinn, Ian W.; Young, Donn; Proffitt, John H.; Heerema, Nyla A.. "Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.." Cancer Research. Vol. 63, no. 1. (January 2003.): 36-38.

Byrd JC; Lucas, David, M; Mone, Andrew, P; Kitner, Joshua, B; Drabick, Joseph, J; Grever, Michael R. "KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.." Blood. Vol. 101, no. 11. (January 2003.): 4547-50.

Byrd JC; Lucas, David M.; Mone, Andrew P.; Kitner, Joshua B.; Drabick, Joseph J.; Grever, Michael R.. "Krn5500: A novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.." Blood. Vol. 101, no. 11. (January 2003.): 4547-4550.

Blum, William G.; Bolwell, Brian J.; Farag, Sherif S.; Lin, Thomas S.; Avalos, Belinda R.; Penza, Sam L.; Marcucci, Guido; Byrd JC; Kalaycio, Matt E.; Sobecks, Ronald M.; Pohlman, Brad; Brown, Stacey; Elder, Patrick J.; Copelan, Edward A.. "Only those refractory Aml patients with low disease burden can achieve prolonged leukemia-free survival with conventional unrelated donor transplantation.." Blood. Vol. 102, no. 11. (January 2003.): 488a-.

Aron, Jennifer, L; Parthun, Mark, R; Marcucci, Guido; Kitada, Shinichi; Mone, Andrew, P; Davis, Melanie, E; Shen, Tiansheng; Murphy, Timothy; Wickham, Joseph; Kanakry, Chris; Lucas, David, M; Reed, John, C; Grever, Michael, R; Byrd JC. "Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.." Blood. Vol. 102, no. 2. (January 2003.): 652-8.

Pavletic, Steven Z.; Bociek, R. Gregory; Foran, James M.; Rubocki, Ronald J.; Kuszynski, Charles A.; Wisecarver, James L.; Hatcher, Lori; Lucas, David M.; Byrd JC; Grever, Michael R.; Joshi, Shantaram S.; Hardiman, Penny; Smith, Lynette M.; McGuire, Timothy R.; Bierman, Philip J.; Vose, Julie M.; Armitage, James O.; Talmadge, James E.. "Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation.." Transplantation (Hagerstown). Vol. 76, no. 5. (January 2003.): 877-881.

Farag, Sherif S.; Flinn, Ian W.; Lehman, Tesresa; Modali, Rama; Byrd JC. "Fcgammariiia and Fcgammariia polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.." Blood. Vol. 102, no. 11. (January 2003.): 675a-.

Eisenbeis, Charles, F; Caligiuri, Michael, A; Byrd JC. "Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?." Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 9, no. 16 Pt 1. (January 2003.): 5810-2.

Xiao, Jim, J; Byrd JC; Marcucci, Guido; Grever, Michael; Chan, Kenneth K. "Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood.." Rapid communications in mass spectrometry : RCM. Vol. 17, no. 8. (January 2003.): 757-66.

Weber, Donna; Treon, Steven P.; Emmanouilides, Christos; Branagan, Andrew R.; Byrd JC; Blade, Joan; Kimby, Eva. "Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.." Seminars in Oncology. Vol. 30, no. 2. (January 2003.): 127-131.

Kay, Neil E.; Lin, Thomas; Call, Timothy; Jelinek, Diane F.; Bone, Nancy D.; Dewald, Gordon W.; Heerema, Nyla A.; Tschumper, Renee; Smith, Lisa; Geyer, Susan M.; Byrd JC. "Pentostatin combination therapy for untreated B-chronic Lymphocytic Leukemia.." Blood. Vol. 102, no. 11. (January 2003.): 676a-.

Kasamon, Yvette L.; Byrd JC; Grever, Michael R.; Diehl, Louis F.; Lucas, Margaret S.; Garrett, Elizabeth S.; Flinn, Ian W.. "Il-2 does not protect against fludarabine and cyclophosphamide induced immunosuppression.." Blood. Vol. 102, no. 11. (January 2003.): 637a-.

Byrd JC; Rai, Kanti R.; Peterson, Bercedis L.; Appelbaum, Frederick R.; Morrison, Vicki A.; Kolitz, Jonathan E.; Shepherd, Lois; Hines, John D.; Schiffer, Charles A.; Larson, Richard A.. "The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (cll) patients.." Blood. Vol. 102, no. 11. (January 2003.): 73a-.

Byrd JC; Peterson, Bercedis L.; Morrison, Vicki A.; Park, Kathleen; Jacobson, Robert; Hoke, Eva; Vardiman, James W.; Rai, Kanti; Schiffer, Charles A.; Larson, Richard A.. "Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (calgb 9712).." Blood. Vol. 101, no. 1. (January 2003.): 6-14.

Byrd JC; Peterson, B; Piro, L; Saven, A; Vardiman, J, W; Larson, R, A; Schiffer, C. "A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. Vol. 17, no. 2. (January 2003.): -.

Byrd JC; O'Brien, Susan; Flinn, Ian; Kipps, Thomas J.; Weiss, Mark A.; Reid, Jennifer; Wynne, Dee; Leigh, Bryan R.. "Interim results from a phase I study of lumiliximab (idec-152, anti-cd23 antibody) therapy for relapsed or refractory Cll.." Blood. Vol. 102, no. 11. (January 2003.): 74a-.

Byrd JC, Peterson B, Lawrence P, Saven A, Vardiman J, Larson R, Schiffer C. "A Phase II Study of Cladribine Treatment for Fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 9211." Leukemia. Vol. 17, (January 2003.): 323-327.

Byrd JC. "Antibody therapy in chronic lymphocytic leukemia." Clinical Advances in Hematology Oncology. Vol. 2, (January 2003.): 89-90.

Bannerji, Rajat; Kitada, Shinichi; Flinn, Ian, W; Pearson, Michael; Young, Donn; Reed, John, C; Byrd JC. "Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 21, no. 8. (January 2003.): 1466-71.

Bains, S, K; Mone, A; Yun Tso, J; Lucas, D; Byrd JC; Weiner, G, J; Green, J M. "Mitochondria control of cell death induced by anti-HLA-DR antibodies.." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. Vol. 17, no. 7. (January 2003.): -.

Johnson, Amy J.; Eisenbeis, Charles F.; Cheney, Carolyn M.; Mone, Andrew P.; Lucas, David M.; Byrd JC. "Rituximab and 17-aag synergistically induce apoptosis in B-cell chronic lymphocytic leukemia (cll).." Blood. Vol. 102, no. 11. (January 2003.): 437a-438a.

Grever, Michael R.; Dewald, Gordon W.; Lucas, David M.; Neuberg, Donna S.; Baird, Maureen E.; Paternoster, Sarah F.; Brockman, Stephanie R.; Lozanski, Gerard; Rizouli, Vassiliki; Gribben, John G.; Flinn, Ian W.; Tallman, Martin S.; Kitada, Shinichi; Reed, John C.; Staudt, Louis M.; Paietta, Elisabeth; Byrd JC. "Zap-70 protein expression varies by interphase cytogenetic group and may predict disease progression to requirement of treatment among select genetic groups in patients with chronic lymphocytic leukemia (cll).." Blood. Vol. 102, no. 11. (January 2003.): 73a-.

Rassenti, Laura Z.; Toy, Traci L.; Huynh, Lang; Greaves, Andrew; Gribben, John G.; Keating, Michael J.; Rai, Kanti R.; Flinn, Ian W.; Byrd JC; Kay, Neil E.; Goldin, Lynn R.; Caporaso, Neil E.; Kipps, Thomas J.. "High similarity between familial and sporadic cases of chronic lymphocytic leukemia.." Blood. Vol. 102, no. 11. (January 2003.): 670a-.

Rassenti, Laura Z.; Huynh, Lang; Toy, Traci L.; Gribben, John G.; Keating, Michael J.; Rai, Kanti R.; Flinn, Ian W.; Byrd JC; Kay, Neil E.; Greaves, Andrew; Weiss, Arthur; Kipps, Thomas J.. "Zap-70 is a more reliable marker of disease progression risk than immunoglobulin mutation status in chronic lymphocytic leukemia.." Blood. Vol. 102, no. 11. (January 2003.): 34a-.

Rai, Kanti R.; Byrd JC; Peterson, Bercedis; Gautier, Marc; Larson, Richard A.. "Subcutaneous alemtuzumab following fludarbine for previously untreated patients with chronic lymphocytic leukemia (cll): Calgb Study 19901.." Blood. Vol. 102, no. 11. (January 2003.): 676a-677a.

Castagna L, Sarina B, Santoro A, Byrd JC, Rai K, Larson RA. "Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia." Blood. Vol. 102, (January 2003.): 2309-2310.

Morrison, Vicki A.; Byrd JC; Peterson, Bercedis L.; Rai, Kanti R.; Larson, Richard A.. "Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (cll) does not increase the risk of infection: Cancer and leukemia group B (calgb) study 9712.." Blood. Vol. 102, no. 11. (January 2003.): 440a-.

Mone, Andrew P.; Cheney, Carolyn; Huang, Peng; Pelicano, Helene; Green, Jennifer; Tso, J. Yun; Johnson, Amy; Byrd JC. "Hu1d10 activates both death and survival pathways in primary human chronic lymphocytic leukemia cells: Hu1d10 induced reactive oxygen species activate the Akt survival pathway.." Blood. Vol. 102, no. 11. (January 2003.): 438a-.

Mone, Andrew P.; Cheney, Carolyn M.; Lin, Thomas S.; Jefferson, Sara; Byrd JC. "Campath-1h induces caspase-independent apoptosis in primary human chronic lymphocytic leukemia cells through a cytoskeletal dependent mechanism.." Blood. Vol. 102, no. 11. (January 2003.): 436a-.

List, Alan F.; Byrd JC; Fenaux, Pierre; Gore, Steven D.; Hellstrom-Lindberg, Eva; Mufti, Ghulam J.; Seymour, John F.; Silverman, Lewis R.; Zimmerman, Linda S.; Beach, C. L.. "Comparative trial of azacitidine versus conventional care in high risk Mds patients: Methodologic challenges in designing an international survival Trial.." Blood. Vol. 102, no. 11. (January 2003.): 333b-334b.

Lin, Thomas, S; Lucas, Margaret, S; Byrd, John C. "Rituximab in B-cell chronic lymphocytic leukemia.." Seminars in oncology. Vol. 30, no. 4. (January 2003.): 483-92.

Lin, Thomas S.; Lucas, Margaret S.; Byrd JC. "Rituximab in B-cell chronic lymphocytic leukemia.." Seminars in Oncology. Vol. 30, no. 4. (January 2003.): 483-492.

Johnson, Amy, J; Mone, Andrew, P; Abhyankar, Vivek; Byrd JC. "Advances in the therapy of chronic lymphocytic leukemia.." Current opinion in hematology. Vol. 10, no. 4. (January 2003.): 297-305.

Venook AP, Klein, CE, Fleming G, Hollis D, Leicham CG, Hohl R, Byrd JC, Budman D, Villalona M, Marshall J, Rosner GL, Ramierz J, Kastrissios H, Ratian MJ. "A Phase I and Pharmacokinetic Study of Irinotecan in Patients with Hepatic or Renal Dysfunction or With Prior Pelvic Radiation: CALGB 9863." Annals of Oncology. Vol. 14, (January 2003.): 1783-1790.

Marcucci, G; Stock, W; Dai, G; Klisovic, M, I; Maharry, K; Shen, T; Liu, S; Sher, D, A; Lucas, D; Zwiebel, A; Larson, R, A; Caligiuri, M, A; Bloomfield, C, D; Chan, K, K; Grever, M, R; Byrd JC. "G3139, a BCL-2 antisense oligo-nucleotide, in AML.." Annals of Hematology. Vol. 83 Suppl 1, (January 2004.): -.

Lucas, D, M; Davis, M, E; Parthun, M, R; Mone, A, P; Kitada, S; Cunningham, K, D; Flax, E, L; Wickham, J; Reed, J, C; Byrd JC; Grever, M R. "The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. Vol. 18, no. 7. (January 2004.): -.

Lu, Qiang; Yang, Ya-Ting; Chen, Chang-Shi; Davis, Melanie; Byrd JC; Etherton, Mark R.; Umar, Asad; Chen, Ching-Shih. "Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors.." Journal of Medicinal Chemistry. Vol. 47, no. 2. (January 2004.): 467-474.

Lozanski, Gerard; Heerema, Nyla A.; Flinn, Ian W.; Smith, Lisa; Harbison, Jennifer; Webb, Jennifer; Moran, Mollie; Lucas, Margaret; Lin, Thomas; Hackbarth, Marcy L.; Proffitt, John H.; Lucas, David; Grever, Michael R.; Byrd JC. "Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions." Blood. Vol. 103, no. 9. (January 2004.): 3278-3281.

Lin, Thomas, S; Moran, Mollie; Lucas, Margaret; Waymer, Sharon; Jefferson, Sara; Fischer, Diane, B; Grever, Michael, R; Byrd JC. "Antibody therapy for chronic lymphocytic leukemia: a promising new modality.." Hematology/oncology clinics of North America. Vol. 18, no. 4. (January 2004.): 895-913, ix.

Farag, Sherif, S; Flinn, Ian, W; Modali, Rama; Lehman, Teresa, A; Young, Donn; Byrd JC. "Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.." Blood. Vol. 103, no. 4. (January 2004.): 1472-4.

Eisenbeis, Charles, F; Grainger, Andrew; Fischer, Beth; Baiocchi, Robert, A; Carrodeguas, Lester; Roychowdhury, Sameek; Chen, Lei; Banks, Amy, L; Davis, Thomas; Young, Donn; Kelbick, Nicole; Stephens, Julie; Byrd JC; Grever, Michael, R; Caligiuri, Michael, A; Porcu, Pierluigi. "Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.." Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 10, no. 18 Pt 1. (January 2004.): 6101-10.

Zhang, Liwen; Freitas, Michael, A; Wickham, Joseph; Parthun, Mark, R; Klisovic, Marko, I; Marcucci, Guido; Byrd JC. "Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry.." Journal of the American Society for Mass Spectrometry. Vol. 15, no. 1. (January 2004.): 77-86.

Mone, Andrew P.; Huang, Peng; Pelicano, Helene; Cheney, Carolyn M.; Green, Jennifer M.; Tso, J. Yun; Johnson, Amy J.; Jefferson, Sara; Lin, Thomas S.; Byrd JC. "Hu1d10 induces apoptosis concurrent with activation of the Akt survival pathway in human chronic lymphocytic leukemia cells.." Blood. Vol. 103, no. 5. (January 2004.): 1846-1854.

Rush, Laura J.; Raval, Aparna; Funchain, Pauline; Johnson, Amy J.; Smith, Lisa; Lucas, David M.; Bembea, Melania; Liu, Te-Hui; Heerema, Nyla A.; Rassenti, Laura; Liyanarachchi, Sandya; Davuluri, Ramana; Byrd JC; Plass, Christoph. "Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets." Cancer Research. Vol. 64, no. 7. (January 2004.): 2424-2433.

Blum, Kristie A.; Lozanski, Gerard; Byrd JC. "Adult Burkitt leukemia and lymphoma." Blood. Vol. 104, no. 10. (January 2004.): 3009-3020.

Keating, Michael; Coutre, Stephen; Rai, Kanti; Osterborg, Anders; Faderl, Stefan; Kennedy, Ben; Kipps, Tom; Bodey, Gerald; Byrd JC; Rosen, Steven; Dearden, Claire; Dyer, Martin J, S; Hillmen, Peter. "Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia.." Clinical lymphoma. Vol. 4, no. 4. (January 2004.): 220-7.

Lin, Thomas, S; Byrd JC. "Monoclonal antibody therapy in lymphoid leukemias.." Advances in pharmacology. Vol. 51, (January 2004.): 127-67.

Lin, Thomas S.; Moran, Mollie; Lucas, Margaret; Waymer, Sharon; Jefferson, Sara; Fischer, Diane B.; Grever, Michael R.; Byrd JC. "Antibody therapy for chronic lymphocytic leukemia: a promising new modality." Hematology-Oncology Clinics of North America. Vol. 18, no. 4. (January 2004.): 895-913, IX, X, XI.

Byrd JC; Stilgenbauer, Stephan; Flinn, Ian W. "Chronic lymphocytic leukemia.." Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. (January 2004.): 163-83.

Byrd JC; Ruppert, Amy, S; Mrozek, Krzysztof; Carroll, Andrew, J; Edwards, Colin, G; Arthur, Diane, C; Pettenati, Mark, J; Stamberg, Judith; Koduru, Prasad R, K; Moore, Joseph, O; Mayer, Robert, J; Davey, Frederick, R; Larson, Richard, A; Bloomfield, Clara D. "Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 22, no. 6. (January 2004.): 1087-94.

Byrd JC. "All B cells are not the same: a story o fCD40 activation." Blood. Vol. 104, (January 2004.): 3847-.

Rassenti, Laura Z.; Huynh, Lang; Toy, Tracy L.; Chen, Liguang; Keating, Michael J.; Gribben, John G.; Neuberg, Donna S.; Flinn, Ian W.; Rai, Kanti R.; Byrd JC; Kay, Neil E.; Greaves, Andrew; Weiss, Arthur; Kipps, Thomas J.. "Zap-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia." New England Journal of Medicine. Vol. 351, no. 9. (January 2004.): 893-901.

Magro, Cynthia, M; Crowson, A Neil; Byrd JC; Soleymani, A David; Shendrik, Igor. "Atypical lymphocytic lobular panniculitis.." Journal of cutaneous pathology. Vol. 31, no. 4. (January 2004.): 300-6.

Bloomfield, C, D; Ruppert, A, S; Mrozek, K; Kolitz, J, E; Moore, J, O; Mayer, R, J; Edwards, C, G; Sterling, L, J; Vardiman, J, W; Carroll, A, J; Pettenati, M, J; Stamberg, J; Byrd JC; Marcucci, G; Larson, R, A; Larson, R A. "Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.." Annals of hematology. Vol. 83 Suppl 1, (January 2004.): -.

Xiao, Jim, J; Huang, Ying; Dai, Zunyan; Sadee, Wolfgang; Chen, Jiyun; Liu, Shujun; Marcucci, Guido; Byrd JC; Covey, Joseph, M; Wright, John; Grever, Michael; Chan, Kenneth K. "Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.." The Journal of pharmacology and experimental therapeutics. Vol. 314, no. 1. (January 2005.): 467-75.

Xiao, Jim, J; Foraker, Amy, B; Swaan, Peter, W; Liu, Shujun; Huang, Ying; Dai, Zunyan; Chen, Jiyun; Sadee, Wolfgang; Byrd JC; Marcucci, Guido; Chan, Kenneth K. "Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.." The Journal of pharmacology and experimental therapeutics. Vol. 313, no. 1. (January 2005.): 268-76.

Raval, Aparna; Lucas, David, M; Matkovic, Jennifer, J; Bennett, Kristi, L; Liyanarachchi, Sandya; Young, Donn, C; Rassenti, Laura; Kipps, Thomas, J; Grever, Michael, R; Byrd JC; Plass, Christoph. "TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 23, no. 17. (January 2005.): 3877-85.

Johnson, Amy J.; Smith, Lisa L.; Zhu, Jiuxiang; Heerema, Nyla A.; Jefferson, Sara; Mone, Andrew; Grever, Michael; Chen, Ching-Shih; Byrd JC. "A novel celecoxib derivative, Osu03012, induces cytotoxicity in primary Cll cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism." Blood. Vol. 105, no. 6. (January 2005.): 2504-2509.

Bolanos-Meade, Javier; Jacobsohn, David, A; Margolis, Jeffrey; Ogden, Adam; Wientjes, M Guillaume; Byrd JC; Lucas, David, M; Anders, Viki; Phelps, Michele; Grever, Michael, R; Vogelsang, Georgia B. "Pentostatin in steroid-refractory acute graft-versus-host disease.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 23, no. 12. (January 2005.): 2661-8.

Liu, Shujun; Shen, Tiansheng; Huynh, Lenguyen; Klisovic, Marko, I; Rush, Laura, J; Ford, Jamie, L; Yu, Jianhua; Becknell, Brian; Li, Yu; Liu, Chunhui; Vukosavljevic, Tamara; Whitman, Susan, P; Chang, Kun-Sang; Byrd JC; Perrotti, Danilo; Plass, Christoph; Marcucci, Guido. "Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.." Cancer research. Vol. 65, no. 4. (January 2005.): 1277-84.

Lin, Thomas, S; Grever, Michael, R; Byrd JC. "Changing the way we think about chronic lymphocytic leukemia.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 23, no. 18. (January 2005.): 4009-12.

Lin, Thomas, S; Flinn, Ian, W; Modali, Rama; Lehman, Teresa, A; Webb, Jennifer; Waymer, Sharon; Moran, Mollie, E; Lucas, Margaret, S; Farag, Sherif, S; Byrd JC. "FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.." Blood. Vol. 105, no. 1. (January 2005.): 289-91.

Lin, T, S; Penza, S, L; Avalos, B, R; Lucarelli, M, R; Farag, S, S; Byrd JC; Copelan, E A. "Diffuse alveolar hemorrhage following gemtuzumab ozogamicin.." Bone marrow transplantation. Vol. 35, no. 8. (January 2005.): -.

Lin, T, S; Flinn, I, W; Lucas, M, S; Porcu, P; Sickler, J; Moran, M, E; Lucas, D, M; Heerema, N, A; Grever, M, R; Byrd JC. "Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. Vol. 19, no. 7. (January 2005.): -.

Dai, Guowei; Chan, Kenneth, K; Liu, Shujun; Hoyt, Dale; Whitman, Susan; Klisovic, Marko; Shen, Tiansheng; Caligiuri, Michael, A; Byrd JC; Grever, Michael; Marcucci, Guido. "Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.." Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 11, no. 8. (January 2005.): 2998-3008.

Byrd JC; Peterson, Bercedis, L; Gabrilove, Janice; Odenike, Olatoyosi, M; Grever, Michael, R; Rai, Kanti; Larson, Richard A. "Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.." Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 11, no. 11. (January 2005.): 4176-81.

Byrd JC; Marcucci, Guido; Parthun, Mark, R; Xiao, Jim, J; Klisovic, Rebecca, B; Moran, Mollie; Lin, Thomas, S; Liu, Shujun; Sklenar, Amy, R; Davis, Melanie, E; Lucas, David, M; Fischer, Beth; Shank, Roshini; Tejaswi, Sooraj, L; Binkley, Philip; Wright, John; Chan, Kenneth, K; Grever, Michael R. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.." Blood. Vol. 105, no. 3. (January 2005.): 959-67.

Byrd JC; Marcucci, Guido; Parthun, Mark R.; Xiao, Jim J.; Klisovic, Rebecca B.; Moran, Mollie; Lin, Thomas S.; Liu, Shujun; Sklenar, Amy R.; Davis, Melanie E.; Lucas, David M.; Fischer, Beth; Shank, Roshini; Tejaswi, Sooraj L.; Binkley, Philip; Wright, John; Chan, Kenneth K.; Grever, Michael R.. "A phase 1 and pharmacodynamic study of depsipeptide (fk228) in chronic lymphocytic leukemia and acute myeloid leukemia." Blood. Vol. 105, no. 3. (January 2005.): 959-967.

Tseng, Ping-Hui; Lin, Ho-Pi; Zhu, Jiuxiang; Chen, Kuen-Feng; Hade, Erinn M.; Young, Donn C.; Byrd JC; Grever, Michael; Johnson, Kara; Druker, Brian J.; Chen, Ching-Shih. "Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor Osu-03012 in overcoming imatinib mesylate resistance." Blood. Vol. 105, no. 10. (January 2005.): 4021-4027.

Farag, S, S; Bolwell, B, J; Elder, P, J; Kalaycio, M; Lin, T; Pohlman, B; Penza, S; Marcucci, G; Blum, W; Sobecks, R; Avalos, B, R; Byrd JC; Copelan, E. "High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.." Bone marrow transplantation. Vol. 35, no. 7. (January 2005.): -.

Issa, Jean-Pierre J.; Byrd JC. "Decitabine in chronic leukemias." Seminars in Hematology. Vol. 42, no. 3, Suppl. 2. (January 2005.): S43-S49.

Mone AP, Puhalla S, Whitman S, Baiocchi R, Cruz J, Byrd JC, Caligiuri MA, Porcu P. "Durable hematologic complete response and suppression of HTLV-1 viral load following Alemtuzumab in AZT/IFN refractory adult T-cell leukemia (ATL)." Blood. Vol. 106, (January 2005.): 3380-3382.

Marcucci, Guido; Stock, Wendy; Dai, Guowei; Klisovic, Rebecca, B; Liu, Shujun; Klisovic, Marko, I; Blum, William; Kefauver, Cheryl; Sher, Dorie, A; Green, Margaret; Moran, Mollie; Maharry, Kati; Novick, Steven; Bloomfield, Clara, D; Zwiebel, James, A; Larson, Richard, A; Grever, Michael, R; Chan, Kenneth, K; Byrd JC. "Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 23, no. 15. (January 2005.): 3404-11.

Faderl, S; Coutre, S; Byrd JC; Dearden, C; Denes, A; Dyer, M J, S; Gregory, S, A; Gribben, J, G; Hillmen, P; Keating, M; Rosen, S; Venugopal, P; Rai, K. "The evolving role of alemtuzumab in management of patients with CLL.." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. Vol. 19, no. 12. (January 2005.): -.

Byrd JC; Rai, Kanti; Peterson, Bercedis, L; Appelbaum, Frederick, R; Morrison, Vicki, A; Kolitz, Jonathan, E; Shepherd, Lois; Hines, John, D; Schiffer, Charles, A; Larson, Richard A. "Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.." Blood. Vol. 105, no. 1. (January 2005.): 49-53.

Byrd JC; Rai, Kanti; Peterson, Bercedis L.; Appelbaum, Frederick R.; Morrison, Vicki A.; Kolitz, Jonathan E.; Shepherd, Lois; Hines, John D.; Schiffer, Charles A.; Larson, Richard A.. "Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of Calgb 9712 and Calgb 9011." Blood. Vol. 105, no. 1. (January 2005.): 49-53.

Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Wickham J, Davis ME, Lucas DM, Fischer B, Shank R, Binkley P, Wright J, Chan KK, Grever MR. "A Minimum Effective Pharmacologic Dose Finding Study of Depsipeptide (FK228) in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia." Blood. Vol. 105, (January 2005.): 959-967.

Byrd JC. "MVA-TRICOM vaccine strategy makes CLL cells an attractive T-cell target." Blood. Vol. 106, (January 2005.): 3334-3335.

Yu, Li; Liu, Chunhui; Vandeusen, Jeff; Becknell, Brian; Dai, Zunyan; Wu, Yue-Zhong; Raval, Aparna; Liu, Te-Hui; Ding, Wei; Mao, Charlene; Liu, Shujun; Smith, Laura, T; Lee, Stephen; Rassenti, Laura; Marcucci, Guido; Byrd JC; Caligiuri, Michael, A; Plass, Christoph. "Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia.." Nature genetics. Vol. 37, no. 3. (January 2005.): 265-74.

Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC. "Phase I Study of Low-Dose IL-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia: No evidence of diminished cellular immune dysfunction." Clinical Cancer Research. Vol. 11, (January 2005.): 8413-8417.

Flinn IW, Byrd JC, Bartlett N, Kipps TJ, Gribben J, Thomas D, Larson RA, Rai KR, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. "A Phase II Study of 24-hour Continuous Infusion Flavopiridol in Chronic Lymphocytic Leukemia. Submitted for publication @Co-First Authors." Leukemia Research. Vol. 29, (January 2005.): 1253-1257.

Willis CR, Goodrich A, Park K, Waselendo JD, Lucas M, Reese A, Diehl LF, Grever MR, Byrd JC. "A phase I/II study examining pentostatin chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma." Annals of Hematology. Vol. 85, (January 2006.): 301-307.

Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK. "Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decatabine (5-aza-2’-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method." Rapid Communications in Mass Spectrometry. Vol. 20, (January 2006.): 1117-1126.

Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. "CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia.." Cancer Research. Vol. 66, (January 2006.): 653-658.

Khan, Khuda, D; Emmanouilides, Christos; Benson, Don M Jr; Hurst, Deborah; Garcia, Pablo; Michelson, Glenn; Milan, Sandra; Ferketich, Amy, K; Piro, Lawrence; Leonard, John, P; Porcu, Pierluigi; Eisenbeis, Charles, F; Banks, Amy, L; Chen, Lei; Byrd JC; Caligiuri, Michael A. "A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.." Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 12, no. 23. (January 2006.): -.

Johnson AJ, Lucas DM, Muthusamy N, Smith L, Edwards R, DeLay M, Croce CM, Grever MR, Byrd JC. "Characterization of the TCL-1 transgenic mouse as a pre-clinical drug development tool for human chronic lymphocytic leukemia." Blood. Vol. 108, (January 2006.): 1334-1338.

Byrd JC, Lin TS, Grever M. "Treatment of relapsed chronic lymphocytic leukemia: old and new therapies." Seminars in Oncology. Vol. 33, (January 2006.): 210-219.

O’Donnell MR, Appelbaum FR, Baer MR, Byrd JCamon LE, Erba HP, Estey E, Foran J, Lancet J, Maness LJ, Maslak PG, Millenson M, Moore JO, Przepiorka D, Shami P, Smith BD, Stone RM, Tallman MS. "Acute myeloid leukemia clinical practice guidelines in oncology." Journal of the National Comprehensive Cancer Network. Vol. 4, (January 2006.): 16-36.

Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas D, Lampson B, Larson RA, Caligiuri MA, Heerema NA. "Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk Adapted Therapy." Journal of Clinical Oncology. Vol. 24, (January 2006.): 437-443.

Byrd JC. "New drugs for chronic lymphocytic leukemia.." Clinical advances in hematology & oncology : H&O. Vol. 4, no. 3. (January 2006.): -.

Ganesan LP, Joshi T, Fang H, Kutala VK, Roda J, Trotta R, Lehman A, Kuppusamy P, Byrd JC, Carson WE, Caligiuri MA, Tridandapani S. "Fc {gamma} R-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways." Blood. Vol. 108, (January 2006.): 718-725.

Chen HC, Byrd JC, Muthusamy N. "Differential role for cyclic AMP response element binding protein-1 in multiple states of B cell development, differentiation and survival." Journal of Immunology. Vol. 176, (January 2006.): 2208-2218.

Blum, Kristie, A; Johnson, Jeffrey, L; Niedzwiecki, Donna; Piro, Lawrence, D; Saven, Alan; Peterson, Bruce, A; Byrd JC; Cheson, Bruce, D; Cheson, Bruce D. "Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.." Cancer. Vol. 107, no. 12. (January 2006.): 2817-2825.

Blum W, Bolwell BJ. Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA. "High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation." Biology of Blood and Marrow Transplantation. Vol. 12, (January 2006.): 61-67.

Gowda A, Byrd JC. "Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia." Current Opinion in Hematology. Vol. 13, (January 2006.): 266-272.

Brena RM, Auer H, Kornacker K, Raval A, Byrd JC, Plass C. "Accurate quantitation of DNA methylation using Combined Bisulfite Restriction Assay (CoBRA) in combination with the Agilentâ„¢ 2100 Bioanalyzer platform." Nucleic Acids Research. Vol. 3, no. 34. (January 2006.): -.

Shanafelt, Tait, D; Byrd JCy, G; Zent, Clive, S; Kay, Neil E. "Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.." Annals of internal medicine. Vol. 145, no. 6. (January 2006.): -.

Raval A, Byrd JC. "Epigenetics in chronic lymphocytic leukemia." Seminars in Oncology. Vol. 2, no. 33. (January 2006.): 157-166.

Mone, A, P; Cheney, C; Banks, A, L; Tridandapani, S; Mehter, N; Guster, S; Lin, T; Eisenbeis, C, F; Young, D, C; Byrd JC. "Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. Vol. 20, no. 2. (January 2006.): -.

Lichtman SM, Hollis D, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd JC, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ. "Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: CALGB 9762." Journal of Clinical Oncology. Vol. 24, (January 2006.): 1846-1851.

Faderl, Stefan; Rai, Kanti; Gribben, John; Byrd JC; Flinn, Ian, W; O'Brien, Susan; Sheng, Shihong; Esseltine, Dixie-Lee; Keating, Michael J. "Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.." Cancer. Vol. 107, no. 5. (January 2006.): 916-924.

Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O’Brien S, Keating MJ. "Phase II study of single-agent bortezomib (VELCADE®) for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia." Cancer. Vol. 67, (January 2006.): 916-924.

Liu, Zhongfa; Liu, Shujun; Xie, Zhiliang; Blum, William; Perrotti, Danilo; Paschka, Peter; Klisovic, Rebecca; Byrd JC; Chan, Kenneth, K; Marcucci, Guido. "Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.." Nucleic acids research. Vol. 35, no. 5. (January 2007.): -.

Knapp, Amy, R; Ren, Chen; Su, Xiaodan; Lucas, David, M; Byrd JC; Freitas, Michael, A; Parthun, Mark R. "Quantitative profiling of histone post-translational modifications by stable isotope labeling.." Methods (San Diego, Calif.). Vol. 41, no. 3. (January 2007.): 312-319.

Alinari, L; Lapalombella, R; Andritsos, L; Baiocchi, RA; Lin, TS; Byrd JC. "Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.." Oncogene. Vol. 26, no. 25. (January 2007.): 3644-3653.

Su, Xiaodan; Zhang, Liwen; Lucas, David, M; Davis, Melanie, E; Knapp, Amy, R; Green-Church, Kari, B; Marcucci, Guido; Parthun, Mark, R; Byrd JC; Freitas, Michael A. "Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.." Analytical biochemistry. Vol. 363, no. 1. (January 2007.): 22-34.

Su, Xiaodan; Jacob, Naduparambil, K; Amunugama, Ravindra; Lucas, David, M; Knapp, Amy, R; Ren, Chen; Davis, Melanie, E; Marcucci, Guido; Parthun, Mark, R; Byrd JC; Fishel, Richard; Freitas, Michael A. "Liquid chromatography mass spectrometry profiling of histones.." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. Vol. 850, no. 1-2. (January 2007.): 440-454.

Neviani, Paolo; Santhanam, Ramasamy; Oaks, Joshua, J; Eiring, Anna, M; Notari, Mario; Blaser, Bradley, W; Liu, Shujun; Trotta, Rossana; Muthusamy, Natarajan; Gambacorti-Passerini, Carlo; Druker, Brian, J; Cortes, Jorge; Marcucci, Guido; Chen, Ching-Shih; Verrills, Nicole, M; Roy, Denis, C; Caligiuri, Michael, A; Bloomfield, Clara, D; Byrd JC; Perrotti, Danilo. "FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.." The Journal of clinical investigation. Vol. 117, no. 9. (January 2007.): 2408-2421.

Motiwala, Tasneem; Majumder, Sarmila; Kutay, Huban; Smith, David Spencer; Neuberg, Donna, S; Lucas, David, M; Byrd JC; Grever, Michael; Jacob, Samson T. "Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.." Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 13, no. 11. (January 2007.): 3174-3181.

Hussain, Syed-Rehan, A; Cheney, Carolyn, M; Johnson, Amy, J; Lin, Thomas, S; Grever, Michael, R; Caligiuri, Michael, A; Lucas, David, M; Byrd JC. "Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.." Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 13, no. 7. (January 2007.): 2144-2150.

Christian, Beth, A; Grever, Michael, R; Byrd, Byrd JC; Lin, Thomas S. "Flavopiridol in the treatment of chronic lymphocytic leukemia.." Current opinion in oncology. Vol. 19, no. 6. (January 2007.): 573-578.

Cheng, Hao; Liu, Zhongfa; Blum, William; Byrd, John, C; Klisovic, Rebecca; Grever, Michael, R; Marcucci, Guido; Chan, Kenneth K. "Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. Vol. 850, no. 1-2. (January 2007.): 206-212.

Ali, Naeem, A; O'Brien, James M Jr; Blum, William; Byrd JC; Klisovic, Rebecca, B; Marcucci, Guido; Phillips, Gary; Marsh, Clay, B; Lemeshow, Stanley; Grever, Michael R. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.." Cancer. Vol. 110, no. 1. (January 2007.): 96-102.

Raval, Aparna; Tanner, Stephan, M; Byrd JC; Angerman, Elizabeth, B; Perko, James, D; Chen, Shih-Shih; Hackanson, Bjorn; Grever, Michael, R; Lucas, David, M; Matkovic, Jennifer, J; Lin, Thomas, S; Kipps, Thomas, J; Murray, Fiona; Weisenburger, Dennis; Sanger, Warren; Lynch, Jane; Watson, Patrice; Jansen, Mary; Yoshinaga, Yuko; Rosenquist, Richard; et al.. "Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.." Cell. Vol. 129, no. 5. (January 2007.): 879-890.

Kay NE, Geyer SM, Lin TS, Call TG, Jelinek DF, Bone ND, Dewald GW, Heerema NA, Schumper RT, Smith LT, Grever MR, Byrd JC. "Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia." Blood. Vol. 109, (January 2007.): 405-411.

Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC. "Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia." British Journal of Hematology. Vol. 5, no. 139. (January 2007.): 837-844.

Flynn, Joseph, M; Byrd JC. "Have we forgotten the purpose of phase III studies?." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 25, no. 35. (January 2007.): 5553-5555.

Blum, William; Klisovic, Rebecca, B; Hackanson, Bjoern; Liu, Zhongfa; Liu, Shujun; Devine, Hollie; Vukosavljevic, Tamara; Huynh, Lenguyen; Lozanski, Gerard; Kefauver, Cheryl; Plass, Christoph; Devine, Steven, M; Heerema, Nyla, A; Murgo, Anthony; Chan, Kenneth, K; Grever, Michael, R; Byrd, Byrd JC; Marcucci, Guido. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 25, no. 25. (January 2007.): 3884-3891.

Blum, Kristie, A; Young, Donn; Broering, Sarah; Lucas, Margaret, S; Fischer, Beth; Lin, Thomas, S; Grever, Michael, R; Byrd JC. "Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 25, no. 35. (January 2007.): 5624-5629.

Rawstron, A, C; Villamor, N; Ritgen, M; Bottcher, S; Ghia, P; Zehnder, J, L; Lozanski, G; Colomer, D; Moreno, C; Geuna, M; Evans, P A, S; Natkunam, Y; Coutre, S, E; Avery, E, D; Rassenti, L, Z; Kipps, T, J; Caligaris-Cappio, F; Kneba, M; Byrd JC; Hallek, M, J; et al.. "International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.." Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. Vol. 21, no. 5. (January 2007.): 956-964.

Pal, Sharmistha; Baiocchi, Robert, A; Byrd JC; Grever, Michael, R; Jacob, Samson, T; Sif, Said. "Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma.." The EMBO journal. Vol. 26, no. 15. (January 2007.): -.

Shah MH, Villalona-Calero MA, Marcucci G, Byrd JC, Grever MR. "Inhibitors and Cardiac Safety." Clin Cancer Res. no. 13. (January 2007.): -.

Zhao, Xiaobin; Lapalombella, Rosa; Joshi, Trupti; Cheney, Carolyn; Gowda, Aruna; Hayden-Ledbetter, Martha, S; Baum, Peter, R; Lin, Thomas, S; Jarjoura, David; Lehman, Amy; Kussewitt, Donna; Lee, Robert, J; Caligiuri, Michael, A; Tridandapani, Susheela; Muthusamy, Natarajan; Byrd JC. "Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.." Blood. Vol. 110, no. 7. (January 2007.): 2569-2577.

Shanafelt, Tait, D; Lin, Thomas; Geyer, Susan, M; Zent, Clive, S; Leung, Nelson; Kabat, Brian; Bowen, Deborah; Grever, Michael, R; Byrd JC; Kay, Neil E. "Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.." Cancer. Vol. 109, no. 11. (January 2007.): 2291-2298.

Grever, Michael, R; Lucas, David, M; Johnson, Amy, J; Byrd JC. "Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.." Best practice & research. Clinical haematology. Vol. 20, no. 3. (January 2007.): 545-556.

Grever, Michael, R; Lucas, David, M; Dewald, Gordon, W; Neuberg, Donna, S; Reed, John, C; Kitada, Shinichi; Flinn, Ian, W; Tallman, Martin, S; Appelbaum, Frederick, R; Larson, Richard, A; Paietta, Elisabeth; Jelinek, Diane, F; Gribben, John, G; Byrd JC. "Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 25, no. 7. (January 2007.): 799-804.

Byrd JC; Lin, Thomas, S; Dalton, James, T; Wu, Di; Phelps, Mitch, A; Fischer, Beth; Moran, Mollie; Blum, Kristie, A; Rovin, Brad; Brooker-McEldowney, Michelle; Broering, Sarah; Schaaf, Larry, J; Johnson, Amy, J; Lucas, David, M; Heerema, Nyla, A; Lozanski, Gerard; Young, Donn, C; Suarez, Jose-Ramon; Colevas, A Dimitrios; Grever, Michael R. "Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.." Blood. Vol. 109, no. 2. (January 2007.): 399-404.

Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM.. "Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia." Leuk Res. no. 12. (January 2007.): 1737-1740.

Zhao, Xiaobin, B; Muthusamy, Natarajan; Byrd JC; Lee, Robert J. "Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes.." Journal of pharmaceutical sciences. Vol. 96, no. 9. (January 2007.): 2424-2435.

Zhao XB, Wu J, Muthusamy N, Byrd JC, Lee RC. "Liposomal Co-encapsulated Fludarabine and Mitoxantrone for Lymphoproliferative Disorder Treatment JPET." J Pharm Sci. no. August 23. (January 2007.): -.

Zhao XB, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum P, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. "A Novel Engineered Anti-CD37 Small Modular Immuno Pharmaceutical (SMIP) Demonstrates Promising Preclinical Activity against B-Cell Lymphoproliferative Disorder." Blood. Vol. 7, no. 100. (January 2007.): 2569-2577.

Tanner SM, Byrd JC. "Advances in genome-wide CLL linkage." Blood. Vol. 110(9), no. 1. (January 2007.): 3094-3095.

Roda JM, Byrd JC. "Fc RIIIa role in rituximab efficacy." Blood. Vol. 110, (January 2007.): 2220-.

Byrd JC; O'Brien, Susan; Flinn, Ian, W; Kipps, Thomas, J; Weiss, Mark; Rai, Kanti; Lin, Thomas, S; Woodworth, James; Wynne, Dee; Reid, Jennifer; Molina, Arturo; Leigh, Bryan; Harris, Sarah. "Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.." Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 13, no. 15 Pt 1. (January 2007.): -.

Byrd JC, Lin TS, Dalton JT, Wu D, Fischer B, Moran M,? Blum KA, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Ramon-Suarez J, Colevas AD, Grever MR. "Flavopiridol Administered in a Pharmacologically Derived Schedule Is Associated with Tumor Lysis Syndrome and Marked Clinical Efficacy in Refractory, Genetically High Risk Chronic Lymphocytic Leukemia." Blood. Vol. 109, (January 2007.): 399-404.

Widhopf Ii GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ.. "Non-stochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3." Blood.. no. August 3. (January 2007.): -.

Plass C, Byrd JC, Raval A, Tanner SM, de la Chapelle A. "Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes." British Journal of Hematology. Vol. 5, no. 139. (January 2007.): 744-752.

Liu Z, Liu S, Xie Z, Blum W, Perrotti D, Paschka P, Klisovic R, Byrd JC, Chan KK, Marcucci G.. "Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method." Nucleic Acids Res.. no. 35. (January 2007.): -.

Cheng H, Liu Z, Blum W, Byrd JC, Klisovic R, Grever MR, Marcucci G, Chan KK. "Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS." Journal of Chromatography B: Analyical Technology in Biomedical Life Schience. Vol. 1-2, no. 850. (January 2007.): 206-212.

Kay, Neil, E; Shanafelt, Tait, D; Byrd JC; Grever, Michael R. "Community-based phase II trial of PCR for CLL/SLL patients.." Cancer biotherapy & radiopharmaceuticals. Vol. 22, no. 5. (January 2007.): 715-717.

Kay, Neil, E; Geyer, Susan, M; Call, Timothy, G; Shanafelt, Tait, D; Zent, Clive, S; Jelinek, Diane, F; Tschumper, Renee; Bone, Nancy, D; Dewald, Gordon, W; Lin, Thomas, S; Heerema, Nyla, A; Smith, Lisa; Grever, Michael, R; Byrd JC. "Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.." Blood. Vol. 109, no. 2. (January 2007.): 405-411.

Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. "Relative value of ZAP-70, CD38, and Immunoglobulin Mutation Status in Predicting Aggressive Disease in Chronic Lymphocytic Leukemia.." Blood. Vol. 5, no. 112. (January 2008.): 1923-1930.

Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC. "Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug." Journal of Clinical Investigation. Vol. 7, no. 118. (January 2008.): 2427-2437.

Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR. "Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium." Blood. Vol. 6, no. 111. (January 2008.): 3190-3199.

Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS. "FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling." Cancer Research. Vol. 4, no. 68. (January 2008.): 1204-1212.

Trotta R, Col JD, Yu J, Ciarlariello D, ThomasB, Zhang X, Allard II J , Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA. "TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells." Journal of Immunology. Vol. 181, (January 2008.): 3784-3792.

Liu, Qing; Zhao, Xiaobin; Frissora, Frank; Ma, Yihui; Santhanam, Ramasamy; Jarjoura, David; Lehman, Amy; Perrotti, Danilo; Chen, Ching-Shih; Dalton, James, T; Muthusamy, Natarajan; Byrd JC. "FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.." Blood. Vol. 111, no. 1. (January 2008.): -.

Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum WG, Porcu P, Garzon R, Byrd JCCaligiuri MA, Chan KK, Wu LC, Marcucci G. "Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF- B-dependent DNA methyltransferase activity in acute myeloid leukemia." Blood. Vol. 4, no. 111. (January 2008.): 2364-2373.

Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JCer MR, Dalton JT. "Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule." Journal of Chromatography B: Analytic Technology in Biomedical Life Science. Vol. 1-2, no. 868. (January 2008.): 110-115.

Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JChelps MA. "Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma." The Drug Monitor. (January 2008.): -.

Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda AW, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. "Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal-center leukemogenic selection." Blood. Vol. 10, no. 111. (January 2008.): 5101-5108.

Klisovic RB, Stock W, Cataland S, Klisovic MI, Lui S, Blum W, Green M, Odenike O, Godley L, Vanden Burgt J, Van Laar E, Cullen M, Macleod R, Besterman JM, Reid GK, Byrd JC. "A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia.." Clinical Cancer Research. Vol. 8, no. 14. (January 2008.): 2444-2449.

Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Vanden Burgt J, Van Laar E, Cullen M, Byrd JC, Marcucci G. "A Phase I Biologic Study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase I, in paients with high risk myeloidysplasia and acute myeloid leukemia." Clinical Cancer Research. Vol. 14, (January 2008.): 2444-2499.

Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G. "Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia." Clinical Cancer Research. Vol. 14, (January 2008.): 3889-3895.

Lapalombella R, Zhao X, Triantafillou G, Yu B, Lin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Lee R , Caligiuri MA, Muthusamy N, Byrd JC. "A novel Raji-Burkitt’s lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents." Clinical Cancer Research. Vol. 14, (January 2008.): 569-578.

Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang D, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. "Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells." Blood. Vol. 13, no. 112. (January 2008.): 5180-5189.

Andritsos L, Johnson AJ, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, Wang D, Knight RD, Chen CS, Byrd JC. "Higher Doses of Lenalidomide Are Associated with Unacceptable Toxicity Including Life Threatening Tumor Flare in Chronic Lymphocytic Leukemia Patients." Journal of Clinical Oncology. Vol. 15, no. 26. (January 2008.): 2519-2525.

Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ. "A novel liposomal formulation of flavopiridol." International Journal of Pharmaceutics. Vol. 1-2, no. 365. (January 2008.): 170-174.

Pathan NI, Hariharan K, Chu P, Cheney C, Molina A, Byrd JC. "Mediation of apoptosis by and anti-tumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines." Blood. Vol. 3, no. 111. (January 2008.): 1594-1602.

Hertlein E, Byrd JC. "CLL and activated NF-�kappa� B: Living partnership." Blood. Vol. 111, (January 2008.): 4427-.

Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic J, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor JM, Vose JM, Yahalom J, Yunus F. "Non-Hodgkin’s Lymphomas." Journal of National Comprehensive Cancer Network. Vol. 4, (April 2008.): 356-421.

Lucas, DM, Byrd JC. "Comprehensive Single Necleotide Polymorphism Study Supports the Role of MDM2 in p53-Competent Chronic Lymphocytic Leukemia." Journals of Clinical Oncology. Vol. 26, (January 2008.): 2244-2245.

Gowda A, Roda J, Hussain R, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Carson WE, Muthusamy N, Byrd JC. "IL-21 Mediates Apoptosis Through Up-Regulation of the BH3 Family Member BIM and Enhances both Direct and Antibody Dependent Cellular Cytotoxicity in Primary Chronic Lymphocytic Cells." Blood. Vol. 9, no. 111. (January 2008.): 4723-4730.

Chen SS, Raval A, Johnson AJ, Herlein E, Liu TH, Jin VX, Sherman JH, Liu SH, Dawson DW, Williams KE, Lanasa M, Liyanarachchi S, Lin TS, Marcucci G, Pekarsky Y, Davuluri R, Croce CM, Guttridge DC, Teitell MA, Byrd JC*, Plass C*. Co-senior author. "Epigenetic changes during disease progression in a murine model of human chronic lymphcytic leukemia." PNAS. Vol. 106, no. 32. (August 2009.): 13433-13438.

Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, and Larson RA. "Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901." Leukemia and Lymphoma. Vol. 50, no. 10. (January 2009.): 1589-1596.

Yang X; Zhao X; Phelps MA; Piao L; Rozewski DM; Liu Q; Lee LJ; Marcucci G; Grever MR; Byrd JC; Dalton JT; Lee RJ. "A novel liposomal formulation of flavopiridol.." International Journal Of Pharmaceutics. Vol. 365, no. 1-2. (January 2009.): 170-.

Yang X; Koh CG; Liu S; Pan X; Santhanam R; Yu B; Peng Y; Pang J; Golan S; Talmon Y; Jin Y; Muthusamy N; Byrd JC; Chan KK; Lee LJ; Marcucci G; Lee RJ. "Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.." Molecular Pharmaceutics. Vol. 6, no. 1. (January 2009.): 221-.

Su X, Lucas DM, Zhang L, Xu H, Zabrouskov V, Davis ME, Knapp AR, Young DC, Payne PR, Parthun MR, Marcucci G, Grever MR, Byrd JC, Freitas MA. "Validation of an LC-MS based approach for profiling histones in chronic Lymphocytic leukemia." Proteomics. Vol. 5, (March 2009.): 1197-1206.

Lucas DM, Edwards RB, Lozanski G, West DA, Jungook DS, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema MA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR. "The Novel plant-derived agent selvestrol has B-cell selective activity in chronic Lymphocytic leukemia and acute lymphblastic leukemia in vitro and in vivo.." Blood. Vol. 113, no. 19. (May 2009.): 4656-4666.

Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia." Leukemia & Lymphoma. Vol. 12, no. 50. (December 2009.): 1958-1963.

Hamadni M, Blum W, Phillips F, Elder P, Andritsos, L, Hofmeister C, O’Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. "Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.." Biology of Blood and Marrow Transplantation. Vol. 11, no. 15. (January 2009.): 1422-1430.

Shanafelt TD, Byrd JC, Laplant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE.. "Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.." British Journal of Haematology. Vol. 146(6), (January 2009.): 660-664.

Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC. "Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia." Leukemia & Lymphoma. Vol. 50, no. 12. (January 2009.): 1977-1982.

Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. "The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic Lymphocytic leukaemia." British Journal of Haematology. Vol. 6, no. 144. (January 2009.): 848-855.

Garzon R, Liu S, Fabbri M, Liu A, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N Havelang V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreef M, Bloomfield CD, Byrd JC, Chan K, Wu, LC, Croce CM, Marcucci G. "MicroRNA -29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1." Blood. Vol. 113, no. 25. (June 2009.): 6411-6418.

Joshi T; Ganesan LP; Cheney C; Ostrowski MC; Muthusamy N; Byrd JC; Tridandapani S. "The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma.." Plos ONE. Vol. 4, no. 1. (January 2009.): e4208-.

Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, RuppertAS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL.. "A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitazel in patients with advanced solid tumors.." Cancer Chemotherapy and Pharmacology. (January 2009.): -.

Blum, KA, Hamandani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC. "Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma." Leukemia and Lymphoma. Vol. 3, no. 50. (January 2009.): 349-356.

Phelps, MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Booker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT. "Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopriodol in relapsed chronic lymphocytic leukemia." Blood. Vol. 12, no. 113. (March 2009.): 2637-2645.

Awan FT; Kay NE; Davis ME; Wu W; Geyer SM; Leung N; Jelinek DF; Tschumper RC; Secreto CR; Lin TS; Grever MR; Shanafelt TD; Zent CS; Call TG; Heerema NA; Lozanski G; Byrd JC; Lucas DM. "Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.." Blood. Vol. 113, no. 3. (January 2009.): 535-.

Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA. "Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma." MAbs. Vol. 1, (January 2009.): 31-40.

Lin,Thomas,S; Stock,Wendy; Xu,Huiping; Phelps,Mitch,A; Lucas,Margaret,S; Guster,Sara,K; Briggs,Bruce,R; Cheney,Carolyn; Porcu,Pierluigi; Flinn,Ian,W; Grever,Michael,R; Dalton,James,T; Byrd,John,C. "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia." LEUKEMIA & LYMPHOMA. Vol. 50, no. 12. (January 2009.): 1958-1963.

Fehniger TA; Byrd JC; Marcucci G; Abboud CN; Kefauver C; Payton JE; Vij R; Blum W. "Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.." Blood. Vol. 113, no. 5. (January 2009.): 1002-.

Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W. "Single agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13." Blood. Vol. 5, no. 113. (January 2009.): 1002-1005.

Christian BA, Grever MR, GByrd JC, Lin TS, Byrd JC. "Flavopiridol in chronic lymphocytic leukemia: A consise review.." Clinical Lymphoma Myeloma. Vol. 3, no. 9. (January 2009.): S179-185.

Chen SS, Sherman MH, Herlein E, Johnson AJ, Teitell MA, Byrd JC*, Plass C*. Co-senior author. "Epigenetic alterations in a murine model for chronic lymphcytic leukemia.." Cell Cycle. Vol. 8, no. 22. (November 2009.): 3663-3667.

Byrd JC. "Hunting for the Achilles' heel of CLL." Blood. Vol. 20, no. 114. (November 2009.): 4324-.

Woyach, JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei, L, Caligiuri MA, Byrd JC. "A phase I/II study of rituximab and etanercept in patients with chronic Lymphocytic leukemia and small Lymphocytic lymphoma.." Leukemia. (January 2009.): -.

Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, LaCasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos JP. "Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909." Journal of Clinical Oncology. Vol. 36, no. 27. (December 2009.): 6101-6108.

Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd JC, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. "A critical role for phosphatase haplodefiency in the selective suppression of deletion 5q MDS by lenalidomide." Proceedings for the National Academy of Science, USA. Vol. 31, no. 406. (January 2009.): 12974-12979.

Blum K, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, Dumouchel J, Drouin M, Lucas DM, Martell RE, Byrd JC. "Phase II study of the histone deacetylase inhibitor MGC0103 in patients with previously treated chronic lymphcytic leukaemia.." British Journal of Haematology. Vol. 147, no. 4. (November 2009.): 507-514.

Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Adritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC. "Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease." Journal of Clinical Oncology. Vol. 27, no. 35. (December 2009.): 6012-6018.

Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S. "Genome wide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma." Blood. Vol. 116, no. 7. (August 2010.): 1025-1034.

Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut, EH Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR, Byrd JC. "Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders." Journal of Clinical Oncology. Vol. 28, no. 3. (January 2010.): 418-423.

Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, and Muthusamy N. "FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma." Clinical Cancer Research. Vol. 16, no. 12. (June 2010.): 3182-3192.

Flynn JM, Andritsos L, Lucas D, Byrd JC. "Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus." British Journal of Hematology. Vol. 149, no. 3. (May 2010.): 388-390.

Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos LA, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, and Byrd JC. "Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation." BRITISH JOURNAL OF HAEMATOLOGY. Vol. 150, no. 2. (July 2010.): 189-195.

Biswas,Sabyasachi; Zhao,Xiaobin; Mone,Andrew,P; Mo,Xiaokui; Vargo,Melissa; Jarjoura,David; Byrd,John,C; Muthusamy,Natarajan. "Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro." LEUKEMIA RESEARCH. Vol. 34, no. 7. (July 2010.): 925-931.

Blum KA, Jung SH, Johnson JL, Lin TS, His ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL. "Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcRIIIa-158 V/F polymorphism." Annals of Oncology. Vol. 21, no. 11. (November 2010.): 2246-2254.

Gowda,Aruna; Ramanunni,Asha; Cheney,Carolyn; Rozewski,Darlene; Kindsvogel,Wayne; Lehman,Amy; Jarjoura,David; Caligiuri,Michael; Byrd,John,C; Muthusamy,Natarajan. "Differential effects of IL-2 and IL-21 on expansion of the CD4(+)CD25(+)Foxp3(+) T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia." MAbs. Vol. 2, no. 1. (January 2010.): 35-41.

Byrd,John,C; Kipps,Thomas,J; Flinn,Ian,W; Castro,Januaro; Lin,Thomas,S; Wierda,William; Heerema,Nyla; Woodworth,James; Hughes,Steve; Tangri,Shabnam; Harris,Sarah; Wynne,Dee; Molina,Arturo; Leigh,Bryan; O'Brien,Susan. "Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia." Blood. Vol. 115, no. 3. (January 2010.): 489-495.

Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 107, no. 16. (April 2010.): 7473-7478.

Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford, Jr, R, Rader R, Muthusamy N, Johnson AJ*, Byrd JC*. Co-senior author. "Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway." Blood. Vol. 115, no. 13. (April 2010.): 2619-2629.

Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd, JC, Johnson AJ. "Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals." Blood. Vol. 116, no. 12. (September 2010.): 2078-2088.

Benson Jr DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, and Caligiuri MA. "The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody." Blood. Vol. 116, no. 13. (September 2010.): 2286-2294.

Sanchez-Aguilera A, Rattmann I, Drew DZ, Muller LUW, Summey V, Lucas DM, Byrd JC, Croce CM, Gu Y, Cancelas JA, Johnston P, Moritz T, Williams DA. "Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia." Leukemia. Vol. 24, no. 1. (January 2010.): 97-104.

Woyach JA, Heerema NA, Zhao J, McFaddin A, Stark A, Lin TS, Andritsos LA, Blum KA, Flynn JM, Jones JA, Byrd JC. "Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease." British Journal of Haematology. Vol. 148, no. 5. (March 2010.): 754-759.

Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S. "Genome wide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma." Blood. Vol. 10, (April 2010.): 1182-.

Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kondadasula SV, Mo X, Chemudupati M, Kanneganti TD, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson, WE 3rd, Byrd JC, Tridandapani S. "Reciprocal Regulation of Activating and Inhibitory Fc gamma Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy." Clinical Cancer Research. Vol. 16, no. 7. (April 2010.): 2065-2075.

Blum W, Phelps MA, KlisovicRB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. Vol. 95, no. 7. (July 2010.): 1098-1105.

Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson, Jr DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N*, Byrd JC*. Co-senior author.. "CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody." Blood. Vol. 115, no. 6. (February 2010.): 1204-1213.

Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. "NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas." Journal of the National Comprehensive Cancer Network : JNCCN. Vol. 8, no. 3. (March 2010.): 288-334.

Jin,Yan; Liu,Shujun; Yu,Bo; Golan,Sharon; Koh,Chee-Guan; Yang,Jintao; Huynh,LeNguyen; Yang,Xiaojuan; Pang,Jiuxia; Muthusamy,Natarajan; Chan,Kenneth,K; Byrd,John,C; Talmon,Yeshayahu; Lee,L,James; Lee,Robert,J; Marcucci,Guido. "Targeted Delivery of Antisense Oligodeoxynucleotide by Transferrin Conjugated pH-Sensitive Lipopolyplex Nanoparticles: A Novel Oligonucleotide-Based Therapeutic Strategy in Acute Myeloid Leukemia." MOLECULAR PHARMACEUTICS. Vol. 7, no. 1. (January 2010.): 196-206.

Koh CG, Zhang X, Liu S, Golan S, Yu B, Yang X, Guan J, Jin Y, Talmon Y, Muthusamy N, Chan KK, Byrd JC, Lee RJ, Marcucci G, Lee LJ. "Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing." JOURNAL OF CONTROLLED RELEASE. Vol. 141, no. 1. (January 2010.): 62-69.

Awan,Farrukh,T; Johnson,Amy,J; Lapalombella,Rosa; Hu,Weihong; Lucas,Margaret; Fischer,Beth; Byrd,John,C. "Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia." Leukemia & Lymphoma. Vol. 51, no. 1. (January 2010.): 27-38.

Jaglowski SM, Byrd JC. "Rituximab in chronic lymphocytic leukemia." Seminars in Hematology. Vol. 47, no. 2. (April 2010.): 156-169.

Kay NE, Wu W, Kabat B, Laplant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD. "Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia." Cancer. Vol. 116, no. 9. (May 2010.): 2180-2187.

Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G. "Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia." Cancer Cell. Vol. 17, no. 4. (April 2010.): 333-347.

Hertlein,Erin; Wagner,Amy,J; Jones,Jeffrey; Lin,Thomas,S; Maddocks,Kami,J; Towns,William,H; Goettl,Virginia,M; Zhang,Xiaoli; Jarjoura,David; Raymond,Chelsey,A; West,Derek,A; Croce,Carlo,M; Byrd,John,C; Johnson,Amy,J. "17-DMAG targets the nuclear factor-kappa B family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition." Blood. Vol. 116, no. 1. (July 2010.): 45-53.

 

Reference Works

January 1991 Scoggin C. Keppen M, Byrd JC, Hutchins L.."Marked Activity of EDAP in a Broad Spectrum of Malignancies." . : 302
January 1991 Scoggin C, Keppen M, Byrd JC, Hutchins L.."Marked Activity of EDAP in a Broad Spectrum of Malignancies" . : 789
January 1994 Wiesen AR, Hospental DR, Byrd JC, Howard RS, Diehl LF."Equilibration of Hemoglobin Following Transfusion" . : 76
January 1994 Edenfield WJ, Byrd JC, Aylesworth C, Dow NS, Dawson N."Extramedullary Leukemia (EML) in Myelodysplastic Syndromes (MDS): Not a True Indication of Impending Acute Myeloid Leukemia (AML)" . : 631a
January 1994 Byrd JC, Weiss RB, Arthur DC, Schiffer CA, Brunetto VL, Carroll D, Omura G, Davey F, Moore JO, Mayer RJ, Bloomfield CD."The Presence of t(8;21)(q22;q22) and Extramedullary Leukemia (EML) at Presentation of Acute Myeloid Leukemia May Influence Prognosis" . : 305a
January 1994 Byrd JC, Hargis JB, Kester KB, Hospental DR, Krutson SW, Diehl LF."Fludarabine Therapy for Lymphoid Malignancies is Associated with a High Number of Opportunistic Infections" . : 138a
January 1994 Byrd JC, Freidman J, Weiss RB, Kweder S, Diehl LF."Fludarabine Therapy for Lymphoid Malignancies is Associated with Hemolytic Anemia" . : 991
December 1994 Hospental DR, Hicks CD, Wisen AR, Byrd JC, Isenbarger D, Salzbery D."Trends in Fungi Recovered from Urine Following Introduction of Fluconzole" .
March 1995 Kester K, Byrd JC, Reardon T, Zacker L, Cragen H, Hargis JB."Granulomatous Pnemocystis Carini Pneumonia: An Emerging Complication of Chemotherapy in Patients with Low-Grade Lymphoid Malignancies" .
January 1995 Byrd JC, Edenfield WJ, Arthur DC, Lawrence D, Shah D, Trikha E, Weiss RB, Schiffer CA, Bloomfield CD."Extramedullary Leukemia is Associated with Pre-Treatment Cytogentic Abnormalities in Patients with Acute Myeloid Leukemia: Results from CALGB 8461" . : 43a
January 1995 Edenfield WJ, Byrd JC, Jones MP, Homoky D, Robson M."Liver Associated Enzyme Elevaton and Hepatic Extramedullary Hematopoiesis Observed with Granulocyte-Colony Stimulating Factor (GCSF) Use in Lymphoid Malignancies" . : 692a
January 1996 Byrd JC, Wiesen AR, Hospental DR, Howard RS, Glass KL, Diehl LF."The Impact of the Administration of Packed Red Blood Cells in the Evaluation of the Post-Transfusion Patient" . : 181a
January 1996 Byrd JC, Shields DS, Dow NS, Burrel L, Aguilera NS, Abbondanzo SL, Diehl LF."Unusual Transformations in Heavily Pre-Treated Patients Receiving Fludarabine" . : 213b
January 1996 Byrd JC, Arthur DC, Lawrence D, Davey F, Schiffer CA, Bloomfield CD."Sole Trisomy 8 in Patients with Acute Myeloid Leukemia (AML) are Rarely Cured with Intensive Chemotherapy: Results of CALGB 8461" . : 188
January 1996 Flinn IW, Byrd JC, Seifer E, Marcellus D, Lee L, Diehl LF, Ambinder RF, Grever MR, Vogelsang G."Fludarabine and Cyclophosphamide as First Therapy for Indolent Lymphoproliferative Disorders: Response Rates and Toxicity" . : 589a
January 1996 Houde LL, Sehn LH, Robson MR, Antin JH, Strickland WR, Byrd JC."Pancreatitis During Therapy of Acute Myeloid Leukemia: Cytarabine related" . : 217a
January 1997 Shinn CA, Byrd JC, Waselenko JK, Miller C, Gore S, Sausville EA, Grever MR."UCN-01 has Marker in vitro Activity Against Both the K-562 Cell Line and Human Acute Leukemia Cells" . : 246b
January 1997 Byrd JC, Waselenko JK, Shinn CA, Miller C, Gore S, Sausville EA, Grever MR."FR901228, a Novel Antitumor Bicyclic Depsipeptide, has Marked in vitro Activity Against Both the K-562 Cell Line and Human Acute Leukemia Cells" . : 238
January 1997 Byrd JC, Waselenko JK, Shinn CA, Flinn IW, Diehl LF, Grever MR."nterleukin-4 Induces Resistance to F-ARA-A and UCN-01 but Not Flavopiridol in a BCL-2 Independent Manner" . : 532
January 1997 Byrd JC, Shinn CA, Bedi A, Waselenko JK, Flinn IW, Diehl LF, Sausville EA, Grever MR."UCN-01: A Promising New Agent for Chronic Lymphocytic Leukemia that Induces Apoptosis Independent of p53 status" . : 306b
January 1997 Byrd JC, Shinn CA, Bedi A, Waselenko JK, Flinn IW, Diehl LF, Sausville E, Grever MR."FR901228, A Novel Bicylic Depsipeptide, has Significant Activity Against Human B-Chronic Lymphocytic Leukemia (B-CLL)" . : 532a
January 1997 Byrd JC, Shinn CA, Bedi A, Waselenko JK, Flinn IW, Diehl LF, Sausville E, Grever MR."Flavopiridol has Marked in Vitro Activity Against Human B-Chronic Lymphocytic Leukemia and Induces Apoptosis Independent of p53 Function" . : 531a
January 1997 Byrd JC, Dow NS, Howard RS, Greenfield SL, Williams CK, Diehl LF."Marked Depletion of Natural Killer Cells in Chronic Lymphocytic Leukemia Patients Receiving Fludarabine: A Consideration for Future Immune-Based Therapy" . : 28a
January 1997 Waselenko JK, Przygodzki R, Grever MR, Shinn CS, Sausville E, Byrd JC."Flavopiridol, UCN-01, FR901228 and Gemcitabine have Significant in vitro Activity in do novo B-Cell Prolymphocytic Leukemia with Aberrant p53 Status" . : 532a
January 1997 Waselenko JK, Grever MR, Shinn CA, Flinn IW, Diehl LF, Byrd JC."Gemcitabine Demonstates Significant in vitro Activity in Heavily Pre-Treated B-Cell Chronic Lymphocytic Leukemia" . : 310b
January 1997 Waselenko JK, Byrd JC, Shinn CA, Miller C, Gore S, Sausville EA, Grever MR."Flavopiridol has Marked in vitro Activity Against Both the K-562 Cell Line and Human Acute Leukemia Cells" . : 248b
January 1997 Waselenko JK, Byrd JC, Shinn CA, Flinn IW, Diehl LF, Sausville E, Grever MR."Carboxyamido-triazole (CAI), A Signal Transduction Inhibitor, Demostrates Marginal Activity Against Human B-Cell Chronic Lymphocytic Leukemia in vitro" . : 524a
January 1997 Houde-McGrail LL, Diehl LF, Hospenthal DR, Howard RS, Dow N, Byrd JC."Herpes Virus Infections in Patients with Low-Grade Lymphoprolifetive Disorders Following Treatment with Fludarabine: Related to the Underlying Disease Process" . : 524a
January 1998 Byrd JC, White CA, Link B, Thomas S, Valasquez WS, Rosenberg J, Grillo-Lopez AJ."Rituximab Therapy in Previously Treated Waldenstrom’s Macroglobulinemia: Preliminary Evidence of Activity" . : 106a
January 1998 Byrd JC, Waselenko JK, Maneatis TA, Murphy T, Weickum R, Ward FT, White CA."Rituximab Therapy in Hematologic Malignancy Patients with Circulating Blood Tumor Cells: Association with Increased Infusion-Related Side Effects and Rapid Tumor Lysis" . : 106a
January 1998 Byrd JC, Shinn CA, Kanakry C, Ravi R, Willis CW, Drabick JJ, Sausville E, Grever, MR."Spicamycin Derivative KRN5500 has Marked in vitro Activity Against Human Chronic Lymphocytic Leukemia Cells Concomitant with Decreased Expression of p27 and Cleavage of Caspase-3" . : 491
January 1998 Byrd JC, Dodge R, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CA."Adult Acute Myeloid Leukemia Patients with t(8;21)(q22;q22) have a Superior Outcome When Repetitive Cycles of High-Dose Cytarabine are Administered" . : 312a
January 1998 Prieto R, Waselenko JK, Johnson TR, Olivere JW, Natarajan S, Byrd JC."Ebstein Barr Virus Associated Primary Central Nervous System Lymphoma Arising in a Patient After Fludarabine and Corticosteroid Treatment" . : 228b
January 1998 Flynn JM, Dawson NA, Howard RS, Byrd JC."Secondary Malignancies in B-Cell Chronic Lymphocytic Leukemia: Type and Optimal Time to Monitor Patients" . : 102b
January 1998 Flinn IW, Goodman S, Post L, Miller CB, Gore S, Diehl LF, Willis C, Ambinder RF, Byrd JC."Dose Finding Study of Liposomal Daunorubicin with Cyclophosphamide, Vincristine, and Prednisone in Patients with Lymphoma" . : 24a
January 1998 Flinn IW, Goodman S, Post L, Jamison J, Miller CB, Gore SD, Diehl L, Willis C, Ambinder RF, Byrd JC."Liposomal Daunorubicin and CVP: A Well Tolerated Regimen for Lymphoma with Little Non-Hematologic Toxicity" . : 236b
January 1998 Flinn IW, Byrd JC, Morrison C, Jamison J, Miller C, Christie RJ, Gore S, Burke P, Vogelsang G, Grever MR."Fludarabine and Cyclophosphamide: A Highly Active and Well Tolerated Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia" . : 104a
January 1998 Flinn IW, Byrd JC, Morrision C, Jamison J, Diehl L, Lucas MS, Seifter E, Marcellus D, Ambinder RF, Grever MR, Vogelsang G."Fludarabine and Cyclophosphamide: A Highly Active and Well Tolerated Regimen for Patients with Previously Untreated Indolent Lymphomas" . : 413a
January 1998 Egorin MJ, Venook AP, Rosner G, Hollis D, Mani S, Hawkins M, Byrd JC, Hohl R, Budman D, Poplin E, Meropol N, Ratin MJ."Phase I Study of Gemicitabine with Organ Dysfuction" . : 187a
January 1998 Shinn CA, Byrd JC, Raji R, Willis CW, Flinn IW, Dawson NA, Sausville E, Grever MR."Depsipeptide is Selectively Cytotoxic Toward Human Chronic Lymphocytic Leukemia Cells and Favorably Alters the BCL-2: Bax Ratio and p27 Expression with Concomitant Cleavage of Caspase-3" . : 103a
January 1998 Murray CK, Estey, EH, Paietta e, Edenfield WJ, Mann KP, Byrd JC."CD56 Expression in Acute Promyelocytic Leukemia is Associated with Poor Treatment Outcome" . : 32a
January 1999 Perkins JG, Flynn JM, Byrd JC."Frequency and Type of Serious Infections in fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL): Implications for Clinical Trials in this Patient Population" . : 540a
January 1999 Flynn JM, Howard RS, Byrd JC."Second Malignancies in B-Cell Chronic Lymphocytic Leukemia: Association with CLL but no Additional Impact with Fludarabine or Alkylator Treatment" . : 298b
January 1999 Flynn JM, Byrd JC, Diehl LF."The Causes of Death and the Impact of Age on the Survival of Patients with Chronic Lymphocytic Leukemia" . : 298b
January 1999 Willis CR, Byrd JC, Shinn C, Flinn IW, Grever MR."UCN-01 Chemosensitizes Human B Chronic Lymphocytic Leukemia (B-CLL) Cells to the Effects of Fludarabine" . : 127a
January 1999 Hastings E, Berenberg J , Jame H, Edenfield J, Byrd JC, Diehl L."Cyclosporine A: An Effective, Non Myelotoxic Treatment for Chronic Lymphocytic Leukemia" . : Abstract #108
January 1999 Pearson MD, Shinn C, Grever MR, Flinn IW, Byrd JC."Rituximab Induces in vitro Apoptosis in Human Chronic Lymphocytic Leukemia Cells (CLL) Independent of Complement Mediated Lysis but Requires Fc Receptor Ligation" . : 313b
January 1999 Murphy TJ, Ling G, Flinn IW, Lucas MS, Park K, Goodrich A, Grever MR, Byrd JC."Infusion-Related Events Following Rituximab Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Association with Inflammatory Cytokines" . : 313a
January 1999 Shinn CA, Byrd JC, Neuberg DS, Flinn IW, Grever MR."Over-Expression of MDM2 in Leukemia Cells in Previously Treated Patients with Chronic Lymphocytic Leukemia" . : 542a
January 1999 Keating MJ, Byrd JC, Rai KR, Flinn IW, Jain V, Binet JL, Bolin R, Hillmen P, Hutchinson and the Campath-1H Collaborative Study Group."Multicenter Study of Campath-1H in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine" . : 705a
January 1999 Byrd JC, Willis CR, Waselenko JK, Park K, Goodrich A, Morrison C, Lucas M, Shinn C, Diehl LF, Grever MR, Flinn IW."Theophylline, Pentostatin, and Chlorambucil; A Dose Escalation Study to Modulate Intrinsic Biologic Resistance Mechanisms in Patients with Relapsed Lymphoproliferative Disorders" . : 308b
January 1999 Byrd JC, Shinn CA, Pearson MD, Flinn IW, Link BK, Wang H, Weiner G, Grever MR."Hu1D10 Induces Apoptosis in vitro in Human Chronic Lymphocytic Leukemia Cells (CLL) Independent of Compliment Mediated Lysis but Requires Fc Receptor Ligation" . : 314a
January 1999 Byrd JC, Shinn CA, Jansure J, Hydom C, Pearson MD, Flinn IW, Grever MR."Campath-1H Induces Apoptosis in Human Chronic Lymphocytic Leukemia Cells (CLL) in vitro Independent of Complement Mediated Lysis or Fc receptor Ligation" . : 126a
January 1999 Byrd JC, Grever MR, Davis B, Lucas MS, Park K, Goodrich A, Morrison C, Murphy TJ, Kunkel L, Grillo-Lopez A, Waselenko JK, Flinn IW."Phase I/II Study of Thrice Weekly Rituximab in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL): A Feasible and Active Regimen" . : 704a
January 1999 Byrd JC."Rituximab Therapy in Patients with Chronic Lymphocytic Leukemia" .
January 2000 Waselenko JK, Burrows A, Lucas M, Ekstrand JR, Myhand R, Lee N, Edenfield WJ, Byrd JC."Low Dose Recombinent Interleukin-2 (rIL-2) Following High Dose Chemotherapy (HDC) and Autologous Peripheral Blood Stem Cell Transplantion (PBSCT) in Patients with Chronic Lymphocytic Leukemia (CLL), Mantle Cell (MCL), and Follicular Lymphoma (FL)" . : 350b
January 2000 Treon D, Agus B, Link B, Rodrigues G, Molina A, Lacy M, Fisher D, Emmanouilides C, Richards A, Clark B, Anderson K, Byrd JC."Rituximab is an Active Agent in Waldenstroms Macroglobulinemia" . : 6a
January 2000 Marcucci G, Bloomfield CD, Balcerzak SP, Kourlas PJ, Stanley HR, Fingert H, Mahraby EA, Lucas D, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA."Phase I Trial of Genasense (G3139, Genta, Inc.), a BCL-2 Antisense (AS), in Refractory (REF) or Relapsed (REL) Acute Leukemia (AL)" . : 119a
January 2000 Link B, Wang H, Byrd JC, Leonard J, Davis T, Hall W, Turner J, Rodrigues G, Levitt D, Weiner G."Phase I Trial of Humanized 1D10 (Hu1D10) Monoclonal Antibody Targeting Class II Molecules in Patients with Relapsed Lymphoma" . : 24a
January 2000 Pearson M, Buj, Shinn C, Waymer SF, Sickler J, Flynn JM, Lucas MS, Flinn IW, Byrd JC."GM-CSF Treatment Does not Up-Regulate Expression of CD20 in vivo in Patients with Chronic Lymphocytic Leukemia" . : 166a
January 2000 Dees E, O’Reilly S, Figg W, Elza-Brown K, Ayelsworth C, Carducci M, Byrd JC, Grever M."A Phase I and Pharmacologic Study of UCN0-1, a Protein Kinase C Inhibitor" . : 205a
January 2000 Kitada S, Pearson M, Flinn IW, Shinn C, Reed JC, Byrd JC."The Mechanism of in vivo Leukemia Cell Clearance by Rituximab in Patients with CLL Involves Apoptosis by a Caspase 9 Pathway" . : 515a
January 2000 Byrd JC, Murphy T, Lucas MS, Haward R, Goodrich A, Park K, Pearson M, Buj V, Waselenko JK, Grever MR, and Flinn IW."Thrice Weekly Rituximab Demonstrates Significant Activity in Chronic Lymphocytic Leukemia" . : 837a
January 2000 Buj V, Shinn C, Pearson M, Byrd JC."Ex vivo Induction of Cytokines by Campath-1H: Preliminary Evidence of an in vitro Model to Predict Infusion-Related Toxicity" . : 165a
January 2000 Ales NC, Helman DL, Shorr AF, Byrd JC."Fludarabine Associated Pulmonary Toxicity in Chronic Lymphoproliferative Disorders: A Case Series" . : 756a
January 2001 Marcucci G, Byrd JC, Cataland SR, Fisher DB, Lucas D, Chan KK, Klisovic M, Young DC, Didier LA, Balcerzak SP, Frankel SR, Kraut EH, Bloomfield CD, Grever MR, Caligiuri MA."Clinical and Biological Activity of Genasense (G3139, genta, inc.) (GS), a BCL-2 Antisense, in Refractory (REF) or Relapsed (REL) Acute Leukemia (AL): A Phase I Study" . : 216b
January 2001 Marcucci G, Bloomfield CD, Balcerzak SP, Fingert H, Maghraby EA, Lucas D, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA."Phase I Trial of Genasense (G3139, Genta, Inc.), a BCL-2 Antisense (AS), in Refractory (REF) or Relapsed (REL) Acute Leukemia (AL)" . : 1149
January 2001 Marcucci G, Bloomfield CD, Balcerzak SP, Fingert H, Maghraby EA, Kourlas P, Lucas D, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA."Biologic Activity of G3139 (Genasense), a BCL-2 Antisense (AS), in Refractory (REF) or Relapsed (REL) Acute Leukemia (AL)" . : 1149
January 2001 Bannerji R, Kitada S, Flinn IW, Pearson M, Lucas D, Grever MR, Reed JC, Byrd JC."Campath-1H Antibody Induces Transmembrane Signaling in vitro and in vivo in Patients with Chronic Lymphocytic Leukemia (CLL) and Promotes Tumor Clearance in Part Through Caspase mediated Apoptosis" . : 808a
January 2001 Bannerji R, Flinn IW, Pearson M, Shinn C, Sickler J, Lucas M, Lucas D, Byrd JC."Campath-1h Antibody Induces Transmembrane Signaling in Vivo in Patients with Chronic Lymphocytic Leukemia (CLL) and Promotes Tumor Clearance via a Caspase-9 Apoptotic Pathway" .
January 2001 Baird ME, Lucas DM, Mone AP, Waymer S, Warrell RP, Byrd JC, Grever MR."G3139 Promotes Release of IL-8 by Chronic Lymphocytic Leukemia Cells Cultured in vitro: Potential Implications for Therapeutic Use" . : 281b
January 2001 Aron J, Murphy T, Parthun MR, Bannerji R, Kanakry C, Lucas D, Flinn IW, Marcucci G, Grever MR, Byrd JC."The Histone Deacetylase Inhibitor Depsipeptide (FR901228) Induces Apoptosis Via Activation of the Caspase 8 Pathway Concurrent with Lysine Specific Acetylation in Chronic Lymphocytic Leukemia Cells" . : 807a
January 2001 Maghraby E, Murphy T, Parthun M, Klisovic M, Sklenar A, Archer K, Whitman S, Grever M, Byrd JC, Marcucci G."Depsipeptide (FR901228) Induces Lysine-Specific Histone Acetylation, Differentiation and Apoptosis is Acute Myeloid Leukemia Cells and Demonstrates Synergy with Decitabine" . : 103a
January 2001 Lucas M, Flinn IW, Goodrich AL, Murphy T, Park K, Grever MR, Lehman T, Byrd JC."TNF- and TNF- Promotor Polymorphisms May Relate to Response to Rituximab Therapy" . : 634a
January 2001 Lucas DM, Baird ME, Neuberg DS, Tallman MS, Flinn IW, Byrd JC, Grever MR."Importance of Culture Conditions for in vitro Chemosensitivity Assessment in Chronic Lymphocytic Leukemia Cells: Preliminary Results From Laboratory Studies, Eastern Cooperative Oncology Group Study 2997" . : 284b
January 2001 Link BK, Wang H, Byrd JC, Leonard JP, Davis TA, Flinn I, Hall WC, Turner JF, Levitt D, Weiner GJ."Phase I Study of Hu1D10 Monoclonal Antibody in Patients with B-Cell Lymphoma" . : 1135
January 2001 Link BK, Wang H, Byrd JC, Leonard JP, Davis TA, Flinn I, Hall WC, Turner JF, Bowles J, Shannon M, Levitt D, Weiner GJ."Prolonged Clinical Responses in Patients with Follicular Lymphoma Treated on a Phase I Trial of the Anti-HLA-DR Monoclonal Antibody Remitogen (Hu1D10)" . : 244b
January 2001 Link BK, Wang H, Byrd JC, Leonard JP, Davis T, Flinn I, Hall WC, Turner JF, Bowles J, Shannon M, Levitt D, Weiner GJ."Prolonged Cilnical Responses in Patients with Follicular Lymphoma Treated on a Phase I Trial of the Anti-HLA-DR Monoclonal Antibody Remitogen (Hu1D10)" .
January 2001 Link BK, Kahl B, Czuczman M, Powell BL, Leonard JP, Ansell S, Porcu P, Byrd JC, Lazarus HM, Flinn I, Jones GJ, Levitt D, Hall W, Weiner GJ."A Phase II Study of Remitogen (Hu1D10), a Humanized Monoclonal Antibody in Patients with Relapsed or Refractory Follicular, Small Lymphocytic, or Marginal Zone/MALT B-Cell Lymphoma" . : 606a
January 2001 Porcu P, Farag S, Marcucci G, Avalos B, Rhoades C, Fisher B, Byrd JC, Grever MR, Caligiuri MA."Phase I Trial of Interleukin-2 (IL-2) and Rituximab in Patients (pts) with Relapsed or Refractory B-Cell Lymphoma (R/R-BCL)" . : 245b
January 2001 Kornblith, Herndon JE, Weiss RB, Zuckerman EL, Rosenberg S, Mertz M, Zhang C, Payne D, Massie M, Holland JF, Bosl G, Byrd JC, Leone L, Norton K, Holland JC."Long Term Adjustment of Survivors of Early Stage Breast Cancer 20 Years After Adjuvant Chemotherapy" . : 1622
January 2001 Byrd JC, Peterson BL, Park K, Morrison VL, Vardiman JW, Jacobson R, Rai K, Larson RA."Concurrent Rituxumab and Fludarabine has a Higher Complete Response Rate Than Sequential Treatment in Untreated Chronic Lymphocytic Leukemia (CLL) Patients: Results From CALGB 9712" . : 772a
January 2001 Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Shiffer CA."Cladribine has Clinical Activity in Patients with Fludarabine Refractory Chronic Lymphocytic Leukemia Who Lack Pre-Treatment Cytopenias: Results From CALGB Study 9211" . : 634a
January 2001 Byrd JC, Peterson B, Park K, Morrison V, Vardiman JW, Jacobson RJ, Rai K, Larson AR."Rituximab Added to Fludarabine Improves Response in Previously Untreated Chronic Lymphocytic Leukemia: Preliminary Results From CALGB 9712" . : 1116
January 2001 Byrd JC, Mrozek K, Dodge R, Carroll AJ, Edwards C, Pettenati MJ, Patil SR, Larson RA, Bloomfield C."Pre-treatment Cytogenetics Predict Initial Induction Success and Overall Survival in Adult Patients with De Novo Acute Myeloid Leukemia: Results From CALGB 8461" . : 457a
January 2001 Bloomfield CD, Byrd JC, Farag SS, Mrozek K, Dodge RK, Archer KJ, Whitman S, Larson RA, Carroll AJ, Caligiuri MA."Cytogenetics for Treatment Stratification in Adult Acute Myeloid Leukemia (AML)" . : S37
January 2002 Rai KR, Byrd JC, Peterson B, Larson RA."A Phase II Trial of Fludarabiine Followed by Alemtuzumab (Campath-1H) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients with Active Disease: Cancer and Leukemia Group B (CALGB) Study 19901" . : 205a
January 2002 Lucas DM, Parthun MR, Mojica RD, Mone AP, Byrd JC, Grever MR."MS-275 Reduces Viability and Induces Changes in Histone Acetylaton in Cells From Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)" .
January 2002 Lucas DM, Davis M, Parthun MR, Mojica RC, Mone AP, Zwiesler J, Byrd JC, Grever MR."MS-275 Promotes Apoptosis in Cells from Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Concurrent with Inhibition of Histone Deactylase" . : 386a
January 2002 Lucas DM, Baird ME, Byrd JC, Tschumper RC, Jelinek DF, Kitada S, Reed JC, Rosenwald A, Staudt LM, Neuberg DS, Tallman MS, Flinn IW, Grever MR."ZAP70 and Caspase-3 Protein Expression Independently Associate with Immunoglobulin VH Gene Mutational Status in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)" . : 381a
January 2002 Lin TS, Stock W, Lucas MS, Porcu P, Abhyankar VV, Jefferson SK, Briggs B, Wang H, Cheney C, Flinn IW, Grever MR, Dalton JT, Byrd JC."A Phase I Dose Escalation Study of Apolizumab (Hu1D10) Using a Stepped Up Dosing Schedule in Patients with Chronic Lymphocytic Leukemia (CLL) and Acute Lymphocytic Leukemia (ALL)" . : 807a
January 2002 Lin TS, Molina A, Penza SL, Farag SS, Avolos BR, Grever MR, Copelan EA, Byrd JC."Diffuse Alevolar Hemmorrhage in Patients Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation after Prior Autologous/Syngeneic Transplantation" . : 378b
January 2002 Lin TS, Flinn IW, Lucas MS, Sickler J, Moran ME, Porcu P, Lucas DM, Grever MR, Byrd JC."Fligrastim and Alemtuzumab (Campath-1H) for Refractory Chronic Lymphocytic Leukemia: High Frequency of Cytomegalovirus Disease and Delayed Neutropenia" . : 807a
January 2002 Lin TS, Elder PJ, Penza SL, Avalos BR, Farag SF, Molina Mrozek E, Belt PS, Porcu P, Marcucci G, Byrd JC, Edward A. Copelan."Autologous Stem Cell Transplants Result in Better 5-year Overall, but Not Progression-Free, Survival Than Allogeneic Transplants in Patients with Indolent Non-Hodgkin’s Lymphoma" . : 644a
January 2002 Abhyankar VV, Lucas MS, Stock W, Aron JL, Briggs BR, Mone A, Porcu P, Wang H, Chen H, Flinn IW, Grever MR, Byrd JC."Phase I Study of Escalated Thrice Weekly Dosing of Hu1D10 in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Minimal Toxicity and Early Observation of in vivo Tumor Cell Apoptosis" . : 1069
January 2002 Raval A, Rush LJ, Funchain P, Flak E, Davis M, Johnson AJ, Byrd JC, Plass C."Aberrant DNA Methylation in Chronic Lymphocytic Leukemia: A Role in Pathogenesis?" . : 379a
January 2002 Kitada S, Young D, Pearson M, Flinn IW, Shinn CA, Reed JC, Byrd JC."Mcl-1/Bax Ratio Is a Predictor for Outcome of Rituximab Therapy in Patients with CLL" . : 376a
January 2002 Kelliher A, Preffer F, Frankel SR, Schlossman R, Mitsiades CS, Mitsiades N, Emmanouilides CE, Kimby E, Byrd JC, Anderson KC, Treon SP."Expression of Serotherapy Target Antigens in Lymphoplasmacytic Lymphoma (Waldenstrom’s Macroglobulinemia)" . : 1112
January 2002 Dewald GW, Paietta E, Goloubeva O, Bennett JM, Brockman SR, Paternoster SF, Lucas D, Neuberg D, Flinn I, Tallman M, Grever MR, Byrd JC."Correlation of Interphase Fluorescence In Situ Hybridization (FISH) Abnomalies with Cell Morphology and Immunophenotyping in Chronic Lymphocytic Leukemia (B-CLL)" . : 594a
January 2002 Bruner RJ, Marcucci G, Binkley P, Xiao J, Chan K, Parthun M, Davis M, Fischer B, Shank F, Moran M, Grever MR, Byrd JC."Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (FR901228) in Fludarabine Refractory Chronic Lymphocytic Leukemia" . : 86a
January 2002 Bruner RJ, Marcucci G, Binkley P, Fischer B, Parthun M, Davis M, Xiao J, Chan K, Wright J, Grever MR, Byrd JC."A Phase I Study to Determine Minimally Effective Pharmacologic Dose of Depsipeptide (FR901228) in Selected Hematologic Malignancies" . : 1059
January 2002 Sooraj LN, Marcucci G, Byrd JC, Bruner RJ, Fischer B, Hatton P, Grever MR, Binkley PF."Cardiovascular Response to Depsipeptide: Absence of Cardiotoxicity in Human Recipients" . : 378b
January 2002 Smith LL, Heerema N, Hackbarth ML, Flinn IW, Young D, Proffitt JH, Byrd JC."Interphase Cytogenetics Are Predictive of Chronic Lymphocytic Leukemia (CLL) Response to Thrice Weekly Rituximab Therapy" . : 546
January 2002 Mone AP, Lucas D Aron J, Cheney C, Johnson AJ, Bains SK, Tso JY, Weiner G, Green J, Grever MR, Byrd JC."Hu1D10 with P13 Kinase Inhibitors" . : 386a
January 2002 Marcucci G, Stock W, Klisovic MI, Guimond M, Sher DA, Moran M, Zwiebel JA, Cataland S, Kefauver C, Chan KK, Frankel SR, Grever MR, Byrd JC."In Vivo Activity of Gemasemse (G3139) (GS), a Bc1-2 Antisense Oligonucleotide in Previously Untreated Patients (pts) >60 Years with Acute Myeloid Leukemia (AML): Initial Report of a Phase I Study in Combination with Daunorubicin and Cytarabine" . : 337a
January 2002 Heinrich MC, Druker BJ, Curtin PT, Paquette R, Sawyers CL, De Angelo DJ, Gilliland GD, Stone RM, Caliguiri MA, Byrd JC, Heaney ML, Nimer SD, Romanko KP, Lambing JL, Lokker NA, Giese NA, Gretler DD."A “First in Man” Study of the Safety and PK/PD of an Oral FLT3 Inhibitor (MLN518) in Patients with AML or High Risk Myelodysplasia" . : 336a
January 2002 Daniels JT, Perkins J, Byrd JC."Rituximab Is Effective for Patients with Splenic Lymphoma with Villous Lymphocytes" . : 312b
January 2003 Rassenti LZ, Toy TL, Huynh L, Greaves A, Gribben JG, Keating MJ, Rai KR, Flinn IW, Byrd JC, Kay NE, Goldin LR, Caporaso NE, Kipps TJ."High Similarity between Familial and Sporadic Cases of Chronic Lymphocytic Leukemia." . : 670a
January 2003 Rassenti LZ, Huynh L, Toy TL, Gribben JG, Keating MJ, Rai, Flinn IW, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ."Zap-70 Is a More Reliable Marker of Disease Progression Risk Than Immunoglobulin Mutation Status in Chronic Lymphocytic Leukemia" . : 34a
January 2003 Rai KR, Byrd JC, Peterson B, Gautier M, Larson RA."Subcutaneous Alemtuzumab Following Fludarbine for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): CALGB Study 19901" . : 676
January 2003 Lucas DM, Zhang L, Freitas MA, Wickham J, Parthun MR, Davis ME, Marcucci G, Byrd JC, Grever MR."MS-275 Mediated Apoptosis and Generation of Reactive Oxygen Species Are Caspase Dependent in B-Cell Chronic Lymphocytic Leukemia (CLL)" . : 431a
January 2003 Liu S, Shen T, Rush LJ, Becknel B, Klisovic MI, Whitman SP, Vukosavljevic T, Byrd JC, Plass C, Marcucci C."AML1/ETO Associates with DNA Methyltransferase 1 (DNMT1) in Inducing Transcriptional Repression of the AML1-Target Gene Interleukin-3 (IL-3)" . : 218a
January 2003 List AF, Byrd JC, Fenaux P, Gore SD, Hellstrom-Lindberg E, Mufti GJ, Seymour JF, Silverman LR, Zimmerman LS, Beach CL."[5056] Comparative Trial of Aazacitidine Versus Conventional Care in High Risk MDS Patients: Methodologic Challenges in Designing an International Survival Trial" . : 333b
January 2003 Farag SS, Flinn IW, Lehman T, Modali R, Byrd JC."FcRIIIa and FcRIIa Polymorphisms Do Not Predict Response to Rituximab in B-Cell Chronic Lymphocytic Leukemia" . : 675a
January 2003 Pathan N, Zou A, Wynne D, Chu P, Thall A, Byrd JC, Hanna H, Leigh B."Lumiliximab (IDEC-152), an Anti-CD23 Antibody, Induces Apoptosis In Vitro and In Vivo in CLL Cells" . : 438a
January 2003 Grever MR, Dewald GW, Lucas DM, Neuberg DS, Baird ME, Paternoster SF, Brockman SR, Lozanski G, Rizouli V, Gribben JG, Flinn IW, Tallman MS, Kitada, Reed JC, Staudt LM, Paietta E, Byrd JC."ZAP-70 Protein Expression Varies by Interphase Cytogenetic Group and May Predict Disease Progression to Requirement of Treatment among Select Genetic Groups in Patients with Chronic Lymphocytic Leukemia (CLL)" . : 73a
January 2003 Ansell S, Byrd JC, Horwitz S, Davis T, Borchmann P, Engert A, Strair R, Khan K, Keler T, Graziano R, Blanset D, Yellin M, Nichol G."Phase I/II Study of a Fully Human Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkins Disease (HD) and Anaplastic Large Cell Lymphoma (ALCL)" . : 181a
January 2003 Morrison VA, Byrd JC, Peterson BL, Rai KR, Larson RA."Adding Rituximab to Fludarabine Therapy for Patients with Untreated Chronic Lymphocytic Leukemia (CLL) Does Not Increase the Risk of Infection: Cancer and Leukemia Group B (CALGB) Study 9712" . : 440a
January 2003 Mone, AP, Cheney C, Huang P, Pelicano H, Green J, Tso JY, Johnson A, Byrd JC."Hu1D10 Activates Both Death and Survival Pathways in Primary Human Chronic Lymphocytic Leukemia Cells: Hu1D10 Induced Reactive Oxygen Species Activate the AKT Survival Pathway" . : 438a
January 2003 Mone AP, Cheney CM, Lin TS, Jefferson S, Byrd JC."Campath-1H Induces Caspase-Independent Apoptosis in Primary Human Chronic Lymphocytic Leukemia Cells through a Cytoskeletal Dependent Mechanism" . : 436a
January 2003 Kay NE, Lin T, Call T, Jelinek DF, Bone ND, Dewald GW, Heerema NA, Tschumper R, Smith L, Geyer SM, Byrd JC."Pentostatin Combination Therapy for Untreated B-Chronic Lymphocytic Leukemia" . : 676a
January 2003 Kasamon YL, Byrd JC, Grever MR, Diehl LF, Lucas MS, Garrett ES, Flinn IW."IL-2 Does Not Protect Against Fludarabine and Cyclophosphamide Induced Immunosuppression" . : 637a
January 2003 Johnson AJ, Eisenbeis CF, Cheney CM, Mone AP, Lucas DM, Byrd JC."Rituximab and 17-AAG Synergistically Induce Apoptosis in B-Cell Chronic Lymphocytic Leukemia (CLL)" . : 437a
January 2003 Marcucci G, Stock W, Zwiebel JA, Cataland SR, Dai F, Moran M, Lucas D, Liu S, Klisovic MI, Kefauver C, Green M, Chan KK, Frankel SR, Grever MR, Byrd JC."Clinical Activity of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in Combination with Daunorubicin and Cytarabine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML)" . : 385a
January 2003 Marcucci G, Dai G, Klisovic MI, Shen T, Liu S, Sher DA, Lucas D, Whitman SP, Vukosavljevic T, Zwiebel JA, Frankel SR, Grever MR, Stock W, Chan KK, Byrd JC."Pharmacologic and Biologic Assessment of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in Combination with Daunorubicin and Cytarabine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML)." . : 874a
January 2003 Byrd JC, Rai KR, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA."The Addition of Rituximab to Fludarabine Significantly Improves Progression-Free and Overall Survival in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients" . : 73a
January 2003 Byrd JC, Brien SO, Flinn I, Kipps TJ, Weiss MA, Reid J, Wynne D, Leigh BR."Interim Results from a Phase I Study of Lumiliximab (IDEC-152, Anti-CD23 Antibody) Therapy for Relapsed or Refractory CLL" . : 74a
January 2003 Blum W, Bolwell BJ, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA."Only Those Refractory AML Patients with Low Disease Burden Can Achieve Prolonged Leukemia-Free Survival with Conventional Unrelated Donor Transplantation" . : 488a
January 2004 Rawstron A, Villamor N, Zehnder J, Ghia P, Ritgen M, Bottcher S, Lozanski G, Mone A, Colomer D, Moreno C, Geuna M, Evans P, Kneba M, Natkunam Y, Coutre S, Caligaris-Cappio F, Hallek M, Byrd JC, Montserrat E, Hillmen P."International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL" . : 8a
January 2004 Rassenti L, Neuberg D, Keating M, Gribben J, Flinn I, Rai K, Byrd JC."CD38 Compared with ZAP-70 or Immmunoglobulin Mutation Status as Predictor of Disease Progression in Chronic Lymphocytic Leukemia. Session Type: Poster Session 75-IIIeil E. Kay, Thomas J. Kipps" . : 767a
January 2004 Lucas D, Zhang L, Davis M, Su X, Sklenar A, Parthun M, Freitas M, Kitada S, Reed J, Marcucci G, Grever M, Byrd JC."The Histone Deacetylase Inhibitor Depsipeptide Mediates Distinct Patterns of Histone Acetylation in Cells Overexpressing Bcl-2" . : 766a
January 2004 Lucas D, Dewald G, Neuberg D, Byrd JC, Lozanski G, Harbison J, Cunningham K, Flinn I, Appelbaum F, Larson R, Tallman M, Grever M."Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Base" . : 272a
January 2004 Lin TS, Dalton J, Wu D, Fischer B, Moran M, Lucas D, Cunningham K, Colevas A, Grever MR, Byrd JC."Single Agent Flavopiridol Given as a 30-Minute Intravenous (IV) Bolus Followed by 4-Hour Continuous Infusion Results in Clinical Activity and Tumor Lysis in Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL)" . : 571
January 2004 Lin T, Heerema N, Swenor J, Lucas M, Moran M, Cheney C, Lucas D, Young D, Caligiuri M, Grever M, Byrd JC."A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities" . : 945a
January 2004 Lin T, Fischer B, Moran M, Lucas D, Shank R, Kraut E, Farag S, Lucas M, Colevas A, Grever M, Byrd JC."Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma" . : 683a
January 2004 Lin T, Biswas S, Naumovski L, Lecane P, Lucas M, Moran M, Mone A, Lucas D, Phan S, Miller R, Byrd JC."Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL)" . : 945a
January 2004 Grever M, Lucas D, Dewald D, Neuberg D, Flinn I, Appelbaum F, Larson R, Tallman M, Gribben J, Byrd JC."Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997" . : 950a
January 2004 Byrd JC, Peterson B, Gabrilove J, Odenike O, Grever M, Rai K, Vardiman J, Larson R."Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805" . : 950a
January 2004 Byrd JC, O'Brien S, Flinn I, Kipps T, Weiss M, Rai K, Lin T, Reid J, Wynne D, Leigh B."Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia" . : 686a
January 2004 Byrd JC, Lin T, Dalton J, Wu D, Fischer B, Moran M, Blum K, Shank R, Lucas D, Lucas M, Suarez J, Colevas A, Grever M."Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL)" . : 101a
January 2004 Byrd JC, Gribben J, Peterson B, Grever M, Lozanski G, Lucas D, Larson R, Caligiuri M, Heerema N."Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted" . : 139a
January 2004 Blum W, Penza S, Farag S, Avalos B, Marcucci G, Lin T, Byrd JC, Elder P, Copelan E."Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens" . : 364b
January 2004 Blum W, Blum K, Kefauver C, Moran M, Chan K, Byrd JC, Cataland S, Grever M, Marcucci G.."Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report" . : 215b
January 2004 Biswas S, Mone A, Sen C, Muthusamy N, Byrd JC."Arsenic Trioxide and Ascorbic Acid Enhances the Cytotoxicity of Hu1D10 towards CLL Cells" . : 948a
January 2004 Porcu P, Baiocchi R, Buckner M, Byrd JC, Magro C."Bexarotene-Induced T-Cell Immunomodulation and Response in CTCL" . : 213a
January 2004 Kitada S, Reed J, Lucas D, Neuberg D, Gribben J, Dewald G, Flinn I, Appelbaum F, Larson R, Tallman M, Byrd JC, Grever M."Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment" . : 274a
January 2004 Faderl S, Rai K, Gribben J, Flinn I, Byrd JC, McConkey D, Schenkein D, Esseltine D, Browning M, Keating M."Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL" . : 293b
January 2004 Benson D, Elder P, Lin T, Blum B, Penza S, Avalos B, Byrd JC, Copelan E, Farag S."Single Institution Experience with Two High-Dose Chemotherapy (HDC) Conditioning Regimens Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM)" . : 388b
January 2004 Ansell S, Byrd JC, Horwitz S, Borchmann P, Engert A, Strair R, Khan K, Fischkoff S, Yellin M."Phase I/II, Open-Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Subjects with Refractory/Relapsed CD30 Positive Lymphoma" . : 721a
January 2004 Naumovski L, Ramos J, Chen J, Sirisawad M, Lucas D, Byrd JC, Miller R."Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors" . : 929a
January 2004 Muthusamy N, Chen H, Frissora F, Byrd JC."Generation and Analysis of Transgenic Mice Reveal a Role for CRE Binding Proteins in Multiple Stages of B Cell Development, Functional Maturation, Proliferation and Apoptosis" . : 833a
January 2004 Motiwala T, Ghoshal K, Majumder S, Kutay H, Neuberg D, Kitada S, Reed J, Dewald G, Flinn I, Appelbaum F, Larson R, Tallman M, Liu T, Plass C, Lucas D, Byrd JC, Jacob S, Grever M."Methylation of the Tumor Suppressor Gene PTPRO (Receptor-Type Protein Tyrosine Phosphatase) Is Associated with Expression of Important Apoptosis-Related Proteins in Chronic Lymphocytic Leukemia (CLL)" . : 767a
January 2004 Mone A, Cheney C, Banks A, Jefferson S, Lin T, Eisenbeis C, Byrd JC."Alemtuzumab Induces Cell Death in Human Chronic Lymphocytic Leukemia Cells through a Lipid Raft-Dependent Mechanism" . : 687a
January 2004 Mone A, Byrd JC."Leflunomide Inhibits Proliferation of Neoplastic B-Cell Lines and Induces Apoptosis in Primary CLL Cells" . : 685a
January 2004 Kay N, Geyer S, Lin T, Call T, Jelinek D, Bone N, Dewald G, Heerema N, Tschumper R, Smith L, Grever M, Byrd JC."Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia" . : 100a
January 2004 Johnson A, Smith L, Zhu J, Heerema N, Guster S, Mone A, Grever M, Chen C, Byrd JC."A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism" . : 946a
January 2004 Zhao X, Biswas S, Mone A, Ledbetter J, Ledbetter M, Grosmaire L, Espling E, Cheney C, Young D, Lee R, Muthusamy N, Byrd JC."Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells" . : 689a
January 2004 Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu Y, Raval A, Liu T, Ding W, Mao C, Liu S, Smith L, Lee S, Rassenti L, Marcucci G, Byrd JC, Caligiuri M, Plass C."Global Assessment of Promoter Methylation in a Murine Model of Cancer Identifies ID4 as a Putative Novel Tumor Suppressor Gene in Human Leukemia" . : 951a
January 2004 Woodworth J, Leigh B, O'Brien S, Flinn I, Kipps T, Weiss M, Rai K, Thall A, Wynne D, Byrd JC."Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia" . : 290b
January 2004 Marcucci G, Stock W, Dai G, Liu S, Klisovic R, Klisovic M, Sher D, Huynh L, Frankel S, Blum W, Larson R, Grever M, Byrd JC, Chan K."Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML)" . : 331a
January 2005 Heerema N, Lozanski G, Lin T, Moran M, Grever M, Byrd JC."Cytogenetic Studies of 539 Chronic Lymphocytic Leukemia (CLL) Patients" . : 348a
January 2005 Wadehra N, Lin T, Ryan T, Schneider A, Pepple A, Johnston J, Dalton J, Banks A, Eisenbeis C, Lai R, Byrd JC, Blum K, Baiocchi R."Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma" . : 677a
January 2005 Porcu P, Mone A, Puhalla S, Whitman S, Baiocchi R, Caligiuri M, Byrd JC."Durable Complete Response (CR) and Suppression of the human T-cell leukemia virus (HTLV-1) Viral Load (VL) with Alemtuzumab in Refractory Adult T-cell leukemia (ATL)" .
January 2005 Lin T, Fischer B, Moran M, Buckner M, Shank R, Kraut E, Porcu P, Farag S, Eisenbeis C, Colevas D, Grever M, Byrd JC."Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma" . : 278a
January 2005 Gowda A, Zhao X, Cheney C, Mehter N, Lozanski G, Lin T, Guster S Drachman J,Muthusamy Natarajan, Byrd JC."Humanized Anti CD-40 Antibody SGN-40 Effectively Induces Cytotoxicity Against Chronic Lymphocytic Leukemia (CLL) Cells through Antibody Mediated Cytotoxicity and Demonstrates Modest Biologic Evidence of CD40" . : 832a
January 2005 Fukuda T, Neuberg DS, Huynh L, Rassenti L, Toy TL, Rai K, Keating MJ, Gribben JG, Flinn IW, Byrd JC, Neil NE, Kipps TJ."Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia" . : 826a
January 2005 Klisovic RB, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel JA, Byrd JC, Grever M, Marcucci G."A Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase (RNR) in Combination with High-Dose Cytarabine (HiDAC) in Relapsed or Refractory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamic (PD) and Clinical Results" . : 782a
January 2005 Stock W, Yu D, Sanford B, Lozanski G, Cataland S, Vij R, Byrd JC, Powell B, Wetzler M, Albitar M, Sher D, Edwards C, Hoke E, Bloomfield C, Larson R."Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102)" . : 46a
January 2005 Shapiro CL, Ramaswamy B, Young D, Lamb T, Lucas D, Shaaf L, Sahenk Z, Collamore M, Byrd JC, Wright J, Grever M."Phase I trial of bortezomib (Velcade™) in combination with paclitaxel in advanced solid tumor patients (pts)" .
January 2005 Moran M, Fischer B, Broering S, Blum K, Lin T, Byrd JC, Grever C, Brooker-McEldowney M."Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule" . : 600a
January 2005 Johnson A, Edwards R, Smith L, Lucas D, Croce C, Muthusamy N, Chen C, Liu Z, Chan K, Grever M, Byrd JC."The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia" . : 20a
January 2005 Blum W, Bruner-Klisovic R, Liu S, Byrd JC, Liu Z, Chan K, Kenneth, Kefauver C, Huynh L, Grever M, Marcucci G."Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity" . : 529a
January 2006 Zhao XB, Trupti JI, Lapalombella R, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC."NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL" . : 138
January 2006 Shanafelt TD, Byrd JC, Geyer SM, Bowen D, LaPlant B, Zent CS, Call TG, Kay NE."The Pentostatin, Cyclophosphamide, and Rituximab Regimen (PCR) Is Highly Active and Well Tolerated Regardless of Patient Age, Creatinine Clearance, and Performance Status: Analysis of a Multi-Center Phase II Trial" . : 130
January 2006 Kay N, Geyer, S, Call T, Shanafelt T, Zent C, Jelinek D, Tschumper R, Bone N, Dewald G, Lin T, Heerema N, Smith L, Grever M, Byrd JC."Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia" . : 130
January 2006 Johnson AJ, Wagner AJ, Smith LL, Lucas DM, De Lay MD, Allison JM, Ivy SP, Lin TS, Byrd JC."The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL" . : 596a
January 2006 Farag SS, Zhang S, Miller M, Buckner M, Kraut E, Chan K, Eng C, Byrd JCrever MR."Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results" .
January 2006 Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas D, Colevas AD, Grever MR, Marcucci G, Byrd JC."Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics" .
January 2006 Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas , Huynh, L, Liu S, Grever MR, Colevas AD, Marcucci G, Byrd JC."Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD)" . : 222b
January 2006 Blum KA, Young D, Broering S, Lucas MS, Lin TS, Grever MR, Byrd JC."The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS" . : 802a
January 2006 Blum KA, Lucas MS, Johnston JS, Dalton J, Young D, Baiocchi RA, Lin TS, Porcu P, Byrd JC."Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma" . : 784a
January 2006 Yu J, Yu Li, Hackanson B, Wei M, Boyd Z, Yokohama A, Liu C, Trotta R, Mao HC, Becknell B, Jaung MS, Liu S, Byrd JC, Marcucci G, Plass C, Caligiuri MA."In Vitro and In Vivo Evidence That TSC-22 Is a Putative Tumor Suppressor Gene in Primary Murine and Human Leukemia" . : 627a
January 2006 West DA, Lucas DM, Davis ME, De Lay MD, Johnson AJ, Guster S, Freitas MA, Parthun MR, Wang D, Kulp SK, Grever MR, Chen CS, Byrd JC."The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia" . : 794a
January 2006 Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti C, Roy DC, Caligiuri MA, Bloomfield CD, Chen CS, Byrd JC, Perrotti D."FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients" . : 151
January 2006 Marcucci ,G Klisovic RB, Wei W, Liu S, Paschka P, Huynh L, Zwiebel JA, Byrd JChan K, Blum W."A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML)" .
January 2006 O'Brien S, Byrd JCrero-Torres A, Flinn IW, Wynne DI, Molina A."Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL)" .
January 2006 Lapalombella R, Zhao XB, Grosmaire L, Ledbetter JA, Muthusamy N, Byrd JC."CD37-SMIPTM Drug Induced Caspase Independent Cellular Cytotoxicity Is Associated with Activation of Phosphotyrosine-Mediated Signaling Events in Primary Chronic Lymphocytic Leukemia (CLL) B Cells" . : 595a
January 2006 Klisovic RB, Blum W, Hackanson B, Kefauver C, Liu S, Liu Z, Chan ZZ, Plass C, Grever MR, Byrd JC."Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation, and clinical response" .
January 2006 Edwards RB, Lucas DM, Lozanski G, Johnson AJ, Su, B, Lin TS, Byrd JC, Grever MR."Silvestrol, a Rocaglate Derivative from the Indonesian Plant Aglaia foveolata, Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells" . : 734a
January 2006 Damon LE, Johnson J, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Byrd JCnker C, Canellos GP."mmuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909" . : 774a
January 2006 Ali NA, O'Brien JM, Blum W, Klisovic RB, Marcucci G, Phillips G, Marsh CB, Lemeshow, Stanley, Byrd, Byrd JCael R."Hyperglycemia in Patients with Acute Myeloid Leukemia Is Associated with Increased Hospital Mortality" . : 476b
January 2006 Rassenti LZ, Neuberg DS, Huynh L, Wierda WG, Gribben JG, Brown JR, Flinn IW, Rai KR, Byrd JCves AW, Kipps TJ."Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia" . : 786a
January 2006 Porcu P, Baiocchi RA, Lee J, Lin TS, Blum K, Grady T, Grever MR, Byrd JC."Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: Preliminary results" .
January 2006 Phelps MA, Wu D, Byrd JC K, Schaaf L, Johnson AJ, Colevas AD Grever MR, Dalton JT."Pharmacokinetic and pharmacodynamic correlations of flavopiridol in the treatment of chronic lymphocytic leukemia" .
January 2006 Lucas DM, Hussain SA, Johnson AJ, Smith,LL, Wagner AJ, Allison JM, Guster SE, Lin TS, Byrd JCrouser, ED, Grever MR."Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells" . : 595a
January 2006 Lozanski G, Sanford B, Yu D, Pearson R, Edwards Colin, Byrd JCfield CD, Stock W."CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights" . : 650a
January 2006 Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Perrotti D, Chen CS, Dalton JT, Byrd JC."FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma" . : 595a
January 2006 Lin TS, Phelps M, Dalton JT, Fischer B, Blum KA, Moran ME, McEldowney MB, Broering S, Colevas D, Byrd JC."Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity" . : 805a
January 2006 Lin TS, L MS, Heerema NA, Matkovich JJ, Moran ME, Cheney C, Lucas DM, Young DC, Caligiuri MA, Grever MR, Byrd JC."A Phase II Study of the TNF-{alpha} Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities" . : 804a
January 2006 Lin TS, Heerema NA, Fischer B, Blum KA, Moran ME, McEldowney MB, Broering S, Lozanski G, Colevas D, Grever MR, Byrd JC."Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality" . : 153
January 2006 Lin TS, Fischer B, Moran ME, Shank RS, Kraut E, Porcu P, Farag SS, Blum KA, Colevas AD, Grever MR, Byrd JC."Flavopiridol, fludarabine and rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL)" .
January 2006 Grever MR, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Appelbaum FR, Larson RA, Tallman MS, Gribben JG, Byrd JC."Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: Prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy" .
January 2006 Ghia EM, Rassenti LZ, Widhopf GF, Neuberg DS, Keating MJ, Wierda WG, Gribben J G, Brown JR, Flinn IW, Rai KR, Byrd JCves AW, Kipps TJ."Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression" . : 785a
January 2006 Byrd JCon JT, Phelps M, Fischer B, Moran M, Blum K, Rovin B, Colevas AD, Grever MR, OSU CLL Team."Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high risk chronic lymphocytic leukemia (CLL)" .
January 2006 Byrd JCBrien S, Flinn IW, Forero-Torres A, Kipps T, Heerema NA, Lin T, Kheoh T, Wynnem D, Molina A."Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results" . : 130
January 2006 Byrd JCan KD, Kipps TJ, Aukerman L, Fox J, Girish S, Guzy S, Bilic S, Solinger A, Dort S, Wang Y, Hurst D, O'Brien S."Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia" . : 803a
January 2006 Browning RE, Lucas DM, Geyer SM, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC."Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia" . : 790a
January 2007 Rattmann I, Zhu D, Croce CM, Byrd JC, Gu Y, Moritz T, Williams DA."The Expression of the GTPase-Deficient, Hematopoietic-Specific RhoH GTPase Is Implicated in Development of Chronic Lymphocytic Leukemia (CLL)" . : 107a
January 2007 Rassenti L, Huynh L, Basak GW, Ghia EM, Van Dyke D, Heerema N, Zahrieh D, DalCin P, Dell’Aquila ML, Koduru P, Byrd JC, Kay NE, Rai KR, Brown JR, Wierda WW, Greaves AW, Kipps TJ."TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP-70" . : 616a
January 2007 Ramaswamy B, Lai JP, Phelps M, Dalton J, Arbogast D, Wilkins D, Colevas D, Byrd JC, Grever MR, Shah M."A Phase I Study of Flavopiridol Using an Alternative Schedule of 30-min Loading Dose Followed by a 4-hour Infusion in Patients (pts) with Advanced Solid Tumors" .
January 2007 Majumder S, Motiwala T, Ghoshal k, Kutay H, Datta J, Lucas D, Byrd JC, Jacob ST."Protein Tyrosine Phosphatase Receptor Type O (PTPRO) Exhibits Tumor Suppressor Properties in K562 Cells by Dephosphorylating Bcr-Abl" . : 857a
January 2007 De Lay MD, Johnson AJ, Lucas DM, Durr DT, Sass EM, Goettl VM, Lehman A, Jarjoura D, Grever MR, Byrd JC."Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia (CLL)" . : 910a
January 2007 Andritsos LA, Jones JA, Lozanski G, Lin TS, Blum KA, Grever MR, Jarjoura D, Byrd JC, Heerema N."del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement" .
January 2007 Andritsos LA, Johnson AJ, Blum WE, Kefauver C, Awan F, Smith LL, Lapalombella R, Wang DS, Knight RD, Chen CS, Byrd JC."Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses" . : 255b
January 2007 Andritsos LA, Fischer B, Lin TS, Blum KA, Jones JA, Moran ME, Byrd JC, Grever MR."Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol" . : 920a
January 2007 Lapalombella R, Zhao XB, Baum PR, Ledbetter JA, Muthusamy N, Byrd JC."Role of CD37SMIP a Novel Engineered Small Modular Immunopharmaceutical in the Treatment of CLL" . : 246a
January 2007 Gowda AC, Ramanunni A, Cheney A, Roda J, Kindsvogel W, Henderson D, Pallavur S, Carson W, Muthusamy N, Byrd JC."IL-21 enhances chemoimmunotherapy mediated death of chronic lymphocytic leukemia cells" .
January 2007 Ghia EM, Rassenti LZ, Widhopf GF, Silverman GJ, Neuberg DS, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ."Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L" . : 227a
January 2007 Garzon R, Liu S, Fabbri M, Liu Z, Pang J, Muthusamy N, Blum WG, Chan K, Byrd JC, Croce CM, Marcucci G."MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML)" . : 220a
January 2007 Timmerman JM, Byrd JC, Andorsky DJ, Siadak MF, DeVries T, Hausman DF, Pagel JM."Recombinant Interleukin-21 Plus Rituximab: Clinical Activity in a Phase 1, Dose-Finding Trial in Relapsed Low-Grade B Cell Lymphoma" . : 759a
January 2007 Porcu P, Baiocchi RA, Lin TS, Blum KA, Curtis P, Grever MR, Byrd JC."A Phase I Trial of Subcutaneous (SQ) Dose-Escalated Alemtuzumab in Patients with T-Cell Lymphoproliferative Disorders (T-LPD)" . : 1001a
January 2007 Pathan N, Byrd JC, Hariharan K, Chu P, Molina A."Lumiliximab (anti-CD23 antibody) mediates apoptosis and antitumor activity in chronic lymphocytic leukemia (CLL) cells and CD23+ lymphoma cell lines" .
January 2007 Lucas DM, Edwards RB, De Lay MD, West DA, Lozanski G, Johnson AJ, Salim AA, Lin TS, Byrd JC, Kinghorn AD, Grever MR."The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL" . : 919a
January 2007 Lin TS, Fischer B, Blum KA, Andritsos LA, Jones JA, Moran ME, Broering S, Heerema NA, Lozanski G, Schaaf LJ, Mahoney LS, Johnson AM, Smith LL, Wagner AJ, Raymond CA, Phelps M, Dalton JT, Grever MR, Byrd JC."Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR)" . : 913a
January 2007 Lin TS, Donohue KA, Lucas MS, Byrd JC, Bengston EM, Peterson BL, Larson RA."Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the" . : 232a
January 2007 Heerema NA, Byrd JC, Andritsos LA, Lozanski G, Blum K, Fischer B, Jones JA, Moran ME, Broering S, Schaaf LJ, Mahoney LS, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps MA, Dalton JT, Grever MR, Lin TS."Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts)" . : 914a
January 2007 Roda JM, Lapalombella R, Baiocchi R, Zhukocsky E, Desjarlias J, Muthusamy N, Byrd JC."Pre-Clinical Activity of a Novel Fc RIIIa Engineered CD19 Monoclonal Antibody in B Cell Chronic Lymphocytic Leukemia and Acute Lymphoblastic Leukemia" . : 695a
January 2007 Roda J, Gowda A, Hussain R, Ramanunni A, Lehman A, Kindsvogel W, Carson WE, Muthusamy N, Byrd JC."IL-21 Promotes Apoptosis through Induction of the BH3 Only Protein Bim and Enhacnes Direct and Innate Immune-Promoted Death of Chronic Lymphocytic Leukemia Cells" . : 917a
January 2007 Morrison VA, Peterson BL, Rai KR, Byrd JC, Larson RA."Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901)" . : 233a
January 2007 Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R, List AF, Gore SD, Seymour JF, Hellstrom-Lindberg E, Bennett JM, Byrd JC, Backstrom JT, Zimmerman LS, McKenzie DR, Beach CL, Silverman LR."Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study" . : 250a
January 2007 Blum WG, Klisovic RB, Johnson A, Kefauver C, Phelps M, Lucas DM, Huynh, L, Liu S, Dalton JT, Grever MR, Marcucci G, Byrd JC."Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule" . : 272a
January 2008 Woyach JA, Lucas MS, Heerema NA, Moran ME, Lucas DM, Young D, Caligiuri MA, Lin TS, Byrd JC."Combination therapy with etanercept and rituximab in relapsed CLL/SLL" .
January 2008 Smoley SA, Van Dyke DL, Kay NE, Heerema NA, dell’ Aquila ML, Koduru P, Dal Cin P, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Kipps TJ, Dewald GW."Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium" . : 390
January 2008 Neviani P, Santhanam R, Ma Y, Marcucci G, Byrd JC, Chen CS, Cortes J, Caligiuri MA, Huettner C, Bhatia R, Roy DC, Perrotti D."Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38– Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals" . : 77
January 2008 Lannutti BJ, Meadows SA, Kashishian A, Steiner B, May S, Johnson AJ, Ulrich RG, Yu A, Gallatin MW, Byrd JC, Puri KD, Giese NA."CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies" . : 12
January 2008 Czuczman MS, Leonard JP, Johnson JL, Jung SH, Hsi E, Byrd JC, Cheson BD."FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]" . : 369
January 2008 Blum WG, Andritsos LA, Johnson AJ, Klisovic RB, Kefauver C, Devine SM, Marcucci G, Byrd JC."Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dos" .
January 2008 Blum W, Klisovic R, Liu S, Garzon R, Kefauver C, Liu Z, Mickle J, Devine H, Devine S, Grever MR, Chan KK, Villalona-Calero M, Byrd JC, Marcucci G."Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age 60) with Previously Untreated Acute Myeloid Leukemia (AML)" . : 1016
January 2008 Blum KA, Liu A, Lucas DM, Baiocchi R, Lin TS, Benson D, Devine SM, Jones J, Andritsos L, Flynn J, Cheng P, Xie Z, Marcucci G, Chan KK, Grever MR, Byrd JC."A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation" . : 1087
January 2008 Blum KA, Baiocchi RA, Alinari L, Lin TS, Porcu P, Jones J, Flynn J, Hicks W, Lucas MS, Wei L, Johnston JS, Byrd JC."A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma" . : 1049
January 2008 Benson D, Andritsos L, Hamadani M, Lin T, Flynn J, Jones J, Blum W, Elder P, Lozanski G, Byrd JC, Devine S."Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation" . : 1133
January 2008 Lin TS, Heerema NA, Lozanski GA, Fischer B, Blum KA, Andritsos LA, Jones JA, Flynn JM, Moran ME, Mitchell S, Johnson AJ, Phelps MA, Grever MR, Byrd JC."Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities" . : 24
January 2008 Lin TS, Fischer B, Blum KA, Porcu P, Kraut EH, Baiocchi RA, Moran ME, Mitchell S, Grever MR, Byrd JC."Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma" . : 557
January 2008 Lin TS, Andritsos LA, Jones JA, Fischer B, Heerema NA, Blum KA, Flynn JM, Moran ME, Phelps MA, Grever MR, Byrd JC."Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)" .
January 2008 Hertlein EK, West DA, Craig RW, Lucas DM, Byrd JC."NF- B Is Active in Mcl-1 Promoter Regulation in Human CLL" . : 790
January 2008 Byrd JC, Castro JE, Flinn IW, Forero-Torres A, Kipps TJ, Heerema NA, Lin TS, Mu H, Tangri S, Brien S."Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study" .
January 2008 Brown JR, Rassenti L, Neuberg D, Greaves A, Byrd JC, Grever MR, Gribben JG, Kay NE, Keating M, Rai KR, Wierda WG, Kipps TJ."Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort" . : 1071
January 2008 Timmerman JM, Byrd JC, Andorsky DJ, Siadak MF, DeVries TA, Hausman DF, Pagel JM."Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma" .
January 2008 Tangri S, Ranuio J, Estrellado A, Byrd JC, O' Brien S, Kipps TJ, Cesano A, Mu H, Harris S."Immunophenotypic characterization of relapsed chronic lymphocytic leukemia patients treated with lumiliximab in combination with FCR" .
January 2008 May SE, Kashishian A, Lin TS, Jones JA, Flynn JM, Ulrich RG, Chen H, Yu AS, Puri KD, Lannutti BJ, Giese NA, Byrd JC, Johnson AJ."CAL-101, a Selective Inhibitor of the p110 Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease" . : 1085
January 2008 Jones JA, Flynn JM, Byrd JC."Rates of Preventable Hospitalization for Ambulatory Care Sensitive Conditions (ACSCs) among Patients with Lymphoid Malignancies (LM)" . : 323
January 2008 Jones JA, Byrd JC, Flynn JM, Hofmeister C."Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care" . : 840
January 2008 Wagner AJ, Hertlein EK, Raymond CA, West DA, Flynn JM, Lin TL, Johnson AJ, Byrd JC."17-DMAG Targets the NF- B Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition" . : 147
January 2008 Kay NE, Wu W, Byrd JC, Kabat B, Jelinek DF, Zent CS, Call T, Lin T, Shanafelt T."Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy" . : 22
January 2008 Flynn JM, Andritsos LA, Lin TS, Byrd JC, Jones JA."Second primary malignancies after chronic lymphocytic leukemia" .
January 2008 Chen SS, Johnson AJ, Claus R, Sablitzky F, Plass C, Byrd JC."Loss of Id4 Accelerates CLL Progression in TCL1 Mice" . : 1081
January 2008 Awan F, Kay NE, Davis M, Wu W, Leung N, Jelinek DF, Tschumper R, Secreto C, Lin TS, Grever MR, Shanafelt T, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas D."Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab" . : 732
January 2008 Andritsos L, Hamadani M, Heerema NA, Benson D, Hofmeister CC, Blum W, Flynn J, Jones JA, Elder P, Lin TS, Lozanski G, Byrd JC, Devine S."Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)" 757.
January 2008 Alinari L, Hertlein E, Goldenberg DM, Lapalombella R, Yan F, Zhang X, Lucas DM, Muthusamy N, Byrd JC, Baiocchi RA."Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma" . : 327
January 2009 Hertlein EK, Triantafillou G, Hessler J, Zhang X, Jarjoura D, Lucas DM, Lee RJ, Muthusamy N, Goldenberg DM, Byrd JC."Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells" . : 301
January 2009 Hertlein EK, Lin TS, Wagner AJ, Towns II W, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Byrd JC, Johnson AJ."The HSP90 Inhibitor 17-DMAG Targets NF-κB to Induce Apoptosis in CLL and Prolongs Survival in a CLL Mouse Model" . : 305
January 2009 Heerema NA, Byrd JC, Cin PD, Dell' Aquila ML, Koduru P, Aviram A, Smoley S, Rassenti LZ, Greaves A, Brown JR, Rai KR, Kipps TJ, Kay NE, van Dyke D."Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study" . : 645
January 2009 Andritsos L, Furman RR, Flinn IW, Foreno-Torres A, Flynn JM, Muthusamy N, Rafiq S, Stromatt S, Byrd JC."A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity" . : 1330
January 2009 Andritsos L, Furman R, Flinn IW, Foreno-Torres A, Flynn JM, Stromatt SC, Byrd JC."A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL" .
January 2009 Alinari L, Liu Q, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Lin T, Byrd JC, Baiocchi RA, Muthusamy N."FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma" . : 1436
January 2009 Alinari L, Christian B, Yu B, Shin J, Hertlein EK, Lapalombella R, Yan F, Lesinski G, Zhang Xi, Lozanski G, Muthusamy N, Goldenberg DM, Byrd JC, Baiocchi RA.."Co-Treatment with Milatuzumab (Anti-CD74 mAb) and Rituximab (Anti-CD20 mAb) Results in the Induction of Mantle Cell Lymphoma Cell Death That Is Dependent On Actin Polymerization and Inhibition of NF-Kb" . : 675
January 2009 Maddocks K, Lapalombella R, Blum KA, Blum W, Fischer BB, Muthusamy N, Moran ME, Holtzapfel D, Byrd JC, Johnson AJ, Andritsos L."Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia" . : 1339
January 2009 Lucas DM, Sass EJ, Edwards RB, Pan L, Lozanski G, Heerema NA, Byrd JC, Kinghorn AD, Grever MR."Resistance to the Novel Translation Inhibitor Silvestrol Is Mediated by Elevated Mcl-1 Expression" . : 691
January 2009 Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu Y-Z, Hickey C, Yu J, Mishra A, Becker H, Li C, Briesewitz R, Baiocchi RA, Chan KK, Caligiuri MA, Byrd JC, Perrotti D, Garzon R, Marcucci G."Evidence of MicroRNA-29b and Sp1/N B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications" . : 387
January 2009 Flynn JM, Johnson AJ, Andritsos L, Blum KA, Jones JA, Wiley EA, Hu W, Hessler J, Smith LL, Lucas DM, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC."The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia" . : 365
January 2009 Flinn IW, Byrd JC, Furman RR, Brown JR, Lin TS, Bello C, Giese NA, Yu AS."Preliminary Evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies" .
January 2009 Flinn IW, Byrd JC, Furman RR, Brown JR, Benson DM, Coutre SE, Kahl BS, Smith BD, Wagner-Johnston ND, Spurgeon SE, Giese NA, Yu AS."Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies" . : 380
January 2009 Butchar JP, Mehta Pl, Justiniano SE, Guenterberg KD, Kanneganti TD, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson WE, Byrd JC, Tridandapani S."TLR7/8 Differentially Regulates Fcγ Receptor Expression and Function" . : 1391
January 2009 Browning RL, Wang SH, Ramanunni A, Muthusamy N, Byrd JC."Transcriptional up-Regulation of IL-21 Receptor-ά On CLL Cells by CpG685 through An NF-κB Mediated Pathway Provides a Rationale for Combination Strategies with IL-21" . : 1079
January 2009 Blum WG, Klisovic R, Liu S, Kefauver C, Grever MR, Schaaf L, Chan K, Byrd JC, Villalona-Calero M, Marcucci G."Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older" .
January 2009 Blum W, Klisovic RB, Walker A, Garzon R, Liu S, Schaaf LJ, Humphries K, Grever MR, Devine SM, Byrd JC, Marcucci G."Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)" . : 815
January 2009 Woyach JA, Ruppert AS, Heerema NA, Peterson B, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC."Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712" . : 226
January 2009 Woyach JA, Byrd JC, Zhao J, McFaddin A, Ruppert AS, Lin TS, Andritsos L, Blum KA, Flynn JM, Jones JA, Heerema NA."Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease" . : 508
January 2009 Rafiq S, Cheney C, Thompson PA, Siadak T, Algate P, Cerveny C, Byrd JC, Muthusamy N."Glycovariant CD37 Small Modular Immuno-Pharmaceutical (TruADhanCeTM SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells" . : 693
January 2009 Hassane D, Balys M, Marcucci G, Byrd JC, Jordan CT, Guzman ML."Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML)" . : 817
January 2009 Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Liu S, Pang J, Walker A, Klisovic RB, Garzon R, Grever MR, Villalona-Calero M, Byrd JC, Chan KK, Marcucci G."Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine" . : 1454
January 2009 Chandler JC, Klisovic RB, Phelps MA, Walker A, Garzon R, Yang X, Schaaf L, Schwind S, Becker H, Liu, S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, Blum W."Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia" . : 346
January 2009 Byrd JC, Lapalombella R., Ramanunni A, Andritsos LA, Flynn JM, Baum P, Thompson P, Muthusamy N."Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM" .
January 2009 Stock W, Sanford B, Lozanski G, Vij R, Byrd JC, Powell BL, Wetzler M, Sher D, Edwards C, Kelly M, Richards S, Sung C, Malnassy G, Hoke E, Bloomfield CD, Larson RA."Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102)" . : 345
January 2009 Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke E, Bengtson EM, Atkins JN, Link BK, Rai KR, Larson RA."Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated" . : 92
January 2009 Lannutti BJ, Meadows SA, Kashishian A, Steiner B, Pogosov G, Sala-Torra O, Johnson AJ, Byrd JC, Radich J, Giese NA."CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment" . : 120
January 2009 Jones JA, Flynn J, Moran M, Lin T, Byrd JC."Trends in pneumonia (PNA) hospitalization among patients (pts) with chronic lymphocytic leukemia (CLL)" .
January 2009 Jaglowski SM, Lin TS, Elder P, Scholl D, Byrd JC, Devine SM, Andritsos L."Barriers to Reduced-Intensity Conditioning (RIC) Transplant in Patients with Chronic Lymphocytic Leukemia" . : 559
January 2009 Jaglowski SM, Byrd JC, Jones JA."In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP)" . : 569
January 2009 Baum PR, Cerveny C, Gordon B, Nilsson C, Wiens J, Rafiq S, Lapalombella R, Muthusamy N, Byrd JC, Wahl A."Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma" .
January 2009 Bai LY, Ma Y, Kulp SK, Wang SH, Chiu CF, Frissora F, Mo X, Jarjoura D, Byrd JC, Chen CS, Muthusamy N."OSU-DY7, a Novel D-Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway" . : 1453
January 2009 Awan F, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson D, Cheney C, Mo X, Lehman A, Jones J, Flynn JM, Jarjoura D, Baiocchi RA, Desjarlais J, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC."CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody" . : 1435
January 2010 Furman RR, Byrd JC, Flinn IW, Coutre SE, Benson DM Jr., Brown JR, Kahl BS, Wagner-Johnston ND, Giese NA, Yu AS."Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies" . : 7s
January 2010 Kaplan LD, Jung S, Johnson JL, Linker CA, Byrd JC, Stock W, Hsi ED, Cheson BD."A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma" . : 7s

Presentations

"Fludarabine therapy for lymphoid malignancies is associated with a high number of opportunistic infections." Presented at American Society of Hematology, . (December 1993)

"Fludarabine therapy for lymphoid malignancies is associated with hemolytic anemia." Presented at American Society of Clinical Oncology, . (May 1994)

"The presence of t(8;21)(q22;q22) and extrameduallary leukemia (EML) at presentation of acute myeloid leukemia may influence prognosis." Presented at American Society of Hematology, . (December 1994)

"Extramedullary leukemia is associated with pre-treatment cytogenetic abnormalities in patients with acute myeloid leukemia: Results from CALGB 8461." Presented at American Society of Hematology, . (December 1995)

"The impact of the administration of packed red blood cells in the evaluation of the post-transfusion patient." Presented at American Society of Hematology, . (December 1996)

"Fludarabine and cyclophosphamide as first therapy for indolent lymphoproliferative disorders: Response rates and toxicity." Presented at American Society of Hematology, . (December 1996)

"Sole trisomy 8 in patients with acute myeloid leukemia (AML) are rarely cured with intensive chemotherapy: Results of CALGB 8461." Presented at American Association of Cancer Research, . (April 1996)

"New experimental therapeutics in chronic lymphocytic leukemia." Presented at Cancer and Leukemia Group B leukemia core meeting, . (November 1997)

"New therapeutic agents in chronic lymphocytic leukemia." Presented at Cancer Therapy and Evaluation Program, . (December 1997)

"Interleukin-4 induces resistance to F-Ara-a and ucn-01 but not flavopiridol in a bcl-2 independent manner." Presented at American Society of Hematology, . (December 1997)

"FR901228, a novel bicylic depsipeptide, has significant activity against human B-chronic lymphocytic leukemia (B-CLL)." Presented at American Society of Hematology, . (December 1997)

"Flavopiridol has marked in vitro activity against human B-chronic lymphocytic leukemia and induces apoptosis independent of p53 status." Presented at American Society of Hematology, . (December 1997)

"Spicamycin derivative KRN5500 has marked in vitro activity against human chronic lymphocytic leukemia cells concomitant with decreased expression of p27 and cleavage of caspase-3." Presented at American Society of Hematology, . (December 1998)

"Rituximab therapy in previously treated Walderstrom’s macroglobulinemia: Preliminary evidence of activity." Presented at American Society of Hematology, . (December 1998)

"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid tumor lysis." Presented at American Society of Hematology, . (December 1998)

"Adult acute myeloid leukemia patients with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine are administered." Presented at American Society of Hematology, . (December 1998)

"Rituximab Therapy in Patients with Chronic Lymphocytic Leukemia." Presented at 12th Annual Meeting on Monoclonal Antibodies in Cancer, . (October 1999)

"Novel Combination therapies in CLL." Presented at International Workshop on Chronic Lymphocytic Leukemia, . (October 1999)

"How to Logically Combine New Agents in Hematologic Malignancies." Presented at Friday Symposium, . (December 1999)

"Administered Thrice Weekly is Active in CL." Presented at L. American Society of Hematology, San Francisco, CA, US|USA. (December 2000)

"Rituximab Added to Fludarabine Increases Overall Response to Fludarabine: Updated Results from CALGB 9712." Presented at American Society of Hematology, Orlando, FL, US|USA. (December 2001)

"Cytogenetics are predictive of CR and OS in Adult Patients with AML: Results from CALGB 8461." Presented at American Society of Hematology, Orlando, FL, US|USA. (December 2001)

"Biologic Therapies in the Treatment of Hematologic Malignancies." Presented at Super Friday Session, Orlando, FL, US|USA. (December 2001)

"Rituximab Added to Fludarabine Increases Overall Response to Fludarabine: Results from CALGB 9712." Presented at American Society of Clinical Oncology, San Francisco, CA, US|USA. (May 2001)

"New Therapies for Lymphoma." Presented at Lymphoma Research Foundation National Patient Conference, . (October 2002)

"Molecular Therapeutics Meeting Chairperson for Hematologic Malignancies Section." Presented at American Society of Clinical Oncology, . (November 2002)

"Phase I Study of Hu1D10 in CLL and ALL." Presented at NCI Phase I meeting, Washington, DC, US|USA. (March 2002)

"New Monoclonal Antibodies in CLL." Presented at 18th International Workshop on CLL, San Diego, CA, US|USA. (March 2002)

"Developing New Drugs in CLL." Presented at 18th International Workshop on CLL, San Diego, CA, US|USA. (March 2002)

"To Treat or Not To Treat." Presented at CLL Education Session, . (January 2002)

"Novel Use of Nucleoside Analogs in Low-grade Lymphoproliferative Disorders." Presented at ASH, . (January 2002)

"Developments with Alemtuzumab (Campath) in CLL/NHL." Presented at 3rd International Congress on Monoclonal Antibodies in Cancer, Quebec, CA|CAN. (August 2003)

"New Therapeutics in CLL." Presented at Anderson Cancer Center Grand Rounds, . (March 2003)

"Histone deacetylase inhibitors in CLL." Presented at Molecular Targeting of Leukemia Session, . (May 2003)

"Early Treatment Intervention of CLL." Presented at Education Session on CLL, . (May 2003)

"Conventional or combined treatment of modalities in chronic lymphocytic leukemia." Presented at Center of Excellence Program, Sloan-Kettering, NY, US|USA. (September 2003)

"Understanding How Monoclonal Antibodies Work." Presented at American Society of Hematology Super Friday Session, . (December 2003)

"State of the art antibodies and advances in CLL – ASH symposium, making the connection between basic science and optimized clinical utility." Presented at Meet the Experts on CLL, . (December 2003)

"Conventional or combined treatment modalities in chronic lymphocytic leukemia." Presented at Memorial Sloan-Kettering Cancer Center, . (December 2003)

"New approaches to chronic lymphocytic leumemia." Presented at A celebration of monoclonal antibody therqapy, Cambridge, MA, US|USA. (October 2003)

"Developing new drugs in hematologic malignancies." Presented at Annual meeting of the UK CLL forum, London. (October 2003)

"New treatment paradigms in CLL." Presented at Dornette lecture, Cincinatti, OH, US|USA. (November 2003)

"Clinical trials: what do they tell us about future treatment for CLL." Presented at Lymphoma treatment today and tomorrow, Tarrytown, NY, US|USA. (November 2003)

"New Treatments in CLL." Presented at Oklahoma Oncology Medical Society, . (January 2004)

"Update of Recent Data with Alemtuzumab." Presented at 8th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (March 2004)

"New Treatment of CLL." Presented at Jonas Lectureship, St. Louis, MO, US|USA. (March 2004)

"Motefaxin gadolinium in Hematologic Malignancies." Presented at 8th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (March 2004)

"Intergrating IL-2 to Enhance Antibody Activity in Lymphomas." Presented at 8th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (March 2004)

"5-Azacytidine: Current Status." Presented at 8th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (March 2004)

"Rituximab in combination therapry of CLL." Presented at 5th International Workshop of the German CLL Study Group, Kloster Irsee, Bavaria, DE|DEU. (September 2004)

"New Developments in CLL." Presented at Aultman Cancer Center, Canton, OH, US|USA. (September 2004)

"Lumiliximab, an antibody targeting CD23 (IDEC-152)." Presented at 4th International Congress on Monoclonal Antibiodies in Cancer, Colorado Springs, CO, US|USA. (September 2004)

"Update on chronic lymphocytic leukemia." Presented at Grand Rounds, . (October 2004)

"New agents for chronic lymphocytic leukemia." Presented at Lymphoma/Myeloma Meeting, New York, NY, US|USA. (October 2004)

"What is the biology of rituximab resistance in chronic lymphocytic leukemia." Presented at Lymphoma…the next questions 2004, San Juan, PR|PRI. (April 2004)

"Current Treatment of CLL." Presented at The Community Hospital, Springfield, OH, US|USA. (April 2004)

"Current Treatment of CLL." Presented at Mayo Clinic, Rochester, MN, US|USA. (April 2004)

"Clinical trials and laboratory studies: A partnership." Presented at ASCO, New Orleans, LA, US|USA. (June 2004)

"Treatment risk stratification of CLL." Presented at Chemotherapy Foundation Symposium XXII, New York, NY, US|USA. (November 2004)

"Laboratory to Bedside Epigenetically Targeted Therapies for Patients with Hematological Malignancies." Presented at AACR, Waikoloa, HI, US|USA. (November 2004)

"Management and Treatment of Fludarabine – Refractory CLL." Presented at American Society of Hematology, San Diego, CA, US|USA. (December 2004)

"New Therapies in CLL." Presented at Grand Rounds, Charlottesville, VA, US|USA. (February 2004)

"New Therapies in CLL." Presented at Grand Rounds, Chicago, IL, US|USA. (February 2004)

"Evaluating monoclonal antibodies for B-cell malignancies." Ann Arbor, MI. (February 2004)

"Evaluating monoclonal antibodies and their use in the treatment of Hematologic malignancies." Presented at ProMedical Health System, Toledo, OH, US|USA. (February 2004)

"New therapies for CLL." Presented at Grand Rounds, Shreeveport, LA, US|USA. (September 2005)

"Is there a role for Flavopiridol in CLL treatment." Presented at 11th International Workshop on CLL, Brooklyn, NY, US|USA. (September 2005)

"Leukemia and Lymphoma: Practical Issues and Innovations." Presented at Cleveland Clinic Foundation, Cleveland, OH, US|USA. (March 2005)

"New Therapies for CLL." Presented at Grand Rounds, Chicago, IL, US|USA. (November 2005)

"CLL/SLL." Presented at North American Educational Forum on Lymphoma, Atlanta, GA, US|USA. (October 2005)

"Biology, Diagnosis & Treatment of Lymphomas." Presented at University of Pennsylvania, West Conshohocken, PA, US|USA. (October 2005)

"Flavopiridol administered as a pharmacologically derived schedule has promise for refectory CD5+ B cell malignancies." Presented at Leukemia Research Foundation – Mantle Cell Lymphoma Workshop, New York, NY, US|USA. (January 2005)

"Current therapeutic modalities in the management of CLL." Presented at Grand Rounds, Birmingham, AL, US|USA. (January 2005)

"Risk adapted therapy in CLL." Presented at 9th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (February 2005)

"New therapeutic approaches for CLL." Presented at Grand Rounds, Seattle, WA, US|USA. (February 2005)

"Antibody Therapy in CLL." Presented at Grand Rounds, Seattle, WA, US|USA. (February 2005)

"Prognostic factors in CLL." Presented at 45th Annual Scientific Meeting, Manchester. (April 2005)

"New treatment of CLL." Presented at Grand Rounds, New York, NY, US|USA. (March 2006)

"New treatment approaches for CLL." Presented at Duke University Tumor Board, Raleigh, NC, US|USA. (November 2006)

"Targeting the malignant cell – myeloid disorders." Presented at 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies, Scotsdale, AZ, US|USA. (January 2006)

"Farnesyltranferase inhibitors and other novel therapeutics in myeloid disorders." Presented at 3rd Mayo Clinic State of the Art Symposium on Hematologic Malignancies, Scotsdale, AZ, US|USA. (January 2006)

"Meet the Experts Session." Presented at 48th Annual American Soceity of Hematology meeting, Orlando, FL, US|USA. (December 2006)

"Risk – adapted therapy of CLL." Presented at 10th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (February 2006)

"Novel new therapies in CLL." Presented at Oncology Best Practices 2006, Columbus, OH, US|USA. (February 2006)

"Evolution of the management of CLL over the last 10 years." Presented at 10th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (February 2006)

"5_Azacytidine in MDS." Presented at 10th International Congress on Hematologic Malignancies, Whistler, BC, US|USA. (February 2006)

"Pathways to Therapeutic Angiogenesis in Cancer." Presented at Mayo Clinic Angiogenesis Syposium, Rochester, MN, US|USA. (October 2006)

"New treatment of CLL." Presented at Grand Rounds, Tampa, FL, US|USA. (July 2006)

"Update on Alemtuzumab in CLL." Presented at 6th International Congess on Monoclonal Antibiodies in Cancer, Washington, D.C., US|USA. (August 2006)

"Novel combination of antibodies in leukemia." Presented at 6th International Congess on Monoclonal Antibiodies in Cancer, Washington, D.C., US|USA. (August 2006)

"Cdk inhibitors." Presented at 5th International Congress on Targeted Therapies in Cancer, New York, NY, US|USA. (August 2006)

"CML & CLL." Presented at 11th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (February 2007)

"CLL." Presented at 11th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (February 2007)

"Biology of malignant CLL cells." Presented at 11th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (February 2007)

"An update on the management of chronic CLL." Presented at Oncology Best Practices 2007, Columbus, OH, US|USA. (February 2007)

"The path to progress: clinical trials in blood cancers." Presented at The Leukemia and Lymphoma Society, Ft. Wayne, IN, US|USA. (November 2007)

"Trends in Treating CLL." Presented at National Patient Meeting on CLL, Ontario, CA|CAN. (April 2007)

"New treatment of CLL." Presented at Grand Rounds, Chicago, IL, US|USA. (April 2007)

"Current research." Presented at National Patient Meeting on CLL, Ontario, CA|CAN. (April 2007)

"Antibody therapy in CLL." Presented at Grand Rounds, New York, NY, US|USA. (April 2007)

"Targeting other B-cell surface proteins (including CD22, CD23, CD80)." Presented at 7th International Congress on Monoclonal Antibodies, Quebec, CA|CAN. (August 2007)

"Immune targeted therapies in CLL." Presented at Roswell Park Cancer Institute, Buffalo, NY, US|USA. (August 2007)

"U.S. cooperative group efforts." Presented at National Chapter Office, Washington, D.C., US|USA. (September 2007)

"Flavopiridol: past the checkpoint." Presented at 12th International Workshop on CLL, London. (September 2007)

"Great debates in CLL: Facing today’s controversies and tomorrows challenges." Presented at Super Friday session, Atlanta, GA, US|USA. (December 2007)

"What’s new in the management of CLL." Presented at Current Trends in Leukemia, Kansas City, MO, US|USA. (January 2008)

"Update on new findings of CLL." Presented at 1st Annual ASH Review Symposium, Nashville, TN, US|USA. (January 2008)

"Review of abstracts of CLL." Presented at Annual ASH Review Symposium, Columbus, OH, US|USA. (January 2008)

"Changing horizons on the therapy of CLL." Presented at The Cleveland Clinic Cancer Center Grand Rounds, Cleveland, OH, US|USA. (January 2008)

"Monoclonal Antibody Therapy." Presented at Henry Kunkel Society Annual Meeting, Santa Margherita Ligure, IT|ITA. (May 2008)

"New Findings in Chronic Lymphocytic Leukemia." Presented at Grand Rounds, Little Rock, AR, US|USA. (October 2008)

"Antibody and Small Modular Immune Pharmaceutical Therapies for Patients with CLL: A Major Step Forward." Presented at iSBT Conference, San Diego, CA, US|USA. (October 2008)

"10 Most Influential Things in the Treatment of Blood Cancer." Presented at Central Ohio Chapter, Columbus, OH, US|USA. (October 2008)

"Review of ASH." Presented at Highlighst of ASH, Seattle, WA, US|USA. (February 2008)

"Past, Present and Future Series; CLL." Presented at 12th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (February 2008)

"Management of Patients with newly Diagnosed Low-Risk Chronic Lymphocytic Leukemia." Presented at 12th International Congress on Hematologic Malignancies, Whistler, BC, CA|CAN. (February 2008)

"ASH Review 2007: A Case Directed Summary." Presented at Hematological Malignancies 2008: A Comprehensie Revies of the 49th Annual Meeting, Cincinnati, OH, US|USA. (February 2008)

"New Agents." Presented at VII International Workshop of the GCLLGS, Cologne, DE|DEU. (September 2008)

"Flavopiridol and other CDK Inhibitors." Presented at 4th International Conference Leukemia 2008, Houston, TX, US|USA. (September 2008)

"Chemotherapy Advances in the Treatment of Chronic Lymphocytic Leukemia." Presented at 4th International Conference Leukemia 2008, Houston, TX, US|USA. (September 2008)

"A Patient with Active Phase CLL." Presented at 4th International Conference Leukemia 2008, Houston, TX, US|USA. (September 2008)

"New Findings in CLL." Presented at Grand Rounds, Rochester, NY, US|USA. (April 2008)

"CLL: Integration of Biology and Therapeutic options." Presented at 5th International Chicago Lymphoma Symposium, Chicago, IL, US|USA. (April 2008)

"CLL for the Internist - What to Follow and When to Refer." State College, PA. (November 2009)

"Management of Relapsed/Refractory Chronic Lymphocytic Leukemia." Columbus, OH. (September 2009)

"Chronic Lymphocytic Leukemia and Variants." Presented at Cancer Medicine and Hematology, Boston, MA. (September 2009)

"Chronic Lymphocytic Leukemia." Cleveland, OH. (September 2009)

"New Therapies in CLL." Presented at Grand Rounds, Ann Arbor, MI. (November 2009)

"Update on CLL." Presented at 13th International Congress on Hematological Malignancies, Whistler, BC, US|USA. (February 2009)

"Treatment of Fudarabine Refactory CLL." Presented at 13th International Congress on Hematological Malignancies, Whistler, BC, CA|CAN. (February 2009)

"Chronic Lymphocytic Leukemia." Presented at Malignancies 2009: A Comprehensive Review of the 50th Annual Meeting of the American Society of Hematology, Cincinnati, OH, US|USA. (February 2009)

"New Therapies in CLL." Presented at 2009 Canadian Conference on Lymphoproliferative Disorders, Lake Louise, Albereta, CA|CAN. (March 2009)

"FCR – the best therapy for CLL?." Presented at 2009 Canadian Conference on Lymphoproliferative Disorders, Lake Louise, AB, CA|CAN. (March 2009)

"Building the Bridge Between the Laboratory and Clinic for Novel Immunotherapies in Chronic Lymphocytic Leukemia." Presented at American Association for Cancer Research 2009 Annual Meeting, Denver, CO, US|USA. (April 2009)

"Developing New Drugs for CLL." Presented at Grand Rounds, Houston, TX, US|USA. (January 2009)

"CLL." Presented at Hematology Highlighs, Chicago, IL, US|USA. (January 2009)

"Chronic Lymphocytic Leukemia." Presented at Annual ASH Review Symposium, Columbus, OH, US|USA. (January 2009)

"Novel Targeted Therapies in CLL." Presented at International Association for Comparative Research on Leukemia and Related Diseases Symposium XXIV, Columbus, OH. (October 2009)

"Biologic Therapies in Biologic Therapies in Chronic Lymphocytic Leukemia." New York, NY. (October 2009)

"Chronic Lymphocytic Leukemia: Novel Therapies." Presented at Highlights of ASH, Washington, DC. (January 2010)

"Lenalidomide as an immune therapeutic for CLL." New York, NY. (April 2010)

"Poster Discussion." Presented at Leukemia Section, ASCO, Chicago, IL. (June 2010)

"Immune Therapies of CLL." Lexington, KY. (March 2010)

"Immune Based Therapies for Lymphoid Malignancies." Tampa, FL. (March 2010)

"Chronic Lymphocytic Leukemia: Molecular Insights, Prognostic Factors, and Therapeutic Advances." Presented at Dana-Farber Cancer Institute Master Class for Oncologists, Pasadena, CA. (May 2010)

"Chronic Lymphocytic Leukemia: Molecular Insights, Prognostic Factors, and Therapeutic Advances." Presented at Dana-Farber Cancer Institute Master Class for Oncologists, New York, NY. (May 2010)

 

Professional Activities

1999 - present Speaker, Patient Group on New Therapies in CLL. Balitmore, MD.
2000 - present Speaker, Waldenstrom's Macroglobulinemia National Patient Meeting.
2001 - present Speaker, New Therapies in CLL, Patient Support Group. Bethesda, MD.
2001 - present Patient Group "CLL and NHL". Columbus, OH.
2001 - present Weekly T32 Hematology-Oncology Research Journal Club. Didactic Conferences.
2001 - present Weekly Fellow Clinical Case Conference. Didactic Conferences.
2002 - present Speaker, Regional Patient Meeting on CLL. Columbus, OH.
2003 - present OMEN Teleconference: New Prognostic Factors and Therapy for CLL. Media Didactic Conferences.
2004 - present Speaker, Team in Training. Leukemia and Lymphoma Society of America. Columbus, OH.
2004 - present Speaker, Springfield Cancer Center Conference. Springfield, OH.
2004 - present Speaker, Leukemia and Lymphoma Society Meeting. Leukemia and Lymphoma Society. Columbus, OH.
2005 - present Speaker, Light the Night Walk. Leukemia and Lymphoma Society of America. Columbus, OH.
2006 - present Speaker, Light the Night Walk. Leukemia and Lymphoma Society of America. Columbus, OH.
2006 - present Board Member, Leukemia and Lymphoma Central Ohio Chapter.
2007 - present Speaker, Patient Group "CLL and NHL". Columbus, OH.
2007 - present Speaker, Light the Night Walk. Leukemia and Lymphoma Society of America. Columbus, OH.
2007 - present Speaker, Leukemia and Lymphoma Society. Leukemia and Lymphoma Society of America.
2007 - present Speaker, Leukemia and Lymphoma Society. Leukemia and Lymphoma Society of America.
2007 - present Speaker, Leukemia and Lymphoma Society. Leukemia and Lymphoma Society of America. Columbus, OH.
2008 - present Speaker, Light the Night Walk. Leukemia and Lymphoma Society of America. Columbus, OH.
2008 - present Speaker, Leukemia and Lymphoma Society Meeting on CLL. Leukemia and Lymphoma Society. Columbus, OH.
2008 - present Speaker, Leukemia and Lymphoma Society. Leukemia and Lymphoma Society of America.
2009 - present Organizer, National Patient Education Meeting on CLL. Leukemia and Lymphoma Society. Columbus, OH.